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“Opportunity is missed by most people because it is dressed in 
overalls and looks like work.” Thomas Edison 
    




Appropriate placental development in early gestation is essential for subsequent placental function and 
hence optimal fetal growth and pregnancy outcome. Placental insufficiency has been implicated in 
common disorders of pregnancy, which result in fetal and maternal mortality or morbidity, and also 
increase the risk of poor health in adult offspring.  
 
Prior to the onset of maternal blood flow to the placenta at ~10 weeks of gestation, placentation occurs 
in a relatively hypoxic environment, which is essential for healthy pregnancy. IGF-II is abundantly 
expressed by the invasive trophoblast and may interact with oxygen to regulate placentation. 
Additionally, maternally-derived IGFs may act on the placenta and the mother to regulate fetal growth. 
This thesis investigated the role and interaction of oxygen and IGF-II on human placental outgrowth 
during early pregnancy in vitro. Furthermore, the impact of maternal IGF treatment during early to mid 
pregnancy, on placental development and substrate transfer, nutrient partitioning between the mother 
and fetus, and fetal growth, were also determined in mid and late gestation in guinea pigs.  
 
We have demonstrated, using human early first trimester placental villous explants, that IGF-II mediates 
the effect of hypoxia on placental outgrowth. Culture of placental explants in hypoxia, or with exogenous 
IGF-II, enhanced trophoblast outgrowth and inhibited TGF-β1 activation, a negative regulator of 
trophoblast function. In addition, culture of explants in hypoxia induced Igf2  gene expression in 
outgrowing trophoblast, without altering Upar, Igf1r, Igf2r or Tgfβ1 transcription. We propose that this 
novel interaction of oxygen, IGF-II and TGF-β1 during pregnancy is an important determinant of 
placental development. Furthermore, we showed that exogenous IGF-II stimulates villous explant 
trophoblast outgrowth in placenta from >10 weeks gestation, suggesting that IGF-II may be a potential 
therapeutic agent to enhance placental growth.  
 
In guinea pigs, maternal treatment with IGF-I or IGF-II, in early to mid pregnancy, has sustained 
anabolic effects on fetal growth, enhanced fetal survival and increased placental delivery, and fetal and 
maternal utilization of, glucose and amino acids near term. These effects were also evident by mid 
gestation following earlier IGF-I treatment. Despite these similar pregnancy outcomes, there were IGF 
specific effects on the placenta and mother, suggesting that IGFs may mediate some of their effects via 
different pathways. IGF-I administration severely reduced maternal adiposity in late pregnancy,    
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suggesting persistent diversion of nutrients to the fetus. In contrast, IGF-II elicited its effects by 
substantially improving development of the placental exchange region, which correlated with placental 
function.  
 
We have suggested that the discrete effects of IGF-I and IGF-II stem from distinct interactions of the 
IGFs with various receptors. Maternal administration of an analogue of IGF-II that selectively interacts 
with IGF2R (Leu27-IGF-II), revealed that many of the effects of IGF-II treatment, were mediated by 
IGF2R, while IGF-I presumably acts through IGF1R. 
 
Together, this work has highlighted the major and somewhat complementary roles of maternal IGFs 
during the first half of pregnancy, in regulating placental development, fetal growth and pregnancy 
success. Importantly, it indicates the potential use of maternal IGFs in diagnostic and therapeutic 
approaches to pregnancy complications.    




This work is original and has not been accepted for the award of any other degree or diploma in any 
university or other tertiary institution. To the best of my knowledge, this thesis does not contain material 
previously written or published by another, except where due reference in the text has been given.  
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1.1  Determinants of pregnancy success 
During pregnancy it is necessary to ensure adequate nutrient allocation to the fetus, while providing 
sufficient substrate is also partitioned to the mother to meet the energy requirements needed to 
maintain maternal health and her capacity to support the conceptus. To ensure an adequate flow of 
oxygen and nutrients to the developing conceptus, during normal pregnancy, the mother undergoes a 
number of physiological, “adaptive” changes, which in turn are influenced by factors including genetics, 
nutrition, lifestyle and hormonal milieu. The placenta, is central to these processes, as it is not only the 
organ responsible for the exchange of substrates between the mother and fetus, but also synthesises a 
number of steroid and peptide hormones, secreted into the maternal circulation, that modulate maternal 
physiology and adaptation to pregnancy. 
 
1.2  Maternal adaptation to pregnancy 
Alterations in the regulation of maternal appetite, body composition, cardiovascular function, energy 
consumption and metabolism occur during pregnancy, which ensure an adequate flow of nutrients, 
oxygen and water to the developing fetus (Butte 2005; Owens 1991). Furthermore, despite the mother 
eating intermittently during the day, throughout pregnancy she must continuously supply nutrients to the 
fetus to sustain its exponential growth (Butte 2000; Hytten and Leich 1971). To achieve this, the mother 
changes her metabolism of fat and glucose and acquires a state of insulin resistance. At the same time, 
women increase their basal hepatic glucose production during pregnancy by 16-30% (Assel, Rossi et al. 
1993; Catalano, Roman-Drago et al. 1998; Catalano, Tyzbir et al. 1992), while increasing their daily rate 
of carbohydrate utilization by 34% (Butte 2000), to meet the demands of the conceptus. Despite 
increased carbohydrate utilization, insulin-stimulated glucose uptake in late pregnancy is 50-70% lower 
than that of non-pregnant women (Catalano, Tyzbir et al. 1991; Catalano, Tyzbir et al. 1993; Catalano, 
Tyzbir et al. 1992; Ryan, O'Sullivan et al. 1985), suggesting diminished maternal peripheral insulin 
sensitivity. The development of relative insulin resistance during pregnancy is thought to be due to 
inhibition of post-receptor insulin signaling as pregnant women displayed reduced phosphorylation and 
activity of the insulin receptor tyrosine kinase in skeletal muscle (rectus abdominus), compared with 
non-pregnant controls (Shao, Catalano et al. 2000). This increased insulin resistance reduces maternal 
glucose utilization, sparing carbohydrates for the rapidly growing fetus.  
 
Placental elaboration of hormones, including estrogen, prolactin, progestins, which are released into the 
circulation of the mother are thought to contribute to the observed maternal metabolic changes (Butte Chapter 1    Introduction 
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2000; Catalano 1999; Ryan and Enns 1988). Certainly, changes in glucose tolerance and β-cell 
responsiveness to glucose during pregnancy coincide with increases in circulating cortisol, prolactin, 
placental lactogen, estrogen, and progesterone levels, which all have been shown to modulate glucose 
metabolism and insulin action (Butte 2000; Picard, Wanatabe et al. 2002). Therefore the placenta 
determines nutrient delivery to the fetus both directly as the organ responsible for their transfer, and 
indirectly, as a major source of endocrine modulators of maternal metabolism to increase their 
availability. 
 
1.3  Placenta 
1.3.1  Introduction  
The placenta develops during pregnancy and is the functional interface between the mother and fetus. 
During pregnancy, the placenta performs six essential functions that ensure a suitable environment for 
optimal fetal development. The placenta 1) anchors the conceptus to the maternal endometrium, 2) 
supplies the developing fetus with oxygen and nutrients, transporting them from the mother into the 
umbilical circulation whilst removing waste products, 3) prevents immunological rejection of the semi-
allogeneic conceptus by the maternal immune system, 4) synthesises an array of hormones, cytokines, 
growth factors and other bioactive molecules critical to the maintenance of pregnancy and preparation 
for lactation, 5) enables passive immunity for the fetus through the transport of maternal antibodies and 
6) acts as a barrier to pathogens (Bauer, Harding et al. 1998; Cross, Werb et al. 1994; Gude, Roberts et 
al. 2004; Redman, Sargent et al. 1993; Robinson, Chidzanja et al. 1995; Robinson, Seamark et al. 
1994). Through these functions, the placenta is able to modulate the maternal environment to support 
normal fetal development, as well as maintaining the health of the mother.  
 
The process of placental development is dynamic and highly regulated. It involves an orchestrated 
balance of placental trophoblast cell proliferation, differentiation and invasion. Placentation is initiated at 
the time of implantation when the trophoectoderm layer surrounding the blastocyst makes contact with 
the uterine wall. During pregnancy, trophoblasts invade and remodel the uterine endometrium and its 
vasculature, forming a feto-maternal interface with access to the maternal circulation. This process is 
crucial for efficient exchange of oxygen and nutrients. The highly proliferative, invasive, lack of cell 
contact inhibition and immune privilege properties of trophoblasts are reminiscent of a metastasising 
cancer. However, during normal pregnancy, trophoblast behaviour is tightly regulated, such that Chapter 1    Introduction 
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trophoblast invasion remains confined to the first third of the myometrium and continues only until about 
the middle of pregnancy.  
 
1.3.2  Human placentation in early pregnancy 
1.3.2.1  Blastocyst apposition, attachment and implantation 
In humans, at around 5 to 6 days post-fertilisation, the blastocyst attaches to the uterine epithelium at 
the embryonic pole. At this time the trophectoderm layer of the blastocyst in contact with the epithelium 
rapidly proliferates and divides into two trophoblast layers (Figure 1.1a). Some of these proliferating 
cells called cytotrophoblasts (CTBs), lose their cell membranes and fuse to form a multinucleated 
cytoplasmic mass known as the syncytiotrophoblast (STB) (Benirschke 1990). Those cells that 
constitute the blastocyst wall and do not lose their cell membranes form the CTB layer. Finger-like 
projections of the STB intrude through the luminal epithelium eroding and invading the underlying 
endometrial stroma by degrading local extracellular matrix (Pijnenborg, Robertson et al. 1981), enabling 
the blastocyst to progressively implant into the maternal endometrium (Figure 1.1a).  
 
1.3.2.2  Formation of placental lacunar networks 
At around 9-10 days, isolated spaces known as lacunae begin to appear within the STB and maternal 
capillaries around the implanted embryo expand and become dilated to form sinusoids (Benirschke 
1990; Fox 1989; Moore 1974; Redman, Sargent et al. 1993) (Figure 1.1b). As the STB moves further 
into the uterine endometrium, more lacunae appear, and those near each other fuse to form lacunar 
networks, which are the precursors of placental intervillous spaces (Burton, Jauniaux et al. 1999) 
(Figure 1.1c) 
 
1.3.2.3  The formation of placental villi  
Between the 11th and 13th day, cytotrophoblasts beneath the STB proliferate to form local masses that 
evaginate into the STB mass, forming the primary stem villi (Benirschke 1990; Fox 1989; Moore 1974; 
Redman, Sargent et al. 1993) (Figure 1.1d). Some of the CTB within the primary villus fuse with the 
overlying syncytium and lose their cell membranes to enable further expansion of the multinucleated 
mass. Extension of the CTB core allows the villus to push into blood-filled lacunae, forming intervillous 
spaces. 
 
Shortly after primary villi appear, they begin to branch and by days 15 to 16 of pregnancy the 






Figure 1.1 Schematic representation of human placental development during the 
first trimester.  
 
On gestational days 5 to 6, the blastocyst contacts the uterine epithelium at the 
embryonic pole, inducing trophoblast to proliferate and differentiate into 
syncytiotrophoblast (STB) and cytotrophoblast (CTB) (A). Expansion of the STB 
allows the blastocyst to slowing embed within the uterine endometrium. By day 9, 
lacunae begin to appear within the STB and maternal capillaries around the 
implanting embryo expand and become dilated to form sinusoids (B). By 10 days, the 
embryo is completed implanted within the endometrium and lacunae fuse with those 
adjacent to form lacunar networks, which are the precursor of placental intervillous 
spaces (C). Between days 11 and 13, primary stem villi form by the proliferation of 
CTBs beneath the STB (D). By days 15 to 16 of pregnancy the extraembryonic 
mesenchyme lying beneath the CTB grows into the core of each primary stem villus, 
forming secondary stem villi (depicted in cross-section) (E). Villous mesenchymal 
cells differentiate into fetal blood capillaries from day 21 of gestation, which connect 
to the embryo and form tertiary stem villi (seen in cross-section) (F). 








NOTE:  This figure is included on page 5 of the print copy of the 
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embryo) and lying beneath the CTB proliferates and grows into the centre of each primary stem villus, 
forming secondary stem villi (Benirschke 1990; Fox 1989; Moore 1974; Redman, Sargent et al. 1993) 
(Figure 1.1e). By 21 days of gestation, the mesenchymal cells in the villi differentiate into connective 
tissue and fetal blood capillaries that connect to the embryo, establishing the uteroplacental circulation 
and creating tertiary stem villi (King 1987) (Figure 1.1f). 
 
1.3.2.4  Trophoblast differentiation 
CTB of the tertiary villi may enter the villous or extravillous pathways. In villi that float in the intervillous 
space, CTBs progress along the villous pathway proliferate and fuse with the overlying syncytium, which 
mediates nutrient and gas exchange for the developing fetus. CTBs at the tips of villi in contact with the 
decidua proliferate, penetrate and extend through the overlying villous syncytium allowing contact to be 
made with the maternal tissue and proceed along the extravillous pathway (Pijnenborg, Bland et al. 
1981; Pijnenborg, Robertson et al. 1981). These CTB extensions form cell columns that aggregate with 
adjacent columns to form the cytotrophoblastic shell, which constitutes the maternal-fetal interface and 
encompasses the entire conceptus. Columns of CTB anchor the tips of villi to the maternal decidual 
stroma and are thought to play a role in the structural integrity of the maternal-fetal interface.  
 
1.3.2.5  Extravillous cytotrophoblast 
From anchoring villi, invasive CTBs, called extravillous cytotrophoblasts (EVTs) detach from cell 
columns individually or in small clusters called CTB islands and colonize the maternal interstitium and 
vasculature, termed interstitial and endovascular invasion, respectively (Burton, Jauniaux et al. 1999; 
Pijnenborg, Bland et al. 1983; Pijnenborg, Bland et al. 1981; Redman, Sargent et al. 1993) (Figure 1.2). 
To become extravillous, CTBs undergo an “epithelial to mesenchymal transformation” (see below). This 
invasive process results in the circumferential expansion of the placenta therefore increasing the 
surface area for exchange between the mother and the fetus and dilated maternal arterioles, which are 
no longer responsive to maternal vasocontrol and promotes blood flow to the placenta (Kam, Gardner et 
al. 1999; Pijnenborg, Dixon et al. 1980; Pijnenborg, Vercruysse et al. 2006; Pijnenborg, Vercruysse et 
al. 1998). Virtually all of the 100-150 maternal spiral arteries in the placental bed are invaded and 
transformed into distended vessels with diameters of 200-300 μm (Lyall 2005) that promote blood flow 
to the placenta, which constitutes 30% of the maternal cardiac output by term (Khong, De Wolf et al. 
1986; Martin 1968) 
 
 









NOTE:  This figure is included on page 7 of the print copy of the 









Figure 1.2 Schematic representation of the feto-maternal interface during the 
first trimester in human pregnancy. 
From tips of anchoring villi (AV), CTB proliferate and form cell columns (CC), 
which make direct contact with the maternal decidua. Column CTB (cCTB) 
proliferate and differentiate into extravillous cytotrophoblast (EVTs), which invade 
the maternal interstitium and vasculature. Also depicted in this figure, is a floating 
villus, which floats in the intervillous space and mediates nutrient and gas exchange 
for the developing fetus. 














 Chapter 1    Introduction 
Amanda N Sferruzzi-Perri  8 
1.3.2.5.1  Interstitial invasion 
Interstitial EVTs invade the decidual stroma and reach the endometrial/myometrium boundary by the 
eighth week of gestation (Pijnenborg, Bland et al. 1981). Subsequently, they invade deeper into the 
decidua, reaching the first third of the myometrium and concentrate around maternal spiral arteries 
(Pijnenborg, Bland et al. 1983). Interstitial CTBs surrounding spiral arteries have been suggested to 
“prepare” them for  
endovascular trophoblast migration by initiating medial necrosis and fibrinoid deposition in the spiral 
arterioles (Kam, Gardner et al. 1999) and release of vasoactive agents such as carbon monoxide (Lyall 
2003). Terminal differentiation of interstitial EVTs occurs when they fuse to form the non-invasive, 
multinuclear placental bed giant cells (Pijnenborg 1996). 
 
1.3.2.5.2  Endovascular invasion 
Endovascular invasion commences at least as early as 4-6 weeks of gestation, where myometrial 
arteries are reached by 10 weeks of gestation (Pijnenborg, Bland et al. 1983) and may migrate as far as 
the first third of the myometrium (Brosens 1975; Brosens, Robertson et al. 1967). EVTs become 
endovascular when they enter the vessel lumen by penetration of, and transmigration through, the 
endothelium (Kam, Gardner et al. 1999). Following EVT invasion, EVTs can then also enter the vessel 
lumen by migrating from the cytotrophoblastic shell along the inner walls of the maternal spiral arterioles 
that have become continuous with IVS (Kam, Gardner et al. 1999).  
 
Within the spiral arterioles, endovascular EVTs progressively replace the vascular endothelial cells, the 
smooth muscle layer and deposit a fibrinoid matrix, as well as replacing the neural tissue in myometrial 
segments of arteries (Aplin 1991; Pijnenborg, Bland et al. 1983). This transforms the narrow spiral 
arterioles into dilated tubes, unresponsive to vasoconstrictive control and capable of high conductance 
(Brosens, Robertson et al. 1967) (Figure 1.3) 
 
1.3.2.5.3  Trophoblast epithelial – mesenchymal transformation 
The ability of EVTs to invade maternal tissues, involves (1) changes in cell-cell associations, (2) cell 
adhesion to the ECM, (3) polar degradation of the ECM in the direction of migration and (4) active 
movement through the matrix. In order to become extravillous and invade, CTBs undergo a temporally 
and spatially regulated “epithelial to mesenchymal transformation”, losing their intercellular junctions and 
expressing an altered repertoire of adhesion molecules (Aboagye-Mathiesen, Laugesen et al. 1996; 
Aplin 1991; Damsky, Fitzgerald et al. 1992; Damsky, Librach et al. 1994; Vicovac and Aplin 1996) 









NOTE:  This figure is included on page 9 of the print copy of the 









Figure 1.3 Photomicrograph showing the presence of endovascular EVT 
within maternal spiral arteries during human pregnancy. 
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The villous CTB layer, a polarised highly organised and proliferative epithelium, expresses high levels of 
laminin and collagen IV, the intercellular binding molecule E-cadherin and also the α6 and β4 integrins, 
which hetero-dimerise to form the α6β4  laminin receptor (Figure 1.4). As cells leave the villous 
basement membrane to form cell columns, expression of laminin is lost and fibronectin expression is 
acquired (Damsky, Librach et al. 1994). E-cadherin, α6 and β4 are down-regulated and are 
accompanied by an upregulation of the α5 and β1 integrin subunits (Aplin 1997; Aplin, Haigh et al. 
1999; Damsky, Librach et al. 1994) (Figure 1.4). Secretion of matrix metalloproteinase-2 (MMP-2; 
gelatinase A) allows degradation of the ECM (Bischof, Martelli et al. 1995; Bischof, Meisser et al. 2000; 
Huppertz, Kertschanska et al. 1998). Expression of the serine protease, urokinase-type plasminogen 
activator (uPA) activates plasmin, which in turn activates latent MMPs, which enable further degradation 
of ECM (Chakraborty, Gleeson et al. 2002; Floridon, Nielsen et al. 1999; Floridon, Nielsen et al. 2000). 
CTB expression of the uPA receptor (uPAR) allows interaction with different integrins (β1, β2, β3 and 
β5 integrins subunits and the αvβ3 and αvβ5 integrins) that promote cytoskeletal reorganisation 
(Chapman 1997; Degryse, Orlando et al. 2001) and cell migration (Carriero, Del Vecchio et al. 1999; 
Chapman 1997; Degryse, Orlando et al. 2001; Wei, Lukashev et al. 1996; Xue, Mizukami et al. 1997).   
 
In more distal regions of the cell column, CTBs cease proliferation and differentiate further to become 
more invasive by the induction of α1 integrin expression allowing CTBs to leave the cell column 
(Aboagye-Mathiesen, Laugesen et al. 1996) (Figure 1.4). The integrin heterodimers, α5β1 and α1β1, 
allow CTBs to interact with fibronectin and laminins/collagens, respectively, and are characteristic of 
endothelial integrins. Interaction of CTBs with fibronectin is thought to be involved in anchorage to the 
decidua while interaction with laminin and collagen is essential for invasion and migration (Damsky, 
Librach et al. 1994). No E-cadherin or α6β4 expression is evident on the surface of these highly 
invasive CTBs, permitting the detachment of individual cells (Figure 1.4).   
 
Up-regulation of MMP-9 expression, allows additional digestion of the endometrial ECM (Bischof, 
Martelli et al. 1995; Bischof, Meisser et al. 2000; Bischof, Meisser et al. 2002; Huppertz, Kertschanska 
et al. 1998; Kemp, Kertschanska et al. 2002; Librach, Feigenbaum et al. 1994; Librach, Werb et al. 
1991) (Figure 1.4). Trophoblast interaction with the ECM proteins, such as paxillin and vinculin (Kabir-
Salmani, Shiokawa et al. 2003) through phosphorylation of the focal adhesion kinase (FAK), which is 
used to mediate ECM effects on cellular gene expression, is also critical to EVT invasion (Ilic, Genbacev 
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Figure 1.4 Phenotypic changes that occur along the CTB invasive pathway. 
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(PAIs) are expressed predominantly by the decidua but also by the EVTs themselves to control 
trophoblast invasiveness. 
 
Trophoblasts also up-regulate HLA-G, a trophoblast-specific HLA class I molecule and L-selectin 
(Genbacev, Prakobphol et al. 2003), during the invasive process. The latter is characteristically 
expressed by leukocytes and may aid EVT invasion by modulating maternal immune responses during 
pregnancy and permit their movement through the decidua (McMaster, Librach et al. 1995; Paul, Rouas-
Freiss et al. 2000).  
 
Endovascular EVTs undergo additional changes in their expression of cell surface molecules, which 
allow them to interact with, and ultimately ‘mimic’, endothelial cell behaviour (Figure 1.4). Endovascular 
EVTs express classical endothelial integrins α1β1 (as described previously), the fibrinogen receptor 
α4β1,  αvβ3 (binds to vitronectin and fibronectin) as well as VE-cadherin (vascular-endothelial 
cadherin), VCAM and PECAM (Zhou, Fisher et al. 1997). Furthermore, EVTs secrete vascular 
endothelial growth factor (VEGF)-C and placental growth factor (PlGF) and express angiopoietin (Ang) 
2, factors heavily involved in maternal spiral arterial interaction and remodelling (Zhou, Bellingard et al. 
2003). Along the invasive pathway, EVTs up-regulate their expression of insulin-like growth factor   
(IGF)-II (Han, Bassett et al. 1996; Ohlsson, Holmgren et al. 1989; Ohlsson, Larsson et al. 1989), which 
plays fundamental roles in modulating trophoblast function (see section 1.3.5.1.7.2). EVTs are known to 
upregulate chemokine receptors as they invade the uterine stroma and vasculature, which is thought to 
be important for “homing” of trophoblast to the maternal endothelium (Hannan, Jones et al. 2006). 
 
1.3.2.5.4  Importance of EVT invasion to pregnancy outcome 
Poor invasion of the endometrium by EVTs results in insufficient maternal blood perfusion of the 
placenta, restricting nutrient supply to the developing conceptus, and is associated with common and 
major disorders of pregnancy (Figure 1.5). These include, miscarriage (Khong, Liddell et al. 1987), 
intrauterine growth restriction (IUGR) (Khong, De Wolf et al. 1986; Khong, Liddell et al. 1987), 
preeclampsia (Khong, De Wolf et al. 1986), placental abruption (Dommisse and Tiltman 1992), preterm 
labour (Kim, Bujold et al. 2003; Kim, Chaiworapongsa et al. 2002) and stillbirth (Khong, De Wolf et al. 
1986; Robertson, Brosens et al. 1967). Combined, these disorders can lead to fetal and maternal 
mortality and morbidity, affect more than 1 in 5 first-time pregnancies in Western countries (Laws and 
Sullivan 2004) and may be higher than 40% in developing nations (Albertsson-Wikland, Wennergren et 
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Figure 1.5 Schematic representation of the process of invasion and 
remodelling of the maternal spiral arteries by invasive cytotrophoblast 
(EVTs) during pregnancy.  
In normal pregnancy, EVTs remodel decidual and first third of the myometrial 
arteries, resulting in dilation of spiral arteries. This accommodates a dramatic increase 
in maternal blood supply to the uterus that is essential for fetal growth during 
pregnancy. Insufficient invasion and remodelling of the maternal uterine vasculature 
can lead to early pregnancy loss (miscarriage) or the development of pregnancy 
diseases which can lead to fetal and maternal mortality and morbidity. CTB = 
cytotrophoblast, IUGR = intrauterine growth restriction, IVS = intervillous 
space, PE = preeclampsia, PTB = preterm birth, STB = syncytiotrophoblast. 
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Furthermore, perturbed fetal growth, which is usually diagnosed by reduced weight, length and/or 
increased thinness for gestational age at birth (Karlberg, Albertsson-Wikland et al. 1996; Robinson, 
Seamark et al. 1994) (Figure 1.6), is a significant cause of perinatal morbidity and mortality 
(Fitzhardinge 1985; Kramer 1990; Kramer, Olivier et al. 1990; Low, Handley-Derry et al. 1992; Smith, 
Smith et al. 1998) and increases the risk of poor health in childhood and adult life (Barker 1998; Barker 
2004a; Barker 2004b; Barker 2004c). This predisposition to adult disease forms the fetal programming 
hypothesis, which proposes that events that take place in utero can profoundly affect the structure,  
 
function or metabolism of major organs or tissues thus affecting susceptibility to disease later in life 
(Barker 1995). Specially, IUGR is associated with atherosclerosis (Martyn, Gale et al. 1998), coronary 
heart disease (Barker 1995), hypertension (Barker, Bull et al. 1990), insulin resistance, non-insulin 
dependent diabetes (Barker 1998; Barker and Clark 1997) and elevated plasma cholesterol (Barker, 
Martyn et al. 1993) in the offspring later in adult life.  
 
Based on the growing epidemiological evidence that appropriate EVT invasion and placental function is 
critical to pregnancy success and in the long-term programming of adult disease, it is important that 
mechanisms regulating trophoblast differentiation into the extravillous lineage are defined. Certainly, 
EVTs of preeclamptic pregnancies express high levels of the α6β4, α5β1 and αvβ6 integrins as well 
as E-cadherin, fail to switch on α1β1, αvβ3, VE-cadherin, VCAM-1 and PECAM-1 (Zhou, Damsky et al. 
1993; Zhou, Damsky et al. 1997; Zhou, Fisher et al. 1997) and express significantly less MMP-2 and 




1.3.2.6  Placental transport 
Probably the most important and well-known functions of the placenta is its transport of nutrients and 
oxygen from the maternal circulation to the fetus. The placenta is also a metabolically active organ that 
extracts approximately 40 to 60% of the total glucose and oxygen supplied by the uterine circulation 
during pregnancy (Bauer, Harding et al. 1998). The remaining nutrients and metabolites are transferred 
across the placenta to the fetus by nutrient specific processes, including passive diffusion, facilitated 
diffusion, active transport, endocytosis, or exocytosis, as reviewed by (Murphy, Smith et al. 2006). 
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Figure 1.6 Photograph demonstrating the growth of appropriately grown 
(left) and growth restricted (right) babies at birth. 
The latter have reduced weight, length and/or increased thinness for gestational age. 
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The primary barrier to substrate transfer in the placenta varies between species. In humans there is only 
one layer of STB separating the fetal and maternal blood circulations (Figure 1.7). The microvillous 
apical membrane (MVM) of STB is in direct contact with the maternal blood, whilst the basal cell 
membrane (BM) faces the fetal capillaries. Nutrients must pass through both membranes for delivery to 
the fetus. Embedded on the surface of the STB membranes, are carrier molecules responsible for 
transporting nutrients. The regulation of transporter function is not completely understood however 
transporters on the two membranes must act in concert to achieve appropriate net transfer of nutrients 
from mother to fetus. Studies of placental transport, in vitro, have employed the use of isolated STB 
plasma membranes and more recently have measured uptake by human placental villous explants. In 
vivo animal studies have utilized radiolabelled non-metabolisable analogues of specific nutrients, which 
are administered to the mother prior to death and their subsequent uptake by placental and fetal tissues 
measured. 
 
1.3.2.6.1  Determinants of transport capacity 
As pregnancy advances, the increasing demands of the fetus are met by modulation of placental 
transport capacity. Such changes include a reduction in the thickness of the syncytiotrophoblast barrier 
for exchange, increased surface area across which placental transport can occur and placental blood 
perfusion. Furthermore, permeability of substrate, abundance and localization of transporters at the cell 
surface and substrate concentration gradient influence transplacental capacity.  
 
Transport by passive diffusion (of oxygen, carbon dioxide and urea) is limited by the placental exchange 
area and blood flow. Facilitated diffusion involves transfer down a concentration gradient by a carrier 
molecule, without a requirement for additional energy. Active transport requires both carrier proteins and 
the input of additional energy (Bauer, Harding et al. 1998). Glucose and amino acids are the main 
substrates utilized by the fetus, and thus we have focused on transport of these nutrients. 
 
1.3.2.6.2  Glucose  
Fetal gluconeogenesis is relatively low and thus the fetus is critically dependent on placental delivery of 
glucose from the mother. Glucose transfer is a facilitated process, dependent on the difference between 
maternal and fetal circulating glucose concentrations (Schneider, Calderon et al. 1981) and is mediated 
by glucose transporters (GLUTs). The human placenta expresses GLUT-1, GLUT-3 (Hahn, Hartmann et 
al. 1995; Illsley 2000; Jansson, Wennergren et al. 1993; Tadokoro, Yoshimoto et al. 1996), GLUT-4 
(Ericsson, Hamark et al. 2005b) and GLUT-12 (Gude, Stevenson et al. 2003; Rogers, Macheda et al. 









NOTE:  This figure is included on page 17 of the print copy of the 









Figure 1.7 Representation of the placental barrier for substrate transfer between 
the maternal and fetal circulations in humans. 
The microvillous apical membrane (MVM) of syncytiotrophoblast is in direct contact 
with the maternal blood, whilst the basal cell membrane (BM) faces the fetal 
circulation. The pathway for exchange is denoted by --------. Illustration from Jansson 
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the fetus by increasing Glut-1 mRNA throughout pregnancy (Sakata, Kurachi et al. 1995) and increased 
placental surface area for exchange from the second half of pregnancy (Teasdale and Jean-Jacques 
1985). These gestational changes at the feto-maternal interface result in a 50% increase in the uptake 
of glucose by the human placenta from 1st trimester to term, as measured in vitro in villous explants 
(Ericsson, Hamark et al. 2005a). 
 
GLUT-1 is the primary mediator of glucose transfer. In the placenta it is the predominant glucose 
transporter expressed by the STB in term human placenta and uptake of glucose by the placenta is 
directly correlated to its abundance (Jansson, Wennergren et al. 1993). Other work comparing GLUT-1 
density on the MVM and BM isolated from term human placenta have revealed that there is a 3-fold 
greater distribution of this transporter on the MVM plasma membrane than on the BM (Jansson, 
Wennergren et al. 1993; Tadokoro, Yoshimoto et al. 1996; Takata, Kasahara et al. 1992). Furthermore, 
it has been estimated that the glucose transport capacity of the MVM is approximately 20-fold higher 
than that of BM (Jansson, Wennergren et al. 1993). The surface area of MVM is over 5-fold greater than 
the BM due to the development of microvilli, which is thought to contribute to the asymmetrical 
expression of GLUT-1 (Teasdale and Jean-Jacques 1985).  
 
Investigators have hypothesized that transport across the BM is the rate-limiting step in placental 
glucose transport (Illsley, Hall et al. 1986). This high MVM transport capacity may act to maximize the 
glucose concentration gradient between the STB and fetal plasma (Illsley 2000) and enhance placental 
transport of glucose to the fetus. An alternate explanation for the differential expression of GLUT-1 on 
the MVM and BM may be that the placenta utilizes much of the glucose taken up for its own metabolic 
purposes and thus less transporter is required on the BM to meet the demands of the fetus. 
Nevertheless, studies performed on placental samples from women suffering from insulin-dependent 
diabetes mellitus have indicated that GLUT-1 expression and glucose transport was increased on the 
BM, without an alteration on MVM (Gaither, Quraishi et al. 1999; Jansson, Wennergren et al. 1999). 
Studies performed on placenta from women suffering gestational diabetes have been less conclusive. 
Gaither and colleagues, demonstrated increased GLUT-1 expression and glucose transport in BM in 
gestational diabetic women (Gaither, Quraishi et al. 1999), whilst others reported no difference 
(Jansson, Ekstrand et al. 2001). Furthermore, there is no difference in GLUT-1 expression and activity 
in term or preterm human placenta from IUGR pregnancies (Jansson, Wennergren et al. 1993; Jansson, 
Ylven et al. 2002; Kainulainen, Jarvinen et al. 1997), although the babies are hypoglycemic (Marconi, 
Paolini et al. 1996; Nicolini, Hubinont et al. 1989). There is also no effect of experimental induction of 
IUGR in guinea pigs on glucose transfer by the placenta (Jansson and Persson 1990). The differences Chapter 1    Introduction 
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in placental glucose transport effects between studies warrant further investigation, particularly on the 
control and role of placental glucose transfer in regulating fetal growth. Interestingly, insulin receptors 
are most abundant on fetal endothelium in placenta, suggesting that the fetus may signal to the 
placenta to alter its transport function (Hiden, Maier et al. 2006). Support for this has been observed in 
past studies performed in sheep (Harding, Liu et al. 1994; Jensen, Harding et al. 1999; Owens, Kind et 
al. 1994) and mice (Constancia, Angiolini et al. 2005). 
 
1.3.2.6.3  Amino acids 
High rates of protein synthesis occur in the fetus. Therefore, placental delivery of amino acids, 
particularly those that are essential, are required to ensure growth. Amino acids are also potent 
stimulators of fetal insulin release (Milner and Hill 1984) and it has been estimated that 20-40% of the 
energy supplied to the fetus, is in the form of amino acids (Bauer, Harding et al. 1998). It is not 
surprising then, that reduced fetal plasma amino acid concentrations are associated with restricted 
growth at term in humans (Cetin, Corbetta et al. 1990). In general, transport of amino acids is an active 
process, as the concentrations of most amino acids in the fetus are greater than those in the mother 
(Battaglia 1992; Beckman, Pugarelli et al. 1990; Lemons, Adcock et al. 1976; Montgomery and Young 
1982). However, some amino acids may be transporter via facilitated diffusion (Verrey, Closs et al. 
2004). There are different families of amino acid transporters defined by the class of amino acids they 
transport and may have overlapping specificities (Jansson 2001; Regnault, de Vrijer et al. 2002b; 
Regnault, Friedman et al. 2005). Transport systems may be coupled to an electrochemical gradient of 
sodium ions through co-transport of sodium, termed sodium-dependent transporters (systems A, ASC 
and β). Conversely, there are also sodium-independent transporters (system L, X-AG. Y+, bo,+ and y+L) 
(Jansson 2001). Based on the central role System A transporters play in fetal growth and metabolism 
(Regnault, Friedman et al. 2005), this system will be discussed.  
 
System A transporters interact with short side-chain neutral amino acids, including glycine, alanine, 
glutamine and serine (McGivan and Pastor-Anglada 1994), which are generally gluconeogenic. The 
human placenta has a greater distribution of System A transporters on the MVM than on the BM 
(Hoeltzli and Smith 1989). Indeed, the MVM displays a 3-fold greater System A transporter activity, 
compared with BM (Johnson and Smith 1988). This suggests that factors in the maternal circulation 
have the potential to alter placental amino acid uptake and transfer to the fetus by the regulation of 
System A on MVM. 
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MVM vesicles prepared from placentas of small for gestational age babies (Dicke and Henderson 1988; 
Mahendran, Donnai et al. 1993) and IUGR (Glazier, Cetin et al. 1997; Jansson, Scholtbach et al. 1998; 
Jansson, Ylven et al. 2002) have reduced system A amino acid transporter activity. These are 
consistent with studies showing reduced placental delivery of maternally-administered radiolabelled 
amino acids, such as leucine, to the umbilical circulation in women bearing growth restricted babies 
(Paolini, Marconi et al. 2001) and reduced placental System A transport capacity, following experimental 
induction of IUGR by unilateral uterine arterial ligation in guinea pigs (Jansson and Persson 1990). 
Indeed, in vivo inhibition (by 40%) of System A transport between days 7 and 20 of gestation results in 
IUGR in rats near term (Cramer, Beveridge et al. 2002). Recent work performed in pregnant rats fed a 
low protein diet revealed that reductions in placental System A transporter gene expression and activity 
occurred prior to the onset of fetal growth restriction (Jansson, Pettersson et al. 2006). These studies 
provide evidence that impaired placental amino acid transporter activity restricts amino acid supply to 
the fetus and may contribute to reduced fetal growth.  
 
The activity of System A transporters is also impaired in women suffering metabolic disease during 
pregnancy. For instance, cultured placental MVM from human gestational diabetic and insulin 
dependent diabetes mellitus women display increased System A transport activity (Jansson, Ekstrand et 
al. 2002). However, this is in contrast to findings of another research group that reported reduced 
System A transport in pregnancies complicated by insulin dependent diabetes mellitus, which result in 
macrosomia (Kuruvilla, D'Souza et al. 1994). Inconsistencies may reflect differences in populations 
sampled, as there was increased placental weight in the former study (Jansson, Ekstrand et al. 2002) 
and no effect on placental weight in the latter study (Kuruvilla, D'Souza et al. 1994). Nevertheless, 
System A transporters clearly play dominant roles in the regulation of fetal growth and therefore, a 
better understanding of their regulation may help to understand the pathogenesis of pregnancy 
disorders including IUGR.   
 
1.3.3  In vitro study of placentation 
There is conflicting data regarding the control of trophoblast proliferation versus differentiation along the 
invasive pathway, in vitro. This may be explained by different methodologies used by investigators and 
therefore should be considered before making conclusions. For instance, when comparing studies that 
use different trophoblast cell lines, the source of the cell lines (normal or malignant tissue and first 
trimester or term placenta), how they were isolated, the degree of differentiation of the cell line and 
validity of the criteria used to characterise the cell line as being villous or extravillous CTBs all should be Chapter 1    Introduction 
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considered (Blaschitz, Hutter et al. 2000; Frank, Genbacev et al. 2000; King, Thomas et al. 2000; Ma, 
Yang et al. 2001; Shiverick, King et al. 2001). The same concerns exist when investigators use isolated 
trophoblast subpopulations prepared from one placenta, or generated from pools of placentae.  
 
The development of the human placental villous explant system in vitro in the mid 1980s (Fisher, Cui et 
al. 1989; Fisher, Leitch et al. 1985) enabled the basic architecture of placental tissue at anchorage sites 
to be maintained allowing mechanisms of EVT function and regulation to be investigated. This is 
important as cell-matrix and cell-cell interactions are known to be critical modulators of autocrine and 
paracrine actions of a variety of molecules. In 1985 and 1989, Fisher and associates reported that 
human placental villi cultured on an extracellular matrix (produced by specific cell lines) promoted focal 
attachment and subsequent outgrowth and migration of CTBs from the tips of villi by digestion of the 
matrix (Fisher, Cui et al. 1989; Fisher, Leitch et al. 1985). This finding was a landmark in understanding 
placental development, as it provided evidence that adhesion to a permissive extracellular matrix was 
sufficient to stimulate CTB proliferation and migration.  
 
Later studies confirmed and extended these findings revealing that culture of human villi on an ECM 
induced differentiation along the invasive pathway, with developing CTB columns up-regulating cell-
surface expression of α5β1 and α1β1, fibronectin and down regulating α6β4 expression, as seen in 
vivo (Aplin, Haigh et al. 1999; Genbacev, Schubach et al. 1992). This validates the use of villous 
placental explants as in vitro models for the study of trophoblast differentiaition along the invasive 
pathway. 
 
1.3.4  In vivo study of placentation 
Rodents have commonly been used in studies investigating placental function as they display 
haemochorial placentation and the advent of gene knockout and transgenic mice and rats has facilitated 
such studies. However, the guinea pig offers additional advantages for the study of placentation and 
extrapolation to humans.   
 
1.3.4.1  Guinea pig placentation 
The guinea pig, like the human, displays an invasive, haemonochorial (a single trophoblast layer in 
contact with maternal blood), discoidal placenta. The amniotic cavity, which is formed by cavitation, and 
the development of the allantoic mesenchyme are similar in both species (Pijnenborg, Robertson et al. 
1981). In the guinea pig, trophoblasts migrate and invade arteries that traverse the placenta, promoting Chapter 1    Introduction 
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maternal blood flow to it, as occurs in humans. In addition, the guinea pig placenta exerts similar 
endocrine control of pregnancy to that of the human in that it acquires the ability to substitute for the 
ovaries producing abundant progesterone and esterone, to maintain pregnancy (Enders 1965).  
 
Guinea pig pregnancy lasts for 59 to 72 days, with a litter of two to five fetuses, which are precocious at 
birth. The blastocyst adheres to the uterine epithelium anti-mesometrially on day 5 or 6 post-conception. 
By the 7th day, the blastocyst is completely implanted in the maternal endometrium (Kaufmann 1969; 
Kaufmann and Davidoff 1977) (Figure 1.8a). Proliferation and differentiation of the trophoblast into a 
nucleated mass of STB and an underlying, thin layer of CTB enables STB invasion towards the uterine 
cavity (Figure 1.8b). By the 10th day, this invasion has caused the original uterine lumen to disappear, 
whilst a new uterine lumen begins to form anti-mesometrially. Projections of the syncytium called basal 
syncytial sprouts perforate the yolk sac, which surrounds the conceptus, like roots of a tree (Figure 
1.8c). These syncytial sprouts proliferate intensely and invade the maternal endometrial decidua 
developing the junctional zone, through which maternal arteries will course into the main placenta 
(Kaufmann 1969; Kaufmann and Davidoff 1977).   
 
Within the next few days, the syncytium transforms into a sponge-like area (trophospongium) as 
localised areas of the STB disintegrate forming lacunae (as in humans) (Figure 1.8d). Due to expansion 
of the STB, the basal syncytial sprouts come into contact with and erode endometrial blood vessels, 
allowing blood to flow into the trophospongium by the 12th day of gestation. On day 14, the 
extraembryonic mesoderm associated with the allantois called the central excavation, extends into the 
syncytium acquiring a mushroom-like shape with finger-like lamellar projections of mesenchyme lined by 
CTB (Figure 1.8e). The roof of this central excavation will form the main placenta-subplacenta 
boundary, with the main placenta proximal to the developing fetus.   
 
From this central excavation, the extraembryonic mesenchyme proliferates and increasingly invades the 
trophospongium radially around the connecting stalk causing intermingling of connective tissue with the 
syncytium of the main placenta (Figure 1.8f). The trophospongium, interspersed with mesenchyme, 
forms a convoluted structure, known as the labyrinth with trophospongium septae (called the 
interlobium) extending in the direction of the uterus as well as towards the embryo (Kaufmann and 
Davidoff 1977). On day 14 of gestation, mesenchymal cells in the labyrinth begin to differentiate into 
fetal capillaries and from day 21 onwards, extensive capillarization occurs (Kaufmann and Davidoff 
1977).  
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Figure 1.8 Schematic representation of placental development in the guinea pig. 
By the 7
th day of gestation, the blastocyst is completely implanted in the maternal 
endometrium (a). Proliferation and invasion of the syncytiotrophoblast (STB) and 
underlying cytotrophoblast towards the primary uterine lumen (PUC) on gestational 
day 9, causes it to disappear, while a new uterine lumen forms (NUC) (b). Projections 
of syncytium (basal sprouts) perforate the yolk sac as seen on the 10
th day of gestation 
(c). By day 12, the allantois attaches to the chorion, as the syncytium transforms into 
the trophospongium (TS, d). The extraembryonic mesoderm progressively invades the 
TS, forming a mushroom shape by the 15
th day of gestation (e). The extraembryonic 
mesoderm invades the TS radially around the connecting stalk and differentiates into 
fetal capillaries (day 20-32 of gestation, f). 
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Furthermore, rapid proliferation of the mesenchyme into projections allows growth of the labyrinth from 
the 22nd day of gestation. Within the labyrinth, modulation of the exchange interface occurs. Trophoblast 
encompasses maternal blood spaces on one side and fetal vessels on the other. These thin to create a  
reduced barrier for exchange (Enders 1965), allowing for efficient substrate and gas transfer between 
the two circulations. 
 
In contrast to the labyrinth, the interlobium region of the mature main placenta is devoid of fetal 
capillaries. It is, however, interspersed with maternal blood spaces. Interlobial trophoblasts are thought 
to resorb substrates from the maternal circulation permitting synthesis of structural proteins as well as 
energy generation for growth of the labyrinth until term (Kaufmann and Davidoff 1977).  
 
In the subplacenta, at around day 20, a branching network of STB forms by thickening of the lamellar 
folds that eventually extend centrally into the basal syncytial sprouts (Kaufmann and Davidoff 1977), 
similar in structure to the secondary villi in human placentation. Extraembryonic mesenchyme of the 
allantois differentiates into fetal blood vessels, which course through the interlobium and labyrinth and 
extend into the basal syncytial sprouts of the subplacenta, forming the primitive fetal circulation.  
 
As early as 15 days of gestation, trophoblasts have been identified within the myometrium and 
surrounding maternal blood vessels (Carter, Tanswell et al. 1998) (Figure 1.9). At 35 days of gestation, 
the maternal myometrial and to a lesser extent, the mesometrial arteries that traverse the placenta and 
the myometrium, respectively, are invaded by trophoblasts (Hees, Moll et al. 1987; Nanaev, Chwalisz et 
al. 1995a; Verkeste, Slangen et al. 1998) (Roberts et al., unpublished). This is associated with dramatic 
increases in uterine arterial dilatation, resulting in a 2 to 3-fold increase in vessel diameter (Kaufmann 
and Davidoff 1977). There appear to be two populations of endovascular trophoblasts within the guinea 
pig maternal arteries, the syncytiotrophoblast, sometimes referred to as multinucleated giant 
trophoblasts and the uninuclear trophoblasts that are aligned as overlapping sheets rather than a 
syncytium. The origin of these invasive trophoblasts and whether they perform different functions is 
undefined. It has been demonstrated, however, that the trophoblasts that surround blood vessels and to 
a lesser extent, endovascular trophoblasts, induce changes in the vasculature through the synthesis of 
nitric oxide, such that the vessels become widely dilated with a disorganised muscle layer that enables 
perfusion of blood into the placenta (Nanaev, Chwalisz et al. 1995a).  
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Figure 1.9 Trophoblast invasion of the maternal vasculature in the guinea 
pig. 
Trophoblast (t) can be seen within the maternal spiral arteries (mv) on day 
15 (A) and 35 (B) of gestation by immuno-labelling for cytokeratin (CK) 
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Around day 50, intra-arterial trophoblasts progressively replace the endothelium and destroy the 
maternal artery walls and its elastic laminae (Hees, Moll et al. 1987; Nanaev, Chwalisz et al. 1995a; 
Verkeste, Slangen et al. 1998) in a similar fashion to endovascular EVTs in the spiral arterioles in 
humans. In the guinea pig, trophoblast invasion of the adventitial layer also induces dedifferentiation of 
arterial smooth muscle cells (Nanaev, Chwalisz et al. 1995b; Nanaev, Kosanke et al. 2000a; Nanaev, 
Kosanke et al. 2000b). By term, these cells have been seen to migrated more than three quarters the 
way along the mesometrial arteries (Verkeste, Slangen et al. 1998) (Roberts et al., unpublished). There 
is a 13-fold increase in mean cross-sectional area of these vessels (Moll, Espach et al. 1983), which 
have reduced vasculature reactivity compared to the non-pregnant state and in mid gestation (Clausen, 
Larsen et al. 2003). As gestation proceeds, the labyrinth expands at the expense of the interlobial 
syncytium (Kaufmann and Davidoff 1977), decreasing the thickness of the STB layer and increasing the 
surface area for diffusion across the STB (Roberts, Kind et al. 2002) (Figure 1.10). 
 
1.3.5  Factors influencing the placenta 
The formation of the placenta as a suitable feto-maternal interface involves spatial and temporal 
regulation of trophoblast proliferation, differentiation and invasion. Environmental factors including 
oxygen concentration, extracellular components (collagen type I, decorin, PAIs, vitronectin), growth 
factors (insulin-like growth factor (IGF)-I and -II, epidermal growth factor, transforming growth factor 
(TGF)-α and -β, leukaemia inhibitory factor, vascular endothelial growth factor), cytokines (colony 
stimulating factor, interluekin-1β, -6, -10 and -15, leptin) and hormones (progesterone, human 
gonadotropin) influence trophoblast function through autocrine and paracrine actions (Morrish, Dakour 
et al. 1998). The combination and concentration of these present at any one time regulate trophoblast 
function. As there is a greater body of evidence to suggest that insulin-like growth factor-II plays a 
critical and essential role in the formation of the placenta and may modulate nutrient partitioning 
between the mother and conceptus, we have primarily focused our studies on this factor. We have also 
discussed the effects of IGF-I on trophoblast function and pregnancy outcome for comparison with IGF-
II actions. Oxygen concentration and TGFβ1 will also be discussed as previous studies performed in 
our laboratory suggest an interaction of IGF-II with these factors in controlling cytotrophoblast function. 
 
1.3.5.1  Insulin-like growth factor (IGF)-axis 
The insulin-like growth factors (IGFs, also known as somatomedins) belong to a family of peptides also 
consisting of insulin, relaxin and nerve growth factor, which exhibit highly homologous amino acid 
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Figure 1.10 Representative illustration of the guinea mature placenta. 
Labyrinth, interlobium and subplacenta components are indicated. 
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three disulphide bridges, with molecular weights of approximately 7.5kDa. IGFs share 50% homology 
with human pro-insulin and have a short D extension peptide at the carboxyl terminal of the A domain 
that is not present in either pro-insulin or insulin (Rinderknecht and Humbel 1978; Sara and Hall 1990). 
Two different isoforms of IGF have been identified, IGF-I and IGF-II that share 62% similarity with each 
other (D'Ercole 1996; Rinderknecht and Humbel 1978) and have been described to possess insulin 
synergizing activity (Mauras and Haymond 2005). 
 
IGFs have metabolic, mitogenic, anti-apoptotic, differentiating and transformation effects on a wide 
variety of cell types (Jones and Clemmons 1995). The diversity of IGF functions is achieved through 
binding to receptors with different affinities and different effects. IGFs can bind to two types of IGF 
receptor, IGF1R and IGF2R, as well as the insulin receptor (InsR), and IGF1R-InsR hybrids. IGFs can 
bind to six IGF binding proteins (IGFBP-1 to IGFBP-6), which in turn are regulated by IGFBP proteases 
and several other IGFBP-interacting molecules and -related peptides (Figure 1.11). This complex IGF 
system regulates and propagates IGF actions in several tissues. 
 
1.3.5.1.1  IGF-I 
The human IGF-I gene is located on chromosome 12q22 (Rotwein 1991) and consists of 6 exons and 5 
introns (LeRoith and Roberts 1993). The IGF-I gene contains different promoters and multiple 
transcription start sites, which allow the generation of multiple IGF-I mRNA transcripts (LeRoith and 
Roberts 1993). IGF-I is a key growth factor in many reproductive processes including, folliculogenesis, 
oocyte maturation, sperm motility and fertilisation, uterine proliferation and pre-implantation embryo and 
fetal development (as reviewed by (Kabir-Salmani, Shiokawa et al. 2003)).  
 
1.3.5.1.2  IGF-II 
The human IGF-II gene spans 30kb of chromosomal DNA and is located on chromosome 11p15 (de 
Pagter-Holthuizen, Hoppener et al. 1985). It consists of nine exons, of which exons 7, 8 and the first 
part of exon 9 encode IGF-II. Also four promoters are active in a tissue-specific fashion during growth 
and development. IGF-II over-expression is implicated in a variety of human malignancies, and 
therefore IGF-II is thought to play a role in tumourgenesis (as reviewed by (Moschos and Mantzoros 
2002)). There is also evidence of IGF-II over-expression in patients with Beckwith-Wiedemann 
overgrowth syndrome (Morison, Becroft et al. 1996). Within the fetus and the placenta, the majority of 
transcripts are regulated by the third promoter (Daimon, Johnson et al. 1992) however, in mice, the Igf2 
P0 transcript has been identified and is responsible for trophoblast expression of IGF-II (Constancia, 
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Figure 1.11 Figure depicting the insulin-like growth factor (IGF) system. 
IGF-I and IGF-II must be cleaved from insulin-like growth factor binding proteins 
(IGFBPs) so that they may interact with the type 1 or 2 IGF receptors (IGF1R and 
IGF2R) or insulin receptor (InsR). ALS = acid liable subunit. 
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1.3.5.1.3  Regulation of IGF abundance 
The IGF system is heavily influenced by nutrition, pregnancy, cortisol, sex steroids (particularly 
estrogen), growth hormone (except in guinea pigs) and oxygen concentration and to a lesser extent by 
other molecules such as ghrelin and leptin. Additionally, during pregnancy, considerable changes in the 
maternal IGF system occur, which are thought to be important in determining the partitioning of nutrients 
between the mother and the fetus and regulation of conceptus growth.  
 
1.3.5.1.4  IGF expression 
IGFs are expressed in most tissues, the liver being a major source and their highest concentrations are 
found circulating in the blood, except in rats and mice where IGF-II is undetectable in the circulation 
postnatally. Both Igf genes are expressed in the embryo and then the fetal tissues from the earliest 
stage of pre-implantation development to the final phase of tissue maturation just before birth (Fowden, 
Li et al. 1998; Hill, Petrik et al. 1998; Watson, Watson et al. 1994). During mid to late gestation, Igf2 
gene expression is widespread in fetal tissues and is more abundant than Igf1 gene expression in 
rodents, ruminants and humans (Delhanty and Han 1993; Gicquel and Le Bouc 2006; Hill 1990). The 
concentration of IGF-II in the fetal circulation is also much higher than IGF-I, with a three to ten-fold 
difference in all species studied (Fowden 2003). In rats and mice, IGF-II expression disappears from 
most tissues except the brain by weaning, with the consequence that IGF-II is virtually undetectable in 
adult plasma (Lee, Pintar et al. 1990; Singh, Rall et al. 1991). In humans and other species, like the 
guinea pig, IGF-II remains the most abundant IGF in the circulation throughout life (D'Ercole 1996; Han, 
Lund et al. 1988; Holly 1998).  
 
1.3.5.1.4.1  IGFs in the mother during pregnancy 
During normal pregnancy, substantial changes in the maternal IGF system occur, suggesting that 
endocrine IGFs may play a dominant role in the regulation of placental and fetal growth. Maternal 
plasma concentrations of IGF-I increase early in most species (Donovan, Giudice et al. 1991; Hills, 
English et al. 1996; Nason, Binder et al. 1996; Sohlstrom, Fernberg et al. 2001; Sohlstrom, Katsman et 
al. 1998b; Travers, Madon et al. 1990; Wallace, Da Silva et al. 1997; Wilson, Bennett et al. 1982), whilst 
the abundance of circulating IGF-II increases in some species (Nason, Binder et al. 1996), including 
humans (Gargosky, Moyse et al. 1990; Wilson, Bennett et al. 1982), but remains unchanged in others 
(Donovan, Giudice et al. 1991; Sohlstrom, Katsman et al. 1998b). Nonetheless, IGF-II is the most 
abundant IGF in the maternal circulation during pregnancy in the majority of species.  
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Non-hepatic tissues are thought to contribute substantially to maternal circulating IGF pools during 
pregnancy. Studies in guinea pigs have demonstrated that Igf1 gene expression is induced in maternal 
adipose tissue by pregnancy and that the main source of IGF-II during pregnancy is the placenta 
(Olausson and Sohlstrom 2003). Pregnancy also alters the abundance and stability of the IGFBPs in the 
maternal circulation, which in turn may influence IGF bioavailability. For instance, in the guinea pig, 
IGFBP-1 and IGFBP-2 concentrations increase in the circulation in late pregnancy, whilst that of IGFBP-
4 increases in early gestation and drops to non-pregnant concentrations later (Sohlstrom, Katsman et 
al. 1998b).  
 
While maternal IGFs do not cross the placenta in physiologically important quantities (Brown and 
Thorburn 1989), they may act on the placenta and maternal tissues to regulate nutrient allocation 
between the mother, placenta and fetus (Wallace, Da Silva et al. 1997). IGFs may directly or indirectly 
influence maternal physiological adaptation to pregnancy.  
 
1.3.5.1.4.2  IGFs at the feto-maternal interface 
Both IGFs are expressed at the feto-maternal interface during pregnancy, with similarities in cellular 
localization across species. In general, IGF-II is more abundantly expressed by the placenta (Dhara, 
Lalitkumar et al. 2001; Fowden 2003; Han and Carter 2000) than IGF-I and is a more potent regulator of 
trophoblast function (Hamilton, Lysiak et al. 1998).  
 
1.3.5.1.4.2.1  IGF-I expression at feto-maternal interface 
IGF-I is expressed in the human and other species endometrium across the menstrual cycle, primarily in 
mid to late proliferative and early secretory phases (as reviewed by (Giudice, Mark et al. 1998; Han and 
Carter 2000; Nayak and Giudice 2003)), and is thought to be a mediator of the mitotic actions of 
estradiol (Sato, Wang et al. 2002). During pregnancy, IGF-I is thought to play a role in decidualisation 
because it is predominantly expressed by decidual stromal cells (Correia-da-Silva, Bell et al. 1999; 
Dhara, Lalitkumar et al. 2001; Han and Carter 2000). In the human placenta, the main source of IGF-I in 
the first trimester is the villous mesenchyme (Lacey, Haigh et al. 2002). In the guinea pig, IGF-I is 
expressed weakly in the main placental labyrinth syncytium (compared to IGF-II) and in the subplacental 
mesenchyme and CTB (Han, Carter et al. 1999). These findings suggest a paracrine influence of IGF-I 
on trophoblast function. 
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1.3.5.1.4.2.2  IGF-II expression at the feto-maternal interface 
In situ hybridisation studies have revealed that, in the human placenta, Igf2 is exclusively expressed by 
CTBs as early as 6 weeks of gestation, with highest levels expressed by the invading EVTs in the 
uterine tissue and vasculature (Han, Bassett et al. 1996; Ohlsson, Holmgren et al. 1989; Ohlsson, 
Larsson et al. 1989) (Figure 1.4). The mesenchyme and endothelium, however, also express Igf2, but at 
much lower levels compared with CTB (Ohlsson, Larsson et al. 1989). Igf2 mRNA is absent in the 
villous STB (Han, Bassett et al. 1996).   
 
This pattern of Igf2 expression by trophoblast at the invading front occurs across species. For instance, 
IGF-II is abundantly synthesized by the invasive multinucleate and uninucleate trophoblasts around and 
within the maternal arterioles in guinea pigs (Han, Carter et al. 1999), EVTs in the rhesus monkey, the 
invasive trophoblast glycogen cells in the mouse (Redline, Chernicky et al. 1993) and all trophoblast 
populations in the rat (Zhou and Bondy 1992). These ontogenic studies suggest that IGF-II is important 
in trophoblast invasion and this function is conserved between species.  
 
1.3.5.1.5  IGF receptors 
IGFs can bind to two types of IGF receptor; IGF1R and IGF2R, as well as the InsR, all with differing 
affinity. IGF1R, structurally related to the InsR, is a disulfide-linked heterotetrameric (α2β2) 
transmembrane glycoprotein with an extracellular ligand-binding α-subunit and intracellular β-subunit 
with tyrosine kinase activity (Nissley, Haskell et al. 1985). IGF1R binds IGF-I with a much higher affinity 
than IGF-II, and insulin with little or no affinity (Germain-Lee, Janicot et al. 1992). In contrast, IGF2R is a 
single transmembrane receptor, which is identical to the cation-independent mannose-6-phosphate 
(M6P) receptor consisting of a large extracellular domain (15 contiguous repeats) and a small 
cytoplasmic tail that lacks tyrosine kinase activity (Ludwig, Le Borgne et al. 1995). IGF2R possesses an 
IGF-II binding site in the extracellular domain, distinct from two M6P-binding sites to which IGF-II binds 
with 700-fold higher affinity than IGF1R. Conversely, IGF-I binds to IGF2R with 500-fold less affinity 
than IGF-II, while insulin binds IGF2R with little or no affinity (Jones and Clemmons 1995).  
 
While the affinity of insulin binding to IGF1R is 1/500 to 1/1000 than that of the IGFs, IGFs can act 
through the InsR. IGF-II can bind to the InsR with an affinity that is 1/10 that of insulin and 5-10 times 
greater than that of IGF-I (De Meyts, Wallach et al. 1994). In addition, there are insulin-IGF hybrid 
receptors, composed of an αβ heterodimer of the InsR and an αβ heterodimer of the IGF1R, to which 
the IGFs can bind with high affinity and insulin with 10-fold lower affinity (Soos, Field et al. 1993). Chapter 1    Introduction 
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Human trophoblasts express both IGF receptors, InsR (Abu-Amero, Ali et al. 1998; Desoye, Hartmann 
et al. 1997; Holmes, Porter et al. 1999; Jones, Hartmann et al. 1993; Milio, Hu et al. 1994; Ohlsson, 
Holmgren et al. 1989) and IGF1R-InsR hybrids (Soos, Field et al. 1993) providing support for an IGF-II-
mediated autocrine and/or paracrine control of placental development. Further studies are required to 
elucidate which receptor (IGF1R, IGF2R, InsR or receptor hybrids) mediates IGF-I and IGF-II effects on 
placentation. 
 
1.3.5.1.5.1   IGF1R 
Traditionally, the biological activities of IGF-I and IGF-II were primarily thought to be mediated through 
the IGF1R. A variety of studies have shown that interaction between IGF-I or IGF-II with IGF1R leads to 
cell proliferation in numerous cell types, which involves activation of the insulin receptor substrate-1-
dependent intracellular signalling pathways (Jones and Clemmons 1995). More recently however, there 
is evidence that IGF1R phosphorylates FAK and paxillin which lead to cytoskeletal remodelling and 
migration of cells in vitro (Burridge, Turner et al. 1992; Casamassima and Rozengurt 1998). This has 
been demonstrated in human EVT cells, where IGF-I binding of IGF1R activated αvβ3 (Kabir-Salmani, 
Shiokawa et al. 2003)and α5β1 (Clemmons and Maile 2003) integrins. Consistent with this, IGF1R 
number in trophoblast membranes isolated from term human placenta has been positively correlated 
with placental and birth weights (Diaz, Cardenas et al. 2005). 
 
1.3.5.1.5.2   IGF2R 
Rather than having a role in signal transduction, IGF2R initially appeared to function only as a clearance 
receptor for IGF-II, as mice deficient in the Igf2r gene have increased serum and tissue levels of IGF-II 
(Ludwig, Eggenschwiler et al. 1996). This receptor has a recognised function in the transport of various 
ligands through the endosomal pathway. It has been reported that only about 10% of the cell’s IGF2R is 
present on the cell surface whilst the remaining 90% is found intracellularly on either the Golgi 
apparatus or the endosomal and lysosomal compartments (Boker, von Figura et al. 1997). IGF2R is 
thought to control the extracellular IGF-II concentration by mediating the endocytosis of IGF-II and its 
subsequent degradation in lysosomes (Jones and Clemmons 1995). IGF2R has been described as a 
tumor-supressor, as its downregulation caused an accumulation of IGF-II that stimulated growth upon 
binding to IGF-R1 and InsR in choriocarcinoma cell lines (Lee, Rushlow et al. 2001). 
 
The use of the IGF-II analogue, [Leu27]-IGF-II (Leu27-IGF-II), which cannot bind to the IGF1R nor the 
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but influences myoblast cell differentiation (Rosenthal, Hsiao et al. 1994) and rhabdomyosarcoma 
(Minniti, Kohn et al. 1992) and endothelial cell migration (Volpert, Jackson et al. 1996). The cytoplasmic 
tail of IGF2R contains a putative inhibitory G protein (Gi) coupled receptor binding site (Murayama, 
Okamoto et al. 1990), which is required for IGF-II-IGF2R dependent signalling (Ikezu, Okamoto et al. 
1995). Furthermore, in mice, interaction of the placental angiogenic factor, proliferin with the IGF2R, 
supports a role for the receptor in mediating endothelial cell migration via this intracellular signalling 
pathway (Groskopf, Syu et al. 1997). Consistent with this, hCG stimulation of migration and invasion of 
the choriocarcinoma cell line, JEG-3, has been shown to involve IGF2R (Zygmunt, McKinnon et al. 
2005).  
 
1.3.5.1.5.3   InsR  
Traditionally, InsR was thought to solely mediate metabolic actions within cells. Within the last decade 
however, studies have suggested that IGFs can interact with InsR and may be involved in their growth-
promoting effects (Frasca, Pandini et al. 1999). Studies performed in IGF1R deficient cells over-
expressing the InsR demonstrated that IGF-II (but not IGF-I) can stimulate cell proliferation through InsR 
and that this stimulation was at least 2-fold higher than insulin (Morrione, Valentinis et al. 1997). This 
effect is postulated to have occurred through the alternatively spliced form of the InsR, InsR-A, which 
binds with high affinity to IGF-II, but not IGF-I (Denley, Brierley et al. 2006). Indeed, IGF-II can signal 
through InsR-A and induce cancer cell proliferation, invasion and protection from apoptosis (Sciacca, 
Mineo et al. 2002). Interestingly, placental InsR affinity (Kd values) assessed by binding assays was 
reduced in trophoblast membranes isolated from term placenta obtained from preeclamptic women 
compared to normotensive women (Diaz, Cardenas et al. 2005). These studies suggest that InsR, 
particularly the InsR-A may play a role in placental development and pregnancy outcome.  
 
1.3.5.1.5.4   IGF1R-InsR hybrids 
IGF1R-InsR hybrids represent the major form of IGF1R in human term placenta, with immnoblotting and 
immunoprecipitation studies revealing that 70% of IGF1R in the placenta is heterodimerised with InsR 
(Bailyes, Nave et al. 1997; Soos and Siddle 1989). Heterodimers of InsR and IGF1R display lower 
affinity for insulin than InsR isoforms alone (Pandini, Frasca et al. 2002), therefore their formation may 
be a mechanism for switching the major ligand binding InsR from insulin to IGFs (Bailyes, Nave et al. 
1997).  
 
Given the major effects of IGFs on trophoblast function, the relative abundance of hybrid receptors in 
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dominant role orchestrating placental development. Further studies are required to elucidate this 
possibility. 
 
1.3.5.1.6   In vivo studies of the IGFs  
1.3.5.1.6.1   Rodent studies 
Direct support for a role of both IGFs in fetal growth and for IGF-II, but not IGF-I, in placental 
development has been provided by the generation of targeted gene deletion and transgenic mice (Table 
1.1). Deletion of either Igf gene results in a similar degree of fetal growth restriction, where birth weight 
is 60% of normal (Baker, Liu et al. 1993; DeChiara, Efstratiadis et al. 1990). 
 
In mice, deficiency of a functional Igf2 gene reduces placental weight by 17% on day 13.5 and by 25% 
on day 16.5 of gestation, with a fetal weight reduction of 40% at this time (term = 19 days) (Baker, Liu et 
al. 1993; DeChiara, Efstratiadis et al. 1990). There is a 50% reduction in the average number of cells in 
the labyrinth and junctional zones in the Igf2 deficient placenta in late gestation. The latter contains a 
smaller proportion of invasive giant cells and glycogen cells (Lopez, Dikkes et al. 1996). Glycogen cells 
have been thought to be analogous to human EVT and are the main source of IGF-II in late murine 
pregnancy (Redline, Chernicky et al. 1993). In contrast, in mouse chimeras with paternal duplication of 
chromosome 7 which results in Igf2 over-expression (Ferguson-Smith, Cattanach et al. 1991) or in mice 
that are deficient in Igf2r and display elevated serum and tissue concentrations of IGF-II (Lau, Stewart 
et al. 1994; Ludwig, Eggenschwiler et al. 1996), placental and fetal growth is increased. This is thought 
to be due to the over-stimulation of IGF1R by excess IGF-II (Efstratiadis 1998). Combined, these 
suggest that IGF-II plays a dominant role in regulating the number and differentiation of trophoblast 
populations in the placenta (Fowden 2003).  
 
IGF-II effects on fetal growth may be secondary to impacts on the placenta as placental amino acid 
transporter expression is altered in Igf2 deficient mice (Matthews, Beveridge et al. 1999). Certainly, 
recombination experiments in mouse blastocysts where the inner cell mass of an Igf2 deficient murine 
blastocyst was replaced with that of a wildtype are also consistent, as placental and fetal weights were 
reduced on day 16.5 (Gardner, Squire et al. 1999). Furthermore, dexamethasone administration to 
pregnant rats during the last third of pregnancy reduces placental expression of IGF-II and is associated 
with a 50% decrease in placental mass and IUGR (Ain, Canham et al. 2005). Additionally, deletion of 
the P0 transcript in mice, which is responsible for placental-specific expression of Igf2, also resulted in 
placental and fetal growth restriction (Constancia, Hemberger et al. 2002). The reduced fetal growth 
seen in these pregnancies is thought to be due to altered placental structural differentiation, which  Chapter 1    Introduction 
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Table 1.1 Fetal and placental phenotypes of mice genetically deficient in IGF or IGF receptors* 
Gene   Effect   Placenta  Fetal Weight (% WT) 
Igf1  No plasma or tissue IGF-I  Weight = 100% WT 
Structure not assessed 
60 
Igf2  No plasma or tissue IGF-II  Weight = 75% WT  
↓ labyrinth 
↓ junctional zone  
↓ glycogen and giant cells 
60 
Igf2 P0  Reduced placental IGF-II  Weight = 65% WT 
↓ in all placental layers  
↓ surface area for exchange 
↑ thickness of exchange barrier 
75 
Igf1r  No action of IGF at IGF1R  Weight = 100% WT 
Structure not assessed 
45 
Igf2r  Elevated plasma and tissue IGF-II  Weight = 140% WT 
Structure not assessed 
140 
WT = wild type. * Modified from Fowden, 2003. Refer to text for references Chapter 1    Introduction 
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resulted in decreased passive permeability (Constancia, Hemberger et al. 2002; Sibley, Coan et al. 
2004) (Table 1.1). Furthermore, glucose transport was increased throughout and active amino acid 
uptake was initially up-regulated, but ultimately failed (Constancia, Angiolini et al. 2005). The reduction 
in fetal weight was comparable to that induced by global Igf2 gene ablation, indicating that in mice, local 
IGF-II production is required for placental development and subsequent fetal growth.  
 
Ablation of the Igf1 gene also resulted in a similar reduction of birth weight to that seen with Igf2 gene 
ablation, but did not affect placental weight in late gestation. IGF-I administration to pregnant rats, or 
increased endogenous expression in pregnant mice, increases the weight of the fetus but not that of the 
placenta (Gluckman and Harding 1992). A null mutation for the Igf1r gene also resulted in slowing of 
prenatal fetal growth, which is more severe than deficiency of either Igf (45% of normal body weight) 
without any effect on placental size (Baker, Liu et al. 1993). Furthermore, placental growth is normal in 
double-mutants lacking both Insr and Igf1r (Efstratiadis 1998). Although neither of these genotypes 
affect placenta weight, it is possible that IGF-I, IGF1R and InsR are involved in regulating placental 
differentiation and functional capacity thereby affecting fetal growth. However, this possibility is yet to be 
explored in vivo.  
 
The fetus is also thought to signal to the placenta to coordinate growth and function in mice. In chimeric 
embryos with normal IGF-II gene expression in the placenta but IGF-II deficiency in the fetus, placental 
weight is reduced by 14% (Gardner, Squire et al. 1999). Furthermore, recent experiments comparing 
nutrient transfer in Igf2 P0 and complete Igf2 null mice, suggested that IGF-II in the fetus of Igf2 P0 
mothers signals to the placenta to up-regulate nutrient transporter expression (Constancia, Angiolini et 
al. 2005).  
 
1.3.5.1.6.2   Guinea pig studies 
More information on the regulation of fetal growth by IGFs has come from studies performed on guinea 
pigs, which, like humans, display postnatal IGF-II in their circulation (Sohlstrom, Katsman et al. 1998b). 
In the guinea pig, major structural determinants of placental function are strongly predicted by maternal 
IGF-II concentration in mid pregnancy and by maternal IGF-I in late pregnancy (Roberts, Kind et al. 
2002; Roberts, Sohlstrom et al. 2001b). Furthermore, in this species, food restriction alters the 
expression of IGF binding proteins in the maternal plasma and reduces IGF concentrations (Sohlstrom, 
Katsman et al. 1998b) through direct impacts on maternal hepatic gene expression (Grant, Kind et al. 
2005). These alterations in the IGF system of the mother correlate with delayed structural and functional 
maturation of the placenta and with reduced fetal growth (Roberts, Kind et al. 2002; Roberts, Sohlstrom Chapter 1    Introduction 
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et al. 2001a; Roberts, Sohlstrom et al. 2001b). Consistent with this, treatment of the guinea pig mother 
with IGF-I or IGF-II in early to mid pregnancy increases placental and fetal weights by mid gestation 
(Sohlstrom, Fernberg et al. 2001). Whether these anabolic effects of maternal exposure to elevated 
IGFs in early to mid gestation on the fetus and placenta are sustained to term is presently unknown. 
Furthermore, impacts of elevated maternal IGFs on placental development, transport and nutrient 
partitioning within the mother remain to be determined. 
 
1.3.5.1.6.3   Human studies 
In women, reduced plasma IGF-I is associated with placental dysfunction (as indicated by altered 
Doppler velocimetry in umbilical arteries) and small for gestational age (Holmes, Holly et al. 1998; 
Larsen, Main et al. 1996; Stefanidis, Solomou et al. 1998) or growth restricted infants (Holmes, 
Montemagno et al. 1997). In preeclamptic pregnancies, maternal serum IGF-I concentrations at term 
are lower compared with those in normal pregnant women (Giudice, Martina et al. 1997; Halhali, Tovar 
et al. 2000) and in a separate study, maternal IGF-I concentrations in late pregnancy, correlated with 
placental mass (and neonatal fat mass), near term (Clapp, Schmidt et al. 2004). More recently, 
abnormalities in the post-translational processing of IGF-II from inactive pro-IGF-II into the mature 
peptide by proprotein convertase-4 in women has been associated with IUGR (Qiu, Basak et al. 2005). 
Altogether, these studies suggest an important role of maternal endocrine IGFs in determining 
pregnancy success. 
 
Studies associating placental expression of IGF system components with pregnancy outcome have 
been inconsistent and inconclusive. Some studies reported increased Igf1, Igf2 (Abu-Amero, Ali et al. 
1998; Sheikh, Satoskar et al. 2001) and Igf1r (Abu-Amero, Ali et al. 1998) gene expression in term 
human placenta of IUGR pregnancies. Other studies have either shown no difference in IGF1R 
(Holmes, Porter et al. 1999) or reduced IGF1R protein expression (Laviola, Perrini et al. 2005) in term 
human placenta of growth restricted fetuses compared with normal. Another study reported that 
placental expression of IGF1R was comparable and InsR Kd values were higher (without an alteration in 
receptor abundance), in preeclamptic women compared to normal (Diaz, Cardenas et al. 2005). 
Inconsistencies between studies may relate to differences in sampling of the placenta or implantation 
site, clinical classification of pregnancies in which the neonate is growth restricted versus one that is 
small for gestational age and whether detecting gene or protein levels. Caution is warranted when 
drawing conclusions from observations at term as they may not necessarily reflect what is going on in 
early pregnancy, when placental development is most extensive and critical for optimal function. 
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1.3.5.1.7   In vitro studies 
1.3.5.1.7.1  IGF-I effects on placenta 
Exogenous IGF-I stimulates proliferation and secretion of hCG and hPL in first trimester villous explants 
(Maruo, Murata et al. 1995; Murata, Maruo et al. 1994) and choriocarcinoma cell lines (Mandl, Haas et 
al. 2002). IGF-I stimulates the proliferation and migration of mouse ectoplacental cone cells (trophoblast 
stem cells) in vitro (Kanai-Azuma, Kanai et al. 1993). Placental fibroblast-derived IGF-I promotes 
trophoblast migration in first trimester human placental villous explants (Lacey, Haigh et al. 2002). This 
is consistent with elevated MMP-9 activity following IGF-I treatment of first trimester trophoblast primary 
cell cultures (Hills, Elder et al. 2004). IGF-I also promotes trophoblast adhesion to fibronectin (Liu, 
Zhang et al. 2005) and subsequent IGF1R-dependent EVT migration through activation of αvβ3-integrin 
(Kabir-Salmani, Shiokawa et al. 2003) and α5β1 (Clemmons and Maile 2003; Kabir-Salmani, Shiokawa 
et al. 2004), assembly of focal adhesions and alterations in cytoskeletal organisation (Kabir-Salmani, 
Shiokawa et al. 2002). Consistent with this, IGF1R number in trophoblast membranes isolated from term 
human placenta has been positively correlated with placental and birth weights (Diaz, Cardenas et al. 
2005).  
 
IGF-I stimulates glucose and amino acid uptake in cultured human placental trophoblasts (Bloxam, Bax 
et al. 1994; Karl 1995; Kniss, Shubert et al. 1994; Yu, Iwashita et al. 1998). In late gestation, IGF-I is 
thought to act as a survival factor for STB, as it inhibits TNFα- and IFNγ-induced apoptosis in 
syncytialised trophoblast cultures from third trimester placenta (Smith, Francis et al. 2002). Additionally, 
in late pregnancy, IGF-I may modulate placental blood flow, as exposure to IGF-I inhibits release of 
vasoconstrictors, such as thromboxane B2 and prostaglandin F2α, in human term placental explants 
(Siler-Khodr and Forman 1993; Siler-Khodr, Forman et al. 1995) and can stimulate the production of 
nitric oxide in vascular endothelial cells (Zeng and Quon 1996). 
 
1.3.5.1.7.2   IGF-II effects on the placenta 
IGF-II stimulates glucose and amino acid uptake in cultured human CTBs (Kniss, Shubert et al. 1994). 
IGF-II stimulates DNA synthesis (Ohlsson, Holmgren et al. 1989) and increases MMP-2 and MMP-9 
activity (Hills, Elder et al. 2004) in first trimester CTB cultures. Furthermore, IGF-II has been reported to 
stimulate EVT cell migration (Irving and Lala 1995; McKinnon, Chakarborty et al. 2000; McKinnon, 
Chakraborty et al. 2001) and invasion independent of IGF1R in vitro (Hamilton, Lysiak et al. 1998) via a 
Gi-coupled receptor (Ikezu, Okamoto et al. 1995; Murayama, Okamoto et al. 1990) and phosphorylation 
of the mitogen activated protein kinases; ERK-1 and ERK-2 (Hamilton, Lysiak et al. 1998). IGF-II also Chapter 1    Introduction 
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promotes murine trophoblast differentiation, by transforming ectoplacental cone cells (trophoblast stem 
cells) into trophoblast giant cells in vitro (Kanai-Azuma, Kanai et al. 1993).  
 
IGF-II may also promote placental angiogenesis during pregnancy. It has been shown that IGF-II, 
secreted by human hepatocellular carcinoma cells, promotes vasculogenesis in a three-dimensional 
angiogenesis assay in vitro as well as in a chicken chorioallantoic membrane assay in vivo (Bae, Lee et 
al. 1998). Indeed, IGF-II induces the expression of vascular endothelial growth factor (VEGF) in human 
hepatoma and keratinocyte cells (Kim, Bae et al. 1998; Kwon, Kwon et al. 2004). It has also been 
reported that IGF-II acts through IGF2R to promote placental angiogenesis and vascular remodelling 
(Herr, Liang et al. 2003). IGF-II may also promote angiogenesis through synergising with epidermal 
growth factor (Lee, Bae et al. 2004) or indirectly through activating the hypoxia response pathway 
and/or promote adaptation to hypoxia, as it increases the expression of hypoxia inducible factor (HIF)-
1α protein and induces Vegf transcription (Feldser, Agani et al. 1999). 
 
1.3.5.1.8  Insulin-Like Growth Factor Binding Proteins (IGFBPs)  
The bioavailability of IGFs, but not insulin, is determined at a cellular level by six specific IGFBPs that 
have equal or higher affinity for IGFs than the IGF receptors. In general, IGFBPs have a greater affinity 
for IGF-II than IGF-I, however, binding capacity and effects of IGFBPs on cell function may be affected 
by IGFBP phosphorylation (Yu, Iwashita et al. 1998) or glycosylation (Hossenlopp, Segovia et al. 1990). 
The six high-affinity IGFBPs share 50% homology with each other and up to 80% homology with the 
corresponding IGFBP from different mammalian species (Kelley, Oh et al. 1996; Rechler 1993). The 
main source of IGFBPs in the circulation is the liver. Each IGFBP has a unique tissue and 
developmental stage-specific pattern of expression, suggesting that they have different, regulated 
functions during development and tissue processes. Depending on the IGFBP, it may be regulated by a 
number of factors, including nutrition, insulin, glucagon, glucocorticoids, cytokines, hormones, hypoxia, 
growth hormone, vitamin D and retinoic acid. 
 
1.3.5.1.8.1  IGFBP functions  
IGFBPs have several functions, including transporting and prolonging the half-life of IGFs in the 
circulation, such that less than 1% of the IGFs in the circulation are present in the free form, which is 
mainly due to the high abundance of plasma IGFBP-3, which on its own, is responsible for binding 75-
80% of the IGFs in the circulation (Jones and Clemmons 1995). IGFBPs regulate the transport of IGFs 
between the intra- and extravascular spaces. For instance, IGFBP-3 and IGFBP-5 circulate as large 
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(Coverley and Baxter 1997), which must be shed in order for IGFs to leave the circulation. IGFBPs are 
also thought to localise IGFs to specific cell types and modulate both IGF binding to receptors and 
growth promoting actions (Clemmons 1993; Clemmons 1998; Clemmons, Busby et al. 1995). Therefore, 
IGFBPs are considered to regulate the endocrine actions of IGFs.  
 
In addition, IGFBPs contain functional domains which enable IGF-independent actions (Figure 1.12). 
For instance, IGFBPs may inhibit or enhance cell growth and induce of apoptosis (Wetterau, Moore et 
al. 1999). These functions have best been described for IGFBP-3 and IGFBP-5, which are known to 
interact with the cell surface expressed type V transforming growth factor-β receptor (TβR-V) (Baxter 
2000; Huang, Ling et al. 2003; Leal, Huang et al. 1999). Furthermore, IGFBP-3 binds and activates 
intracellular signalling via the transforming growth factor receptor type-II and -I heteromeric complex and 
inhibits breast cancer growth (Fanayan, Firth et al. 2002; Fanayan, Firth et al. 2000; Oh, Muller et al. 
1993) and smooth muscle cell proliferation (Kuemmerle, Murthy et al. 2004). Additionally, IGFBP-3 and 
IGFBP-5 can translocate to the nucleus (Schedlich, Le Page et al. 2000), supporting the concept that 
IGFBPs have functions unrelated to direct IGF actions.  
 
Furthermore, studies have provided evidence that IGFBPs can interact with extracellular matrix proteins 
via heparin-binding domains (Figure 1.13) (Arai, Busby et al. 1996; Arai, Parker et al. 1994; Russo, 
Bach et al. 1997; Russo, Schutt et al. 2005)and modulate integrin-induced cell proliferation, migration 
and invasion through the expression of an Arg-Gly-Asp (RGD) motif (Chakraborty, Gleeson et al. 2002; 
Irwin and Giudice 1998; Russo, Schutt et al. 2005; Schutt, Langkamp et al. 2004; Wang, Hu et al. 
2006), both independently of IGF actions (Gleeson, Chakraborty et al. 2001; Irwin and Giudice 1998) 
and by enhancing IGF-II actions in vitro (Hamilton, Lysiak et al. 1998). Due to functional redundancy 
between IGFBPs, identifying and defining the specific effects of each IGFBP has been difficult.  
 
1.3.5.1.8.2  Pregnancy and IGFBPs 
At the feto-maternal interface, IGFBP-1 to IGFBP-6 are predominantly expressed by the decidua during 
human pregnancy, with IGFBP-1 being the most abundant (Hill, Clemmons et al. 1993). Additionally, 
IGFBP-3, IGFBP-4 and IGFBP-5 are also expressed by the chorionic mesoderm (Han and Carter 2000). 
Given IGFBP expression at the feto-maternal interface, IGFBPs may play a significant role in 
modulating IGF actions in the placenta, as well having IGF-independent effects. 
 
In the maternal circulation, the abundance and stability of the IGFBPs change during pregnancy 
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Figure 1.12 Figure depicting the generalised structure of an insulin-like growth 
factor binding protein (IGFBP) and functional domains. 
ALS = acid labile subunit, RGD = Arg-Gly-Asp motif. 
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occurs as a result of post-translational modification and protease activity. Proteases for which IGFBPs 
are substrates include plasmin, serine proteases, matrix metalloproteinases, tissue plasminogen 
activator, thrombin, prostate-specific antigen and pregnancy-associated plasma protein-A (PAPP-A) 
(Gargosky, Pham et al. 1992; Wetterau, Moore et al. 1999). Indeed, proteolysis is thought to account for 
the virtual absence of intact IGFBP-2, IGFBP-3, and IGFBP-4 in the peripheral circulation of the mother 
during pregnancy (Irwin, Suen et al. 2000).  
 
Alterations in the abundance of IGFBPs in the maternal circulation have the potential to affect fetal 
growth, through indirectly altering the bioavailability of IGFs required for essential placental growth and 
function for fetal development. For instance, maternal circulating IGFBP-1 is negatively correlated with 
birth and placental weight (Hills, English et al. 1996) and increased concentrations near term are 
associated with severe pre-eclampsia (Anim-Nyame, Hills et al. 2000; Wang, Lee et al. 1996) and 
intrauterine growth restriction caused by uteroplacental insufficiency (Langford, Blum et al. 1994). 
Furthermore, IGFBP-1 over-expression in mice results in IUGR (Murphy 2000; Murphy, Rajkumar et al. 
1995), which is probably linked to perturbations in placental development by decidual over-expression 
of IGFBP-1, and thus reduced IGF-II actions at the feto-maternal interface, leading to placental 
insufficiency (Crossey, Pillai et al. 2002).  Impaired proteolysis of IGFBPs may be an additional 
mechanism for altering the bioavailability of IGFs during pregnancy. For example, reduced maternal 
circulating PAPP-A concentrations, the IGFBP-4 specific protease in early pregnancy have been 
associated with an increased risk for IUGR (Smith, Stenhouse et al. 2002) and miscarriage (Tong, 
Marjono et al. 2004). 
 
1.3.5.2  Hypoxia  
Hypoxia is known to influence the expression of IGF system components and therefore may play a role 
in the regulation of the IGF system at the fetal-maternal interface during pregnancy.  
 
During early pregnancy, placentation occurs in a physiological but hypoxic environment, as the 
extravillous trophoblasts invading uterine spiral arteries initially form endovascular plugs which occlude 
them and prevent maternal blood from entering the IVS (Burton, Jauniaux et al. 1999; Hamilton and 
Boyd 1960; Harris and Ramsey 1966; Hustin and Schaaps 1987). Direct measurements of oxygen 
tension between 8 to 10 weeks of gestation have shown that the partial pressure of oxygen in the 
placenta (<20mmHg) is significantly lower than in the endometrium (~40mmHg) (Burton, Jauniaux et al. 
1999; Rodesch, Simon et al. 1992). By 12 to 13 weeks of gestation, oxygen tension in the IVS increases 
nearly 3-fold, to >60mmHg, which is not significantly different from the endometrium (Burton, Jauniaux Chapter 1    Introduction 
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et al. 1999; Rodesch, Simon et al. 1992), and is associated with changes in antioxidant enzymes 
(Jauniaux, Watson et al. 2000). This indicates that CTBs have begun to substantially remodel the spiral 
arteries and maternal blood is flowing into the IVS by this time (Jaffe and Woods 1993; Jauniaux, 
Jurkovic et al. 1992; Jauniaux, Watson et al. 2000). Certainly, endovascular trophoblastic plugs 
progressively loosen from ~10 weeks of gestation, exposing the developing placenta to maternal blood 
flow (Burton, Jauniaux et al. 1999; Jauniaux, Greenwold et al. 2003; Rodesch, Simon et al. 1992). 
These studies are consistent with acid-base and respiratory gas values in the fetal circulation and 
placental tissue during the first trimester (Jauniaux, Watson et al. 2001). 
 
This low-oxygen environment in early pregnancy is essential for normal embryonic and placental 
development because the early conceptus has little protection against oxygen-generated free radicals 
(Poranen, Ekblad et al. 1996). Furthermore, studies have shown that early onset of maternal blood flow 
into the IVS is associated with early pregnancy loss (Hustin, Jauniaux et al. 1990; Jauniaux, Greenwold 
et al. 2003; Jauniaux, Zaidi et al. 1994), highlighting the importance of oxygen concentration on 
pregnancy success. In contrast, hypoxic exposure in late gestation due to insufficient invasion and 
remodelling of maternal vasculature can be detrimental and results in an increased risk of pregnancy 
complications, such as preeclampsia, intrauterine growth restriction and stillbirths (Kuzmina, Hubina-
Vakulik et al. 2005).  
 
The exact mechanism by which trophoblasts sense oxygen tension is currently unclear. However, 
several potential pathways have been identified. These pathways often utilize redox-sensitive 
transcription factors, of which the hypoxia inducible factor (HIF) family is the best characterized in 
trophoblasts. 
 
1.3.5.2.1  HIF-1 
The adaptive response to low oxygen or hypoxia is regulated by a common oxygen-sensing pathway 
involving the formation of the hypoxia-inducible factor-1 (HIF-1) protein complex (Wang and Semenza 
1993), although other transcription factors have also been reported to be involved, including NF-κB and 
AP-1 (Faller 1999). HIF-1 is a basic helix-loop-helix PAS transcription factor that binds to a short DNA 
consensus sequence (5’ -RCGTG- 3’) identified in the 5’ flanking regions of hypoxia-induced genes 
called the hypoxia response element (HRE) (Jiang, Rue et al. 1996; Wang and Semenza 1995). HIF-1 
binds to DNA as a heterodimeric complex composed of 2 subunits, HIF-1β, also known as ARNT 
(arylhydrocarbon receptor nuclear transferase, 91-94kDa) and HIF-1α (120-130kDa) (Wang, Jiang et al. Chapter 1    Introduction 
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1995a; Wang and Semenza 1995). Other isoforms of these subunits, ARNT2 (neuronal-specific) and 
ARNT3 (BMAL-1, circadian) and HIF-2α and HIF-3α have been described but their pattern of 
expression is more restricted.  
 
Both HIF subunits are constitutively expressed, although under normoxic conditions it is thought that, 
HIF-1α is rapidly degraded by increased ubiquitination and proteolysis through an interaction that 
appears to involve oxygen-dependent hydroxylation (Ivan, Kondo et al. 2001; Jaakkola, Mole et al. 
2001; Masson, Willam et al. 2001; Yu, White et al. 2001) and interaction with the von Hippel-Lindau 
protein (Maxwell, Wiesener et al. 1999) (Figure 1.13). Under hypoxic conditions, the absence of oxygen 
prevents hydroxylation and therefore degradation of HIF-1α (Huang and Bunn 2003), which then 
translocates from the cytoplasm to the nucleus, where it dimerises with HIF-1β to form the active HIF-1 
complex (Wang, Jiang et al. 1995a; Wang, Jiang et al. 1995b) (Figure 1.13).  
 
HIF-1 recruits transcriptional co-activators that induce expression of more than 20 target genes involved 
in energy metabolism including the glucose transporters Glut-1 (Hayashi, Sakata et al. 2004) and Glut-
3, glycolytic enzymes such as lactate dehydrogenase, pyruvate kinase, tyrosine hydroxylase and genes 
mediating angiogenesis, including Vegf, and apoptosis (Maxwell, Wiesener et al. 1999). Transcription of 
genes encoding IGFBP-1 (Tazuke, Mazure et al. 1998), IGFBP-2, IGFBP-3, IGF-II (Feldser, Agani et al. 
1999; Kim, Bae et al. 1998; Steinbrech, Mehrara et al. 2000; Tucci, Nygard et al. 1998), IGF-I 
(Averbukh, Weiss et al. 1998), uPAR (Graham, Fitzpatrick et al. 1998) and TGF-β3 (Nishi, Nakada et al. 
2004) are also induced by hypoxia in specific cell types. However, there is no data on the effect of 
oxygen concentration on IGF-II expression in the human placenta.   
 
Other stimuli such as growth factors, cytokines and hormones may also be involved in regulating HIF-
1α expression. Indeed, investigations have shown that HIF-1α protein stabilisation, HIF-1 DNA binding 
activity, and transactivation of target genes is induced under normoxic atmospheres by the treatment of 
human embryonic kidney cells or mouse embryonic fibroblasts with insulin, IGF-I and IGF-II (Feldser, 
Agani et al. 1999; Zelzer, Levy et al. 1998). More recently, IGF-I treatment of vascular tumor cells lead 
to the accumulation of HIF-1α and HIF-2α, with subsequent induction of the HIF target gene Vegf, by a 
process dependent on IGF1R (Catrina, Botusan et al. 2006). Further studies performed in human colon 
cancer cells have demonstrated that the effect of IGFs on HIF-1α is a result of enhanced protein 
synthesis via effects on the translational machinery and not inhibition of von Hippel-Lindau-mediated 
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Figure 1.13 Figure illustrating regulation of HIF-1α protein stability. 
Under conditions of normal oxygen availability, HIF-1α is hydroxylated and interacts 
with von Hippel-Lindau proteins (VHL), resulting in ubiquitination and subsequent 
proteolytic degradation in the cell cytoplasm. Under hypoxic conditions, HIF-1α 
cannot be hydroxylated, and thus remains stable and can translocate to the nucleus 
where it dimerises with HIF-1β and then activates the transcription of genes 
containing hypoxia response elements (HRE). 
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As HIF-1 stimulates expression of the Igf2 gene under hypoxia, HIF-1α and IGF-II may be participating 
in an autocrine growth factor loop. Whether this growth factor cooperation exists during early pregnancy 
and orchestrates early placentation is currently unknown. 
 
1.3.5.2.2  Hypoxia and trophoblast 
Oxygen concentration is a major influence on the balance between CTB proliferation and differentiation 
(invasion) during early placentation in humans. Culturing 5-8 week old placental villous explants in a 
hypoxic environment (2% O2; ~14 mmHg) stimulates trophoblast proliferation/outgrowth at tips of 
anchoring villi (Caniggia, Lye et al. 1997; Caniggia, Taylor et al. 1997; Genbacev, Zhou et al. 1997), 
fibronectin synthesis, α5 integrin expression and MMP-2 (Caniggia, Lye et al. 1997; Caniggia, Taylor et 
al. 1997) and FAK (MacPhee, Mostachfi et al. 2001; Seko, Takahashi et al. 1999) activity but inhibits 
upregulation of α1β1 integrins typical of an invasive phenotype (Caniggia, Winter et al. 2000; 
Genbacev, Zhou et al. 1997). However, studies utilising immortalised trophoblast cells obtained from 
explant culture of human first trimester placenta (HRT-8/Svneo) have demonstrated that exposure to 
low oxygen (1% O2) stimulates trophoblast invasion by more than 40% due to reduced TIMP-1 and 
TIMP-2 secretion and increased uPAR expression (and therefore uPA cell surface-associated activity) 
compared with high (20%) oxygen (Canning, Postovit et al. 2001; Graham, Fitzpatrick et al. 1998).  
 
Recent microarray and real time RT-PCR analyses of HTR-8/SVneo to either 20% or 1% oxygen have 
revealed that several genes that encode proteins involved in cell migration like cathepsin and 
protocadherin, angiogenesis, and apoptosis as well as anti-invasive factors including IGFBP-3, laminin, 
collagen, PAI-I, TIMP-3 are upregulated following hypoxia (Koklanaris, Nwachukwu et al. 2006), 
suggesting that a low oxygen environment may “fine-tune” trophoblast function.  
 
Furthermore, hypoxia inhibits syncytial formation in human isolated mononuclear cytotrophoblasts 
(Alsat, Wyplosz et al. 1996), increases cell surface expression of αvβ3 integrin and migration of 
undifferentiated trophoblast cells and B16F0 melanoma cells (Cowden Dahl, Robertson et al. 2005). 
Additionally, hypoxia maintains the rat trophoblast cell line, Rcho-1, in a proliferative state and prevents 
their differentiation into giant cells (Gultice, Selesniemi et al. 2006). Interestingly, in a Rhesus monkey 
study where the abdominal aortic artery was constricted in early second trimester (day 116) to reduce 
uteroplacental blood flow, trophoblast invasion of the uterus and its vasculature by CTBs was increased 
(Zhou, Chiu et al. 1993). 
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Later studies using anti-sense oligonucleotides have demonstrated that the effect of hypoxia on human 
trophoblast function is mediated by HIF-1α (Caniggia 2000). Indeed, both HIF-1α and HIF-2α protein 
are highly expressed by the STB, CTB and fetoplacental vasculature in humans (Nishi, Nakada et al. 
2004; Rajakumar and Conrad 2000; Rajakumar, Doty et al. 2003; Rajakumar, Whitelock et al. 2001), 
consistent with the relative hypoxic environment of the placental intervillous space measured during the 
first trimester of pregnancy. Unexpectedly, hypoxic exposure upregulated the expression of the von 
Hippel-Lindau protein in CTB of first trimester human villous explants in vitro and it is expressed in 
proximal cell columns of human placenta in vivo (Genbacev, Krtolica et al. 2001). This suggests that 
other factors may be involved in the regulation of HIF-1α abundance at the feto-maternal interface.  
 
Later in gestation, studies performed on 10 to 12 weeks old villous explants revealed that relatively high 
oxygen atmospheres (8% and 20%) inhibit CTB proliferation but promote CTB invasion by the increased 
expression of α1 integrin as compared with low oxygen (2%) (Genbacev, Joslin et al. 1996).  
 
From these studies, it appears that there are conflicting data on the role of oxygen in the regulation of 
trophoblast function. One train of thought is that early in the first trimester (prior to 8 weeks) a low 
oxygen environment causes CTBs to proliferate but prevents their differentiation along the invasive 
pathway (Caniggia, Winter et al. 2000; Caniggia and Winter 2002; Genbacev, Zhou et al. 1997). This is 
on the contrary to other researchers, which have demonstrated that low oxygen atmospheres promotes 
trophoblast invasion (Graham, Postovit et al. 2000). This may reflect a difference in the composition of 
culture media used, as the latter investigation supplemented the media with plasminogen, a critical 
mediator of EVT invasion in vivo (Graham, Postovit et al. 2000). 
 
1.3.5.3  Transforming growth factor-β 
In humans, TGFβ is a 25kDa dimeric protein that exists in several isoforms, with TGFβ1 to β3 
expressed in mammals. The TGFβ isoforms share 70-80% structural homology with each other and are 
highly conserved between mammalian species. All three TGFβ isoforms are synthesised at the feto-
maternal interface during the first trimester (Ando, Hirahara et al. 1998; Caniggia, Grisaru-Gravnosky et 
al. 1999; Dungy, Siddiqi et al. 1991) and are believed to be major factors regulating CTB behaviour. 
Although members of the TGFβ gene family are known to have both stimulatory and inhibitory effects 
on cell growth, TGFβ itself is commonly thought to inhibit cell proliferation and invasion (Bischof 2001). 
More research is warranted to determine the specific mechanisms by which TGFβ influences 
placentation and how it is regulated during early pregnancy.   Chapter 1    Introduction 
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1.3.5.3.1  Activation of TGFβ 
TGFβ is secreted in a latent pro-form (LTGFβ) that is complexed with a 110kDa latency-associated 
peptide (LAP) from which biologically active TGFβ is released that can subsequently interact with 
specific cell surface receptors. Studies in human monocytes have revealed that activation of TGF-β1 
involves the binding of LTGF-β1 to the IGF2R (due to M6P residues in LAP) (Dennis and Rifkin 1991; 
Kovacina, Steele-Perkins et al. 1989) (Figure 1.14) which then complexes with the uPAR on the cell 
surface (Godar, Horejsi et al. 1999). The binding of uPA to uPAR allows uPA to cleave plasminogen into 
plasmin. The latter then cleaves the LAP and allows release of TGF-β1. As TGF-β has been shown to 
stimulate the production of the plasminogen activator inhibitor-1 (Fitzpatrick and Graham 1998), it has 
been proposed to regulate its own activity. 
 
1.3.5.3.2  TGFβ receptors 
Active TGFβ binds to the specific cell surface receptors, TGFβ type 1 receptor (TGFβIR), TGFβ type 2 
receptor (TGFβIIR), betaglycan and endoglin (Wrana, Attisano et al. 1994). These are expressed by the  
placenta during pregnancy (Ciarmela, Florio et al. 2003; Mitchell, Fitz-Gibbon et al. 1992; St-Jacques, 
Forte et al. 1994) and the latter two can inhibit trophoblast proliferation and invasion, independent of 
TGF-β (Caniggia, Taylor et al. 1997; Xu, Guimond et al. 2002). TGFβIR and TGFβIIR are serine 
kinases and upon ligand binding, form a heterodimeric receptor complex, which then regulates gene 
expression through the Smad family of proteins.  
 
1.3.5.3.3  TGFβ and trophoblast function 
TGFβ1 and TGFβ2 are synthesised primarily by the decidua and to a lesser extent, the STB and 
extravillous CTBs throughout gestation (Graham, Lysiak et al. 1992; Lysiak, Han et al. 1993; Lysiak, 
Hunt et al. 1995). TGFβ1 is a negative regulator of first trimester CTB cell proliferation (Graham and 
Lala 1992) migration (Irving and Lala 1995) and invasion (Graham and Lala 1991; Graham and Lala 
1992). TGF-β1 is also known to inhibit steroidogenesis in human trophoblasts (Luo, Yu et al. 2002) and 
promotes syncytium formation in isolated first trimester trophoblast primary cultures by increasing 
surface expression of cadherin-11 (Getsios, Chen et al. 1998). Later in pregnancy, TGFβ may play a 
role in promoting placental differentiation, as TGFβ exposure stimulates murine trophoblast stem cell 
line, SM10, differentiation into labyrinthine trophoblast, in vitro (Selesniemi, Reedy et al. 2005). 
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Figure 1.14 Figure demonstrating activation of transforming growth factor 
(TGF)-β1 at the type 2 IGF receptor (IGF2R). 
Latent TGF-β1 bound to IGF2R, can be activated through a simultaneous interaction 
of IGF2R with the urokinase plasminogen activator receptor (uPAR) on the cell 
surface. Urokinase plasminogen activator (uPA) bound to the uPAR, cleaves 
plasminogen into plasmin, which then cleaves the latency associated peptide and 
allows release of active TGF-β1. 
Diagram from Godar et al., 1999, modified by Roberts, CT. 
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TGFβ-1 inhibits trophoblast CTB invasion by inducing the expression of TIMPs and reducing uPA 
activity (Graham and Lala 1991; Khoo, Bechberger et al. 1998). TGFβ-1 also increases the production 
of oncofetal fibronectin, laminin and collagen (Chen, Yang et al. 2005; Feinberg, Kliman et al. 1994) and 
PAI-1 (Graham 1997), up-regulates E-cadherin expression (Karmakar and Das 2004), increases surface 
expression of α1, α5 and αv integrins by first trimester trophoblast and inhibits MMP-9 activation and 
synthesis by CTBs (Meisser, Chardonnens et al. 1999). Interestingly, in vitro studies of murine 
blastocysts demonstrated that TGF-β1 facilitated trophoblast outgrowth through autocrine release of 
parathyroid hormone-related protein (Nowak, Haimovici et al. 1999), indicating that there may be 
differentiation stage and/or species specificity for TGF-β actions. 
 
Like TGF-β1 and TGF-β2, TGF-β3 is known to inhibit the early events of trophoblast differentiation 
along the invasive pathway, however, unlike the other TGF-β isoforms, TGF-β3 is expressed by CTB, 
STB and villous mesenchyme during early placentation (6-8 weeks) and rapidly declines at the end of 
the first trimester (by 9-10 weeks) (Caniggia 2000; Caniggia, Grisaru-Gravnosky et al. 1999). Using 
electrophoretic mobility shift assays, it has been shown that this temporal regulation is mediated by HIF-
1 interacting with a HRE in the Tgfβ3 gene core promoter (Nishi, Nakada et al. 2004). Caniggia and 
associates, have speculated that TGFβ3 mediates the inhibitory effects on CTB differentiation at 5-8 
weeks of gestation (Caniggia 2000).  
 
Recently, the serine proteases, HtrA1 and HtrA3 were demonstrated to inhibit TGF-β signaling by an 
unknown mechanism that required the proteolytic activity of HtrA (Oka, Tsujimoto et al. 2004; Tocharus, 
Tsuchiya et al. 2004). Both HtrA1 and HtrA3 are highly expressed in the human placenta (Nie, Hampton 
et al. 2003), with HtrA3 localized exclusively to the decidua of mice (Nie, Li et al. 2006). Both HtrA 
proteins possess an IGF-binding site and it has been speculated that the IGFs themselves may activate 
this protease family (Zumbrunn and Trueb 1996) as recent reports indicate that HtrA1 binds to, but does 
not cleave, IGF-I in vitro (Tocharus, Tsuchiya et al. 2004). Conversely, TGFβ may in turn regulate IGF-II 
through its regulatory impacts on the abundance of IGFBP-4 protease, PAPP-A (Durham, Riggs et al. 
1994; Ortiz, Chen et al. 2003). Interestingly, TGFβ-1 inhibits IGF-II expression in cultured osteoclasts 
(Gabbitas, Pash et al. 1994). 
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1.4  Conclusion, hypotheses and aims  
Given the pro- and anti-invasive effects of the IGFs and TGF-β on trophoblast function, respectively, as 
well as the abundance of these proteins at the feto-maternal interface, further studies are required to 
determine their interactions as it is likely that together they orchestrate placentation. Indeed, there is 
considerable overlap between the molecules that both the IGFs and TGF-β interact with, including the 
IGF2R. Furthermore, studies suggest that a low oxygen environment is important for early 
cytotrophoblast proliferation and invasion of the maternal decidua. However, later in the first trimester, 
when maternal blood perfuses the placental IVS, an increase in oxygen concentration causes CTBs to 
become less proliferative and more invasive. As Igf2 gene expression is induced by HIF-1 under a 
hypoxic environment in some cells, and IGF-II can stabilise HIF-1α under normoxic conditions, oxygen 
concentration at the feto-maternal interface may also influence the putative IGF and TGF-β interactions.  
 
Further elucidation of the effects and mechanisms of action of maternal IGF-I and IGF-II regulation of 
fetal growth are required. IGFs may affect placental functional development, which can have direct 
impacts on fetal growth by influencing substrate delivery to the fetus. IGFs, however, may also indirectly 
influence fetal growth through modulating maternal adaptation to pregnancy, via synthesis of 




Therefore it is hypothesised that: 
 
1)  CTB expression of IGF-II is induced by a low oxygen environment, which promotes CTB 
proliferation, migration and subsequent invasion by altering CTB gene expression and inhibiting TGF-β1 
activation. 
 
2)  Maternal administration of IGF-I or IGF-II in early pregnancy promotes growth of the placenta with 
increased functional capacity to transfer nutrients to the fetus and therefore enhances fetal development 
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The general aims of this project are: 
 
1)   To determine the effect and interaction of IGF-II with oxygen and TGF-β1 in controlling the balance 
between CTB proliferation and differentiation/invasion during early pregnancy, in vitro.   
 
2i)   To investigate the acute effects of maternal IGF-I or IGF-II treatment during early to mid pregnancy 
on placental transfer capacity, maternal nutrient utilization and fetal growth in mid gestation.  
 
2ii)   To investigate the sustained effects of maternal IGF-I or IGF-II treatment during early to mid 
pregnancy and the contribution of the IGF2R on placental development, maternal body composition and 
fetal growth near term.  
 
2iii)   To investigate the sustained effects of maternal IGF-I or IGF-II treatment during early to mid 
pregnancy and the contribution of the IGF2R on placental transport to the fetus, fetal substrate 
utilization and nutrient partitioning near term.      
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2.1  First trimester human chorionic villous explant culture 
This study was approved by the Human Ethics Committee of the Women’s and Children’s Hospital, 
Adelaide, South Australia and all women gave informed consent. First trimester (7-12 weeks gestation) 
human placenta was obtained immediately following elective terminations of pregnancy by dilatation 
and curettage performed in the Women’s and Children’s Hospital. Gestational age was determined by 
last menstrual period. 
 
2.1.1  Solutions 
2.1.1.1  Villous collection media 
Collection media was prepared the day prior to placental sample collection and stored at 4°C. This 
media consisted of HEPES buffered DMEM/F12 (GIBCO BRL, Grand Island NY, USA) supplemented 
with 10% heat inactivated fetal calf serum (CSL, Australia) and 40 ng/ml gentamycin (GIBCO BRL, 
Grand Island NY, USA). 
 
2.1.1.2  Villous serum-free culture media 
Serum-free culture media was prepared at least 18h prior to sample collection and divided into three 
flasks and equilibrated in either 20% (5% CO2 in 95% air), 1% or 5% oxygen (both in modular 
chambers, 94% or 90% N2 and 5% CO2, respectively) at 37°C. The media consisted of DMEM/F12 
(GIBCO BRL, Grand Island NY, USA), supplemented with 2% Nutridoma NS (filter sterilised, Boehringer 
Mannheim Pty, Australia), 0.04 mM L-glutamine, 20 ng/ml plasminogen and 20 μl/ml antibiotic mix 
(GIBCO BRL, Grand Island NY, USA), comprised of 200μg/ml streptomycin, 0.5 μg/ml amphotericin 
and 200 units/ml penicillin. 
 
2.1.2  Preparation and culture of explants 
Placental villous tissue was washed using sterile cold phosphate buffered saline (PBS, Dulbeccos Mg2+ 
Ca2+ free) to remove blood and decidua and transported on ice to the laboratory in villous collection 
media (refer to 2.1.1.1).  
 
Placental tissue was rinsed and aseptically dissected to remove fetal membranes and any residual 
decidual tissue in serum-free culture media (refer to 2.1.1.2). Placental tissue was then teased and 
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villus with about 4-6 floating branched villi. From each placenta, 48 villous explants were established by 
plating a single villous fragment per culture well of 4 well plates (Becton Dickinson, USA) that had been 
pre-coated for a minimum of 30 minutes at 37°C in a humid incubator with 20 μl of growth factor 
reduced Matrigel (GIBCO BRL, Grand Island NY, USA) diluted 1:1 with serum-free culture media. 
Explants were then assigned to six treatment groups, 20%, 5% or 1% oxygen with or without exogenous 
IGF-II, achieving 8 explants per treatment, per placenta. Plated villous pieces were then covered with 15 
μl of Matrigel, diluted 1:1 with culture media and incubated for at least 25 minutes at 37°C in 5% CO2 in 
air to allow attachment.  
 
200 μl of serum-free culture media that had been equilibrated to 20% (5% CO2 in 95% air), 5% or 1% 
(both in modular chambers, 94% or 90% N2 and 5% CO2, respectively) oxygen for at least 18 hours was 
then added to 16 explants per oxygen concentration and incubated overnight at 37°C in the appropriate 
oxygen environment.  
 
The next morning (~15h), by which time the villous tips had adhered to the bottom of the well, 800 μl of 
the corresponding 20%, 5% or 1% oxygenated culture media  was added per well. IGF-II at a final 
concentration of 125 ng/ml (~17 nmol) (recombinant human IGF-II, GroPep, Australia) or equivalent 
vehicle PBS volume was then added to the appropriate wells. Explants were returned to the same 
oxygen atmospheres and were maintained for 5 days, without changing the media.  
 
On day 6 of culture, villous explants were photographed on a NIKON inverted microscope using an 
Olympus DP12 digital camera, immediately before the culture media was removed and frozen for 
analysis of IGF-II and TGFβ1 protein. Total RNA extraction was performed on the explanted villous 
tissue (see below).  
 
To observe the morphological integrity and growth of the villous explants over the 6 days in culture, 
some explants were photographed daily and were not included in further analyses. Additional villous 
explants were established in wells containing thermanox coverslips beneath the Matrigel (Nunc Brand 
Products, USA) and fresh frozen in OCT following removal of the conditioned media for 
immunohistochemical localisation of proteins. 
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2.1.3  Analysis of villous explant outgrowth morphology 
Digital photos of explants were assessed for villous tip outgrowth by the researcher blinded to treatment. 
EVT cell outgrowth and migration  were quantitated using the ratio  of extravillous cytotrophoblast 
outgrowths/villous tip, where the numerator, EVT outgrowths, represents the number of EVT columns 
sprouting from the villous tips and the denominator represents the total number of villous tips in a single 
explant culture. An arbitrary scale of 0-3 was used to assess both the extent of outgrowth/proliferation at 
the distal end of villous tips and the distance to which cytotrophoblast had detached and migrated away 
from the villous tip and into the surrounding matrix. Additionally, the phenotype of extravillous 
cytotrophoblasts was classified using arbitrary scores of 1 or 3, as being predominantly round or 
dendriform, respectively, with a dendriform score attributed to cells of a migratory phenotype. A score of 
2 was assigned to explants displaying a 50:50 mixture of round and dendriform extravillous 
cytotrophoblasts.  
 
2.1.4  Analysis of villous explant gene expression 
2.1.4.1  Villous explant RNA extraction 
Immediately following the removal of the villous conditioned media, total RNA was isolated from villous 
explants using a Trizol-based approach according to the manufacturer’s protocol for cells grown in a 
monolayer (GIBCO BRL, Grand Island NY, USA).  
 
Briefly, to each villous explant, 300 μl TriZol (GIBCO BRL, Grand Island NY, USA) was added and 
incubated for 5 minutes at room temperature. The undigested villi were removed with forceps, the TriZol 
containing lysed EVTs from 4 wells for each treatment group, were pooled to achieve two tubes 
containing extracted EVT outgrowths. 240 μl of chloroform was added to each pool, shaken for 15 
seconds and incubated at room temperature for 3 minutes. Samples were then centrifuged for 15 
minutes at 12,000 g at 0-4°C to separate the RNA from other cellular components. The top, clear and 
aqueous layer was then discarded. 600 μl of isopropyl alcohol was then added to each tube to 
precipitate the RNA and then incubated for 10 minutes at room temperature. To pellet the RNA, the 
tubes were then centrifuged for 15 minutes at 12,000 g at 0-4°C. The supernatant was removed and the 
pellet was allowed to air dry for 25 minutes before 25 μl of molecular grade water was added to each 
tube and vortexed for 1 minute. RNA was then pooled for each treatment group, allowing one tube of 
RNA in 50 μl to be achieved per treatment, per placenta.  
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2.1.4.2  Determination of RNA quantity and purity 
The quantity and purity of RNA in the sample was determined using a Spectrophotometer (DU-50, 
Beckman Instruments, CA). Samples were considered to be sufficiently pure if the ratio of OD260:OD280 
was > 1.7. The quantity of RNA was then calculated using the following equation:OD260 x 40 x dilution 
factor = RNA μg/ml. Each tube was then frozen at -80°C for subsequent reverse transcription and Real 
Time polymerase chain reaction (PCR). 
 
2.1.4.3  Reverse Transcription  
Reverse transcription was performed in an Applied Biosystems Conventional Thermocycler (Applied 
Biosystems, Warrington, UK). Aliquots of 20μl containing 2 μg of RNA from each sample were reverse 
transcribed. RNA was incubated with 2 μl of random hexamer primers (100 ug/ml; GeneWorks, SA, 
AUS) at 65°C for 10 minutes. Samples were cooled on ice for at least 3 minutes before 18 μl of a 
master mix containing 5x buffer, 100 mM DTTs, 5000 units/μl Expand RTase (all three from Boehringer 
Mannheim Pty, Australia) 10 mM Ultrapure dNTPs (Amersham Pharmacia Biotech, New Jersey, USA) 
was added per sample. Samples were allowed to stand on ice for 3 minutes before they were incubated 
for 10 minutes at 30°C, followed by 45 minutes at 42°C and then for 2 minutes at 95°C. The samples 
were then cooled on ice and the cDNA was stored at -20°C. 
 
2.1.4.4  Primer Design 
Using Primer Express 2.0 software (Applied Biosystems, CA) and Genbank DNA and mRNA 
sequences, oligonucleotide primers for human Igf2, Igf1r, Igf2r, Tgfβ1, Upar were designed within the 
mature peptide region (Table 2.1). Where possible, primers were designed such that the generated 
amplicon overlapped an exon-intron boundary. Standard desalted purity primers were constructed by 
Sigma Genosys (Sigma Genosys, AUS). 
 
2.1.4.5  Real Time Polymerase Chain Reaction (PCR) 
Quantitative PCR was performed in real-time, on an Applied Biosystems 5700 Real Time Thermocycler 
(GeneAmp 5700, Applied Biosystems, Warrington, UK). The PCR reaction mix consisted of 10 μl 1x 
SYBR gene PCR master mix (Applied Biosystems, Warrington, UK), 2 μl cDNA template, 1 μl of each 
forward and reverse primer and 6 μl molecular grade water. The PCR cycle conditions were one cycle 
of 50°C for 2 minutes and 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute. Each sample was analysed in duplicate and plates were set up such that representatives for  
 Chapter 2    Materials and Methods 
Amanda N Sferruzzi-Perri  59 
Table 2.1 Primer sequences designed for Real Time PCR 
Gene Nucleotide 
position 


































Both forward (fwd) and reverse (rev) primers are shown, with amplicon size denoted in base pairs (bp). Chapter 2    Materials and Methods 
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each treatment per placenta were run on each plate. To reduce inter-assay variation, the house keeping 
gene, 18s was run for each sample on the same plate as the gene of interest. 
 
2.1.4.6  Detection of PCR products 
The PCR products were separated by size using gel electrophoresis. PCR products (20 μl) containing 4 
μl of 6x loading buffer were run on a 2% agarose gel (Promega, WI, USA) containing ethidium bromide 
(final concentration of 0.5 mg/ml, Sigma, MO, USA) for 45 minutes at 85 V. pUC19 (GeneWorks, SA, 
AUS) was used as a size marker. The gel was visualised over a UV light box (UVP, San Gabriel, CA, 
USA) to detect bands of PCR products and photographed using a digital camera (DC120, Kodak, 
Eastman, Rochester, USA). 
 
2.1.4.7  Quantification of mRNA levels 
Fluorescence was measured at the end of each cycle, and after 40 cycles, a profile of fluorescence 
versus cycle number was obtained. A fluorescence threshold of 0.14 was set, which lay in the 
exponential phase of amplification. The cycle number at which the amplification of the product crossed 
this threshold was determined and designated as the cycle threshold (Ct). The quantity of amplified 
PCR product was determined by normalising the expression of the gene of interest to the house 
keeping gene,18s, and then expressing it relative to a calibrator using the 2-ΔΔCt formula as described in 
the ABI Prism 5700 User Bulletin (Liu and Saint 2002a; Liu and Saint 2002b). The mean of the 20% 
oxygen without exogenous IGF-II treatment group was designated as the calibrator and was assigned 
an expression level of 100%. 18s did not significantly vary across the six treatments studied. The 
efficiency of each PCR reaction was determined by regression analysis of the sample’s fluorescence at 
each cycle and all reactions occurred at a minimum of 73% efficiency.  
 
2.1.4.8  Optimisation of Real Time PCR reactions 
The optimum concentration of primers were initially determined in preliminary experiments with serial 
dilutions of primer pairs and a quality control uncultured first trimester human villous cDNA sample. The 
lowest primer concentration at which the threshold cycle (CT) of the sample was most different to the CT 
of the non-template control (noise) was selected.  
 
The optimum cDNA dilution for each primer pair was initially determined in preliminary experiments with 
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different to the CT of the non-template control was selected. It was determined that a 1 in 5 dilution was 
required for quantitative analysis of 18s, whereas neat cDNA was used for analysis of all other genes. 
 
The absence of primer dimers and alternative PCR products in the PCR product was revealed by a 
single dissociation peak and confirmed by PCR product visualisation on 2% agarose gels (Promega, WI, 
USA) containing ethidium bromide (final concentration of 0.5 mg/ml, Sigma, MO, USA) for 45 minutes at 
85 V. 
 
2.1.5  Localization of protein in villous explants 
To localise cytokeratin-7 and IGF-II proteins, villous explants grown for 6 days on Matrigel-coated 
thermanox coverslips were fresh frozen in OCT (Tissue-Tek; Sakura, USA) and snap frozen in 
isopentane cooled by liquid nitrogen. Serial 5 μm sections were cut and mounted on silane-coated 
slides (3-aminopropyltriethysilane, Sigma, Australia) and a three-step immunohistochemistry technique 
was employed.  
 
Briefly, sections were fixed in 96% ethanol and washed three times in PBS (Dulbeccos Mg2+ Ca2+ free) 
for 5 minutes. The sections were then incubated for 10 minutes at room temperature with serum-free 
protein block (Dako, Australia) before overnight incubation at 4°C with primary antibody, mouse anti-
human cytokeratin-7 (1:500 dilution in PBS containing 1% BSA and 10% normal human serum, Clone 
OV-TL 12/30, Dako, Australia) or goat anti-human IGF-II (1:50 dilution in PBS containing 10% serum-
free Dako protein block R and D Systems, MN, USA).   
 
The following day, the sections were rinsed in Milli-Q water and washed three times in PBS. Bound 
primary antibody was localised using a biotinylated rabbit anti mouse IgG F(ab’)2 fragment (Dako, 
Australia) or rabbit anti-goat IgG F(ab’)2 fragment (Dako, Australia), for immuno-localisation of 
cytokeratin-7 or IGF-II, respectively. Sections were incubated for 45 minutes at 4°C. The sections were 
then rinsed in milli-Q water and washed three times in PBS and a streptavidin-horseradish peroxidase 
(Rockland, USA) was applied for 30 minutes at 4°C. After the sections were washed as described 
above, the site where the antibodies bound was visualised using diaminobenzidine (Sigma, Australia; 5 
mg/ml in 0.05 M Tris-HCl, pH 7.2) plus 0.02% hydrogen peroxide for 10 minutes at room temperature 
and before light counterstaining in haematoxylin.  Negative controls were incubated with the primary 
antibody diluent on its own. Immuno-histochemical staining was captured using a digital camera under 
an Olympus DP10 camera with an Olympus BX-2 microscope. Chapter 2    Materials and Methods 
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2.1.6  Analysis of villous explant protein secretion by Enzyme-linked Immunosorbant 
Assay  
2.1.6.1  TGF-β1 protein  
Villous-conditioned media were assayed for active and total TGF-β1 protein using a Human Quantikine 
TGF-β1 enzyme-linked immunosorbant assay (ELISA) (R and D Systems, MN, USA), following the 
manufacturer’s instructions. Samples were run in duplicate and media blanks were run on each plate. 
The concentration of total and active TGF-β1 protein present in the media used to culture the villous 
explants was ~16.5 pg/ml and undetectable, respectively, with the minimum detectable concentration of 
TGF-β1 is < 7 pg/ml. Media blanks were subtracted from the unknown samples and TGF-β1 active and 
total protein concentrations were determined using a four-parameter logistic regression curve. The 
mean coefficient of variation for each assay was 2.66%.  
 
2.1.6.2  IGF-II protein 
Villous-conditioned media were assayed for IGF-II protein using the Active IGF-II ELISA (Diagnostic 
Systems Laboratories Inc, Texas, USA) following the manufacturer’s instructions. This ELISA kit 
incorporated an acid-ethanol extraction step to dissociate the IGF-II protein from any binding proteins. 
Samples were run in duplicate and media blanks were run on each plate. The concentration of IGF-II 
protein present in the media without exogenous IGF-II was less than the minimum detectable 
concentration of IGF-II for the assay, which was 24 ng/ml. IGF-II protein concentrations were 
determined from a standard curve. The mean coefficient of variation for each ELISA was 6.1%.  
2.1.7  Statistics 
Data generated from morphological studies were assessed using a linear mixed model repeated 
measures ANOVA with Sidak Post Hoc Tests with the placenta as a subject and each well of a 
particular treatment, as the repeated measure. ELISA data were analysed by a multi-variate ANOVA 
with Bonferoni Post Hoc Test (SPSS Software, Chicago). Data generated from Real Time PCR 
analyses were normalised by ranking ΔCts and compared for each gene using Kruskall Wallis followed 
by Mann-Whitney U Tests. Pearson’s bi-variate correlation analysis was used for associating gene and 
protein expression with villous explant morphology. Differences between treatments or correlations 
considered to be significant were when P < 0.05.   Chapter 2    Materials and Methods 
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2.2  Animals and treatments 
This study was approved by the University of Adelaide, Animal Ethics Committee. Virgin guinea pigs 
(IMVS coloured strain, ~500g, 3-4 months old) were purchased from the Gilles Plains breeding facility 
and housed individually in the University of Adelaide Medical School Animal House in a room with 12 : 
12 h light : dark cycle. Guinea pigs were provided with food (Milling Industries Stockfeeds, Murray 
Bridge, SA, Australia) and water supplemented with vitamin C (400mg/L) ad libitum.  
 
2.2.1  Matings 
Females were examined daily for oestrus, indicated by a ruptured vaginal membrane (complete 
oestrous cycle lasts ~15 days), and mated naturally with a male. The day a copulatory plug was 
observed or in the absence of a plug, the day after females were housed with males, was designated as 
day 1 of pregnancy. From 2 weeks prior to mating, body weight was monitored three times weekly. At 
mating, females were assigned to one of three treatment groups of similar mean weight (~650 g). 
Animals were handled in accordance with University of Adelaide Animal Ethics Committee.  
2.2.2  Surgery 
Surgery was performed on female guinea pigs twice, first to insert mini osmotic pumps and secondly to 
catheterise the carotid artery and jugular vein. All instruments utilised in surgical procedures were 
sterilised prior to use by washing in water treated with pyroneg detergent, sonication and then 
autoclaving or soaking them in 70% ethanol (v/v). All instruments were immersed in chlorhexidine (75% 
methanol, 10% chlorhexidine (Chlorhex C, Jurox, Australia) and 15% Milli-Q) during the surgical 
procedure to maintain sterility. All drapes, cotton gauze, sutures and cotton tips were packaged and 
autoclaved for use on the day. Animals were anaesthetised with atropine sulphate (0.05 mg/kg, sc; 
Apex Laboratories, Australia), xylazine hydrochloride (4 mg/kg, im, Troy Laboratories, Australia), 
ketamine hydrochloride (25 mg/kg, ip; Troy Laboratories, Australia) and locally with lignocaine 
hydrochloride (Troy Laboratories, Australia), unless otherwise stated. The area where the incision was 
to be made (see below) was shaved free of hair and then wiped clean with swabs soaked in Betadine 
(AnalaR, Australia), 70% ethanol and Betadine, again. After a surgical procedure, guinea pigs were kept 
warm at 37°C during recovery. Mothers were killed, following an over-night fast, by overdose of sodium 
pentobarbitone (Lethobarb; Virbac, Australia) on day 35 or day 62 of pregnancy (term ~70 days). 
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2.2.2.1  Minipump insertion 
On day 20 of pregnancy, females were anaesthetised and a small horizontal incision was made in the 
skin, mid-way down the animal’s back and slightly off-centre to expose the muscle layer. With a small 
artery clamp inserted into the incision with the curve faced down, a vertical pocket that reached up 
between the shoulder blades was made by gently opening and closing the clamp. An osmotic minipump 
(Alzet 2002, Alzet, California) was then inserted into the pocket and positioned away from the incision. 
Osmotic minipumps had previously been prepared to deliver vehicle (0.1M acetic acid) or 1mg/kg/day 
IGF-II, Leu27-IGF-II or IGF-I (human recombinant protein, GroPep Pty Ltd., Australia) for 18 days at a 
flow rate of 0.51 μl/h. The mean fill volume of the osmotic minipumps in this experiment was 233 μl 
(221 μl  when accounting for 5% residual volume), which means that 632 μg of IGF-I or IGF-II per day 
was delivered based on weight at mating. The surgical incision was then closed using 9 mm wound clips 
(Becton Dickinson, USA).  
 
2.2.2.2  Catheterization 
Mothers that were scheduled to be killed on day 62 of pregnancy were catherised two days prior to 
post-mortem. Animals were anaesthetised according to weight on day 20 of pregnancy, as described 
above (refer to 2.2.2), however with larger doses of xylazine hydrochloride (6 mg/kg, im, Troy 
Laboratories, Australia) and ketamine hydrochloride (75 mg/kg, ip; Troy Laboratories, Australia). An 
incision of 1-2 cm was made mid way between the head and sternum, to the left of the trachea on the 
ventral side of the neck. The external jugular vein and common carotid artery were located and vascular 
catheters were inserted. Catheters were fastened to the vessels and then to the inside of the neck using 
silk suture (Dysilk black braid 3/0, Dynek, Australia). Catheters were then passed through to the back of 
the neck and exteriorised through the skin and animals allowed to recover. Catheters were flushed twice 
daily with 250 U/ml sterile heparinised physiological saline to maintain patency. 
 
2.2.3  Radioactive analogue administration and post-mortem 
On day 35 or 62 of pregnancy (term ~70 days) following an overnight fast, guinea pigs were 
administered a mixture of [3H]-methyl-D-glucose (MG) and methyl [14C]-amino-isobutyric acid (AIB) 
(both from Amersham, UK) in physiological saline in a single bolus via catheter. To each dam, we aimed 
to treat with 100 μCi / kg of MG and 10 μCi / kg of AIB, but determined the precise dose actually 
administered by weighing syringes containing each isotope before and after the preparation of the 
isotopic mixture. The total administered volume of the isotope mixture was 500 μl for each animal.  
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Maternal blood was collected in heparinized tubes 20 minutes following radioactive analogue 
administration and a final 10-20 ml blood sample was taken before animals were then killed by overdose 
of sodium pentobarbitone (Lethobarb; Virbac, Australia). This chosen 20 minute time-point was based 
on a previous, similar study assessing placental AIB and MG transport and blood flow, in the 
unstressed, awake pregnant guinea pig (Jansson and Persson 1990), where substrate analogues were 
detected in the fetus and placenta 25 minutes following administration to the mother. In animals killed 
on day 62 with patent catheters, blood was sampled (1 ml) every 2 minutes following radioactive 
analogue administration, with the catheter flushed with 1ml of heparinised saline, at each time point.  
 
Viable and resorbing implantation sites were enumerated and the uterus and its contents, viable fetuses 
and placentae were weighed. A 3 mm mid-sagittal placental slice was fixed in paraformaldehyde (PFA, 
4% paraformaldehyde / 2.5% polyvinylpyrolidone-40 in 70 mM PBS (Dulbeccos Mg2+ Ca2+ free)) for 
histology and morphology to estimate structural correlates of placental function. Remaining halves of 
placental tissues were snap frozen for measurement of AIB and MG content (see below) and RNA or 
protein analyses (not performed for the present thesis). In fetuses of mothers killed on day 62, fetal 
biparietal diameter, abdominal circumference and crown to rump length were measured and whole 
blood samples were collected by cardiac puncture in heparinized tubes.  
 
The following tissues of the mother and all fetuses from day 62 of pregnancy were then excised and 
weighed to determine the absolute and relative weights of adrenals, kidneys, pancreas, liver, spleen, 
heart, brain, lungs, gastrointestinal tract, reproductive tract, biceps, triceps, gastrocnemius and soleus 
muscles and retroperitoneal, perirenal and interscapular adipose tissues. Skin and carcass weights of 
the dams and carcass weights of the fetuses were also recorded. Those tissues printed in italics were 
snap frozen in liquid nitrogen and stored at -80°C for determination of MG and AIB content. Fetal and 
maternal whole blood samples were centrifuged at 2,500 rpm for 15 min at 4°C to recover plasma, 
which was stored at -20°C.  
 
2.2.4  Analysis of circulating metabolites and hormones 
2.2.4.1  Assay of plasma glucose 
The quantitative determination of plasma glucose was performed with a COBAS MIRA automated 
sample system using the Glucose HK assay kit, with the C.f.a.s Calibrator, and quality controls: 
Precinorm U and Precipath U (Roche Diagnostics, Australia). This was performed in a single assay with 
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2.2.4.2  Assay of plasma free fatty acids 
The quantitative determination of plasma free fatty acids was performed with a COBAS MIRA 
automated sample system using the WAKO NEFA-C Free Fatty Acid Kit assay kit (NovoChem, 
Australia), with the Quality controls QCS-1 and 2 (Biorad, Australia). This was performed in a single 
assay with the intra-assay coefficient of variation < 1%. 
 
2.2.4.3  Assay of plasma cholesterol 
The quantitative determination of plasma cholesterol was performed with a COBAS MIRA automated 
sample system using the Cholesterol CHOD-PAP assay kit, with the C.f.a.s Calibrator and quality 
controls: Precinorm U and Precipath U (Roche Diagnostics, Australia). This was performed in a single 
assay with the intra-assay coefficient of variation < 1%. 
 
2.2.4.4  Assay of plasma triglycerides 
The quantitative determination of plasma triglycerides was performed with a COBAS MIRA automated 
sample system using the triglycerides assay kit, with the C.f.a.s Calibrator and quality controls: 
Precinorm U and Precipath U (Roche Diagnostics, Australia). This was performed in a single assay with 
the intra-assay coefficient of variation < 1%. 
 
2.2.4.5  Assay of plasma α-amino nitrogen  
Plasma α-amino nitrogen concentration was determined using a previously reported method (Evans, 
Ffolliott-Powell et al. 1993). Plasma samples (100 μl) were deproteinised by adding 800 μl of 0.04M 
H2SO4 and 100 μl of 0.3M sodium tungstate and centrifuged for 15 minutes at 3000 rpm at 4°C. The 
supernatant was removed and pipetted in triplicate into 96 well ELISA plates. 24 μl of sodium 
tetraborate (saturated, pH = 9.6) and 20 μl 0.02 M β- naphthoquinone sulfonate (Sigma, Australia) were 
added to each well, and then plates were placed in a dry oven for 20 minutes at 80°C followed by 5 
minutes in a -20°C freezer. 120 μl of Milli-Q water, 36 μl of acid formaldehyde (0.045M formaldehyde / 
0.6M HCl) and 20 μl 0.05M sodium thiosulphate were added per well and the plates were incubated at 
room temperature for 30 minutes. The plates were read with a dual wavelength ELISA plate reader at 
490 nm and 660 nm. Six standards were prepared with concentrations ranging from 1mM to 0.1mM 
glycine. This was performed in a single assay with the intra-assay coefficient of variation < 8%. 
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2.2.4.6  Assay of maternal plasma hormones 
Maternal plasma estradiol (Ultra-Sensitive Estradiol, DSL) and progesterone concentrations 
(Progesterone assay kit, DSL) were quantified with radioimmunoassay kits. These assays were 
performed by Mr Alan Gilmore (Repromed, Adelaide, Australia) and Mr Fred Amato (Department of 
Obstetrics and Gynaecology, University of Adelaide). This was performed in a single assay with the 
intra-assay coefficient of variation < 3%. 
 
2.2.5  Measurement of maternal circulating IGF-I, IGF-II and total IGFBP 
2.2.5.1  HPLC separation of plasma IGF-I and IGF-II from IGFBP  
This method was performed as previously described (Owens, Kind et al. 1994; Owens, Johnson et al. 
1990). Plasma recovered (90 μl) from mothers killed on day 35 of pregnancy (vehicle, n = 5; IGF-I, n = 
5; IGF-II, n = 3) was acidified with 150 μl of 4x mobile phase (800 mM glacial acetic acid, 200 nM 
trimethylamine, 400 mM hydrochloric acid and 0.05% (w/v) Tween-20, pH of 2.8, filtered using a 0.2μM 
GV Millipore filter and degassed) and 360 μl of Milli-Q was added to make a final volume of 600 μl. 
Samples were vortexed and then incubated at room temperature for 30 minutes.  
 
To de-lipidate the sample, an equal volume (600 μl) of freon (1,1,2-trichloro-1,2,2-trifluoroethane) was 
added and centrifuged for 10 minutes at 10,000 rpm. The upper, aqueous phase was removed and 
filtered by centrifugation for 3 minutes at 10,000 rpm through a microfilter containing a 0.45 μm 
cellulose acetate filter membrane (Alltech Associates Inc., Australia). 300 μl of filtered sample was 
loaded into HPLC injection vials, of which 150 μl was injected onto a Protein-Pak 125 HPLC exclusion 
column (Waters/Millipore, Australia) using an automatic injector (ICI AS 2000, ICI Instruments, 
Australia). Samples were eluted at 1 ml/min in 1x mobile phase. 
 
To establish where IGFs were eluting under these conditions, 36 fractions of 0.5 ml were collected 
(pooled guinea pig plasma) and each fraction was subjected to IGF-I and IGF-II RIA. The IGFBPs eluted 
between 0.5 and 2.5 minutes and free IGFs eluted between 3 and 5.5 minutes. On the basis of this 
elution profile, chromatogram fractions were collected at these times and subjected to RIA. The first 
fraction contained IGFBPs and the third fraction contained the purified IGFs.  
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2.2.5.2  RIA detection of IGFs 
Recombinant human IGF-I and IGF-II (GroPep Pty. Ltd, Adelaide, Australia) were used as standards 
and for preparation of radiolabelled ligands. Ten serial 1:2 standards were prepared with concentrations 
ranging from 2000 pg/tube to 3.91 pg/tube. 100 μl of each sample (HPLC fraction 3) was assayed in 
triplicate in polystrene tubes, to which 200 μl of RIA buffer was added (30mM Na2PO4, 0.02% (w/v) 
protamine sulphate, 10mM disodium EDTA, 0.05% (w/v) Tween-20 and containing 0.02% (w/v) NaH3, 
pH of 7.5). 100μl of 1x mobile phase was added to standard tubes and 60 μl or 30 μl of 0.4M Tris Base 
was added to each tube of the IGF-I or IGF-II assays, respectively, to neutralise to pH 7.4. 50 μl of anti-
IGF antibody and 50 μl radio-iodinated human IGF (20,000 cpm) were also added to every tube. IGF-I 
was measured by RIA using rabbit anti-human IGF-I antiserum (MAC Ab 89/1, GroPep Pty, Ltd, 
Adelaide) at a final dilution of 1/60,000 and a monoclonal mouse anti-rat IGF-II antibody (kind gift from 
Dr K Nishikawa, Kanaza Medical University, Ishakawa, Japan) was used at a final concentration of 
1/500 to measure IGF-II by RIA. Tubes were briefly vortexed and incubated for 18-20 hours at 4°C. As a 
measurement of total radioactivity (TC), three tubes that contained only radio-iodinated human-IGF 
were included in the assay. Additionally, three blank tubes were prepared containing RIA buffer and 
human-IGF. To serve as a positive control, a reference sample of known IGF concentration was run.  
 
For the IGF-I assay, 50 μl of sheep anti-rabbit IgG (Silenus, Australia), diluted 1/20 in RIA buffer and 10 
μl of rabbit IgG (Dako, Australia), also diluted 1/20 in RIA buffer, were added to each tube. For the IGF-
II assay, 50 μl of sheep anti-mouse IgG (Silenus, Australia), diluted 1/20 in RIA buffer and 10 μl of 
mouse IgG (Dako, Australia), also diluted 1/20 in RIA buffer, were added to each tube. Tubes were 
vortexed and incubated at room temperature for 30 minutes. 1 ml of ice-cold polyethylene glycol (6% 
(w/v) polyethylene glycol 6000 in 0.9% (w/v) NaCl) was added to all tubes expect TC, vortexed and then 
centrifuged for 20 minutes at 4000 rpm, at 4°C (J-6B Beckman Instruments, USA). The supernatant was 
carefully aspirated and the pellet was counted for 125I using a gamma scintillation counter (1261 
Multigamma, LKB Pharmacia and Wallace, Sweden). 
 
Cross-reactivity of IGF-II in the IGF-I RIA was less than 1% (Francis, McNeil et al. 1989; Francis, Owens 
et al. 1989) and that of IGF-I in the IGF-II RIA was less than 2.5% (Carr, Owens et al. 1995). Both IGF-I 
and IGF-II amino acid sequences are remarkably conserved across species. Guinea pig IGF-I and IGF-
II have previously been shown to have 100% amino acid sequence identity to those of human (Bell, 
Stempien et al. 1990; Levinovitz, Norstedt et al. 1992), while guinea pig IGF-II has only one amino acid 
different to that of the rat (Ekstrom, Backlin et al. 1993). We have previously reported that the recoveries Chapter 2    Materials and Methods 
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of IGF-I and IGF-II are >95% for these assays (Sohlstrom, Katsman et al. 1998a). The minimal 
detectable concentrations of IGF-I and IGF-II were 6.64 ng/ml and 9.48 ng/ml, respectively. The 
samples were analysed in a single RIA, where the mean intra-assay coefficients of variation were 3.7% 
and 5.6% for IGF-I and IGF-II RIAs, respectively. 
 
2.2.5.3  Measurement of IGFBP fraction 
The total IGFBP binding capacity in the maternal circulation was indirectly measured as the interference 
of the IGFBPs in fraction 1 in the IGF-I RIA (refer to 2.2.5.2), which has been previously described 
(Francis, McNeil et al. 1989; Francis, Owens et al. 1989; Owens, Johnson et al. 1990). A lower cpm 
value is indicative of increased unbound IGF present in the plasma, therefore the higher the cpm, the 
greater amount of IGFBP is present in the sample to bind to the radio-iodinated IGF-I. The ratio of IGFs 
to IGFBPs provided an index of IGF bioavailability in the maternal circulation. 
 
2.2.6  Western ligand blots 
Individual IGF binding proteins in samples of pooled maternal plasma recovered from vehicle, IGF-I and 
IGF-II treated animals killed on day 35 or day 62 of pregnancy, were identified by Western ligand 
blotting. Samples were prepared by incubating 20 μl of plasma with 130 μl of Milli-Q water and 50 μl of 
4x sodium dodecyl sulfate (SDS) at 65°C for 20 minutes. Prepared samples (20 μl, loaded with a 100 μl 
Hamilton syringe) were then subjected to non-reducing discontinuous sodium dodecyl sulfate-
polyacrylamide gel electrophoresis on a 4% stacking gel and a 12% polyacrylamide separating gel, for 
90 minutes at 20 mA (500 V) followed by overnight at 8 mA. Molecular masses of IGFBP bands were 
calculated from 14C-labeled "rainbow" molecular-weight markers (GE Healthcare, formerly Amersham 
Biosciences, Australia), which were incubated with 10 μl Milli-Q water and 20 μl 4x SDS, at 65°C for 20 
minutes, prior to separation by gel electrophoresis. 
 
Separated proteins were then transferred onto a nitrocellulose membrane at 250 mA for 1 hour (2 gels), 
which were dried overnight. The following day, nitrocellulose membranes were washed in 1% Triton (1% 
Triton X in 2M NaCl / 0.5M Tris base buffer) for a maximum of 30 minutes and blocked with 1% bovine 
serum albumin (BSA, RIA grade, Sigma, Australia) (1% BSA in 2M NaCl / 0.5M Tris base buffer), for 90 
minutes. Membranes were washed in 0.1% Tween (1% Tween 20 in 2M NaCl / 0.5M Tris based buffer) 
for 10 minutes at room temperature with shaking. Nitrocellulose membranes were then probed with 
radio-iodinated human IGF-II (10,000,000 cpm in 1% BSA used for blocking membranes) for 2 hours 
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changes of fresh 0.1% Tween, for 30 minutes each. Nitrocellulose membranes were dried overnight and 
then exposed to X-ray film for 2-4 weeks at -80°C, before developing.  
 
2.2.7  Placental Histology using Masson’s Trichrome Stain 
2.2.7.1  Procedure 
Placental tissue fixed overnight in 4% PFA (refer to 2.2.3) was washed four times in PBS (Dulbeccos 
Mg2+ Ca2+ free) over three days and stored in 70% ethanol at 4°C. Tissues were dehydrated through a 
series of ethanol washes of increasing concentration and de-waxed in two changes of xylene before 
immersion into paraffin wax at 55°C under a vacuum. Tissues were embedded in paraffin and then 5 
μm mid-sagittal sections were cut using a Leica rotary microtome (Leica Mircosystems, USA) and 
placed on silane-coated slides (3-aminopropyltriethysilane, Sigma, Australia). For staining, mid-sagittal 
slices of paraffin embedded placentae were dewaxed using two Safsolvent (Ajax APS Chemicals, 
Australia) treatments of 5 minutes each, rehydrated gradually through ethanol washes to water and then 
placed in PBS. Sections were then stained with Masson’s Trichrome (Drury and Wallington 1980). From 
each dam, 1-3 placentae were randomly selected for histological assessment.  
 
Briefly, sections were stained in Weigert’s Haematoxylin for 15 minutes. Sections were then washed in 
running tap water for 10 minutes, differentiated in 0.5% hydrochloric acid in 70% ethanol and then 
rinsed in tap water. Sections were then stained in red cytoplasmic stain (1% ponceau de xylidine, 1% 
acid fuschin, in 1% acetic acid) for 2 minutes and rinsed in two washes of Milli-Q water. This stain was 
then differentiated in 1% of phosphomolybdic acid (Sigma, Australia) for 1 minute and rinsed in Milli-Q. 
Sections were then stained with methyl blue (1% methyl blue in 1% acetic acid) for 3 minutes and 
washed twice in 1% (v/v) acetic acid in Milli-Q. Using Whatman filter paper, sections were blotted dry 
and then dehydrated through three changes of absolute ethanol and cleared in three changes of 
Safsolvent (Ajax Fine Chemicals, Australia) before mounting in DPX (Ajax Chemicals, Australia) with a 
glass coverslip.  
 
2.2.7.2  Video Image Analysis 
The mid-sagittal cross-sectional areas of the placental interlobium (germinative region) and labyrinth 
(exchange region) were measured in complete mid-sagittal sections using an Olympus BH-2 
microscope with 2x objective and 3.3x ocular lenses and video image analysis software (Video Pro, 
Leading Edge, Adelaide) by the researcher blinded to treatment. The video image was calibrated to 
micrometers using a hemocytometer, allowing direct measurements to be made (Neubauer Bright Line, Chapter 2    Materials and Methods 
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Germany). The proportion (%) of each region in the placenta was then estimated by dividing the cross-
sectional area of that region by the total mid-sagittal cross-sectional area of the placenta. An estimate of 
the volume of these regions was then calculated by multiplying their proportion by total placental weight. 
 
2.2.8  Structure of the placental exchange region (labyrinth) 
2.2.8.1  Procedure 
To distinguish cell types within the placental labyrinth, mid-sagittal sections of placenta were double-
labelled with mouse antibodies to human vimentin (3B4, Dako, Denmark) and human pan cytokeratin 
(C2562, Sigma, USA) to identify fetal capillaries and trophoblast, respectively, and then stained with 
eosin to aid the identification of maternal blood spaces. This employed a triple layer technique for each 
antibody, performed sequentially.  
 
Sections were deparaffinized and brought to PBS as previously described (refer to 2.2.7.1). 
Deparaffinised sections underwent antigen retrieval by incubation at 37°C for 15 minutes in 0.03% 
protease (Sigma, USA). Following three 5 minute washes in PBS, endogenous peroxidase activity was 
quenched by incubating sections with 3% hydrogen peroxide in water for 30 minutes at room 
temperature. Sections were then washed in three changes of PBS for 5 minutes each and blocked for 
non-specific binding with serum-free protein block (Dako, Denmark) for 10 minutes. Without washing off 
the protein block, 3B4 antibody diluted 1:50 with 10% normal guinea pig serum and 1% BSA (made 
fresh w/v in PBS) was applied first and incubated overnight (~18 hours) in a humidified chamber at room 
temperature.  
 
The following day, sections were washed as above, and biotinylated goat anti-mouse IgG secondary 
antibody (Dako, Denmark) was applied for 30 minutes, followed by washing to remove unbound 
secondary antibody. Streptavidin conjugated to horseradish-peroxidase (Rockland Immunochemicals, 
USA) was applied for 40 minutes, then sections were washed as above. 3B4 binding was visualized by 
incubating with 3,3-diaminobenzidine peroxidase substrate and urea hydrogen peroxide tablets 
dissolved in Milli-Q (Sigma FastTM; Sigma, Australia) with 2% (w/v) ammonium nickel (II) sulfate (Sigma, 
USA) to form a black precipitate.  
 
The process was then repeated for the second primary antibody (C2562) diluted 1:50 with PBS, 10% 
normal guinea pig serum, and 1% BSA (made w/v in PBS), but nickel was omitted from the chromogen, 
leaving a brown precipitate. Negative controls used irrelevant mouse IgG in place of the primary Chapter 2    Materials and Methods 
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antibodies or the primary antibody diluent on its own. Samples were then counterstained with filtered 
Gill’s haematoxylin (Sigma, Australia) for 40 seconds, differentiated in 5-10 seconds immersion in 0.5% 
(v/v) ammonia water, 5 seconds in 0.1% (v/v) hydrochloric acid and 5-10 second immersion in 0.5% 
(v/v) ammonia water again. Sections were briefly stained with eosin before they were dehydrated, 
cleared and mounted in DPX (Ajax Fine Chemicals, Australia) with a glass coverslip. 
 
2.2.8.2  Morphometric Analysis 
The mid-sagittal placental labyrinth was then morphometrically analysed, as previously described 
(Roberts, Sohlstrom et al. 2001a). Briefly, the proportions (volume density) and volumes of the 
labyrinthine placental components were quantitated by point counting on ten non-overlapping fields on a 
monitor with a L-36 Merz grid to quantify the proportion, with random systematic sampling using an 
Olympus BH-2 microscope with 20x objective and 3.3x ocular lenses. The volume of each component 
was estimated by multiplying the volume density by the weight of the placental labyrinth. An estimate of 
the surface area per gram of placental labyrinth was quantitated using intercept counting and the total 
surface area of the syncytiotrophoblast for exchange and arithmetic mean trophoblast thickness (the 
layer through which substrate exchange occurs) were calculated (as previously described (Weibel 
1979)). These analyses were performed by the researcher blinded to treatment.  
 
2.2.9  Protein localisation of IGF receptors in the placenta on day 35 of pregnancy 
To determine that the placenta expressed IGF1R and IGF2R at the time of treatment, we localised them 
in placental sections from the cohort of guinea pigs that were killed on day 35 of pregnancy in which 
circulating IGFs had been quantified. Mid-sagittal slices of placentae were immuno-labelled with rabbit 
antibodies raised against human IGF1R (N-20, diluted 1:20, Santa Cruz Biotechnology) and IGF2R (a 
kind gift from Dr Carolyn Scott, Kolling Institute of Medical Research, Sydney, Australia, diluted 1:100). 
This employed a triple layer technique for each antibody performed on serial placental sections, as 
described above (refer to section 2.2.8.1), but using biotinylated goat anti-rabbit IgG secondary antibody 
(Dako, Denmark). Negative controls used irrelevant mouse IgG in place of the primary antibodies or the 
primary antibody diluent on its own. 
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2.2.10  Measurement of plasma and tissue MG and AIB content  
2.2.10.1  Preparation of quench standards 
Te DPM of 3H and 14C in samples was calculated from CPM and efficiency by dual isotope β-scintillation 
counting using quenched standards prepared from tritiated water (3H2O) and 14C-AIB, respectively. Ten 
quench standards were prepared using 1 ml of Milli-Q water, 30 μl of glacial acetic acid, 14 ml of 
aqueous scintillation fluid (Beckman, USA), 50 μl of 3H2O or 14C-AIB (55,000 DPM) and varying volumes 
(0, 0, 10, 20, 40, 60, 80, 100, 120 and 120 μl) of carbon tetrachloride in 20 ml plastic scintillation vials. 
These were shaken, covered with foil and counted the following day after shaking once more by dual 
isotope β-scintillation counting (LS 6500 Beckman, USA) at 0-400 and 400-670 MeV for 3H and 14C, 
respectively. 
 
2.2.10.2  Plasma MG and AIB content determination 
For determination of plasma MG and AIB concentrations, 50 μl of plasma was deproteinised with 100 μl 
of 0.3 N, Ba(OH)2 (Sigma Diagnostics, St Louis) and 100 μl of 0.3 N, ZnSO4 (Sigma Diagnostics, St 
Louis) at 4ºC. After centrifugation at 4000 rpm at 4°C for 15 minutes, 80 μl of deproteinised supernatant 
was mixed with 0.3 ml of water, 30 μl of glacial acetic acid and 14 ml scintillant (Ready Safe, Beckman 
Coulter, USA), before counting to measure 3H and 14C dpm by dual isotope β-scintillation counting (LS 
6500 Beckman Coulter, USA) with quenched standards to indicate MG and AIB content, respectively. 
 
2.2.10.3  Tissue MG and AIB content determination 
For determination of fetal and maternal tissue MG and AIB concentrations, tissues (~100 mg) were 
solubilized with 0.7 ml 1M NaOH for 85 minutes at 65°C and then mixed with 2.1 ml 6% perchloric acid 
to precipitate protein for 20 minutes at 4°C. After centrifugation at 4000 rpm at 4°C for 15 minutes, 1 ml 
of deproteinised supernatant was mixed with 30 μl of glacial acetic acid and 14 ml scintillant (Ready 
Safe, Beckman Coulter, USA) and dual isotope β-scintillation counting (LS 6500 Beckman Coulter, 
USA) with quenched standards (as described for plasma MG and AIB determination).  
 
2.2.10.4  DPM Calculations 
The background DPM was then subtracted from samples, before sample DPM per gram or ml or total 
was adjusted to the same dose of isotope administered to the mother. DPM were represented as DPM / 
ml for plasma samples. For tissues, DPM were represented as DPM / g or total tissue uptake by 
multiplying the DPM / g by the weight of the tissue. Perirenal, retroperitoneal and interscapular fat 
counts were combined to provide a measure of fat uptake; gastrocnemius and triceps counts were Chapter 2    Materials and Methods 
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combined to provide a measure of muscle uptake; heart, spleen, kidney, liver and lung counts were 
combined to provide a measure of visceral tissue uptake; and all tissues assessed for analogue studies 
were combined to represent total tissue uptake. To estimate the transfer capacity of the placenta, the 
total fetal tissue counts were divided by placental weight.  
 
2.2.11  Statistics  
To assess differences in fetal weight distribution between treatments, chi squared tests were performed 
using Microsoft Excel. All other data were analysed using SPSS version 13 (SPSS, Chicago). To assess 
differences in maternal weight gain repeated measures ANOVA with Bonferroni Post Hoc Tests were 
performed. To assess differences in maternal body composition, general linear model univariate 
ANOVA with Bonferroni Post Hoc Tests were performed. To assess differences in fetal and placental 
parameters, linear mixed model repeated measures ANOVA with Sidak Post Hoc Tests were performed 
with the mother as a subject and the fetus or placenta as the repeated measure. The number of viable 
pups per litter were used as a covariate when required. Using Pearson’s two-Tailed Bivariate 
Correlational analyses, associations between MG and AIB uptake and placental structure and maternal 
circulating hormone concentrations were performed.  Data are expressed as mean ± SEM or estimated 
marginal mean ± SEM as required. Data were considered statistically significant when P < 0.05. 
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3.1  Introduction 
The placenta is essential for development of the fetus and the success of pregnancy. It forms the 
functional interface between the developing fetus and mother and plays roles in nutrient, waste, and gas 
exchange, endocrine, immune and metabolic functions (Cross, Werb et al. 1994). The human placenta 
is composed of tree-like structures, called chorionic villi that consist of fetal capillaries in a mesenchymal 
core, which is surrounded by a monolayer of cytotrophoblast, which either fuse to form the overlying 
multinucleate syncytiotrophoblast, or differentiate into extravillous cytotrophoblast (EVT) that form cell 
columns at villous tips and invade the maternal uterine tissue and spiral arteries. Invasion of the 
maternal spiral arteries by the EVT results in remodelling and transformation of vessels into dilated 
capillaries unresponsive to maternal vasocontrol that permit uninterrupted high conductance maternal 
blood flow required for fetal growth (Brosens, Robertson et al. 1967; Kam, Gardner et al. 1999; 
Pijnenborg, Bland et al. 1983). As insufficient invasion and remodelling of maternal vasculature is 
associated with pregnancy complications, such as preeclampsia, intrauterine growth restriction and 
stillbirth (Dommisse and Tiltman 1992; Khong, De Wolf et al. 1986; Khong, Liddell et al. 1987; Kim, 
Bujold et al. 2003; Robertson, Brosens et al. 1967) it is imperative that we understand the factors 
regulating trophoblast function to better understand these pathologies. 
 
It is well established that in humans oxygen concentration/availability at the feto-maternal interface is a 
major influence on cytotrophoblast function during early placentation (Caniggia and Winter 2002; 
Genbacev, Zhou et al. 1997). Indeed, direct connections between the uterine spiral arteries and the 
intervillous space (IVS) of the placenta cannot be observed before the ninth week of gestation (Hamilton 
and Boyd 1960; Harris and Ramsey 1966). Before that stage, the distal segments of the arteries are 
occluded by aggregates of invading EVTs (Burton, Jauniaux et al. 1999; Hamilton and Boyd 1960; 
Harris and Ramsey 1966; Hustin and Schaaps 1987), which expose villous and extravillous trophoblast 
to a relatively hypoxic/low oxygen environment in early pregnancy (~18 mmHg, ~2-3% O2) that is 
considerably lower than that detected in the endometrium (~40 mmHg, 5-6% O2) (Burton, Jauniaux et 
al. 1999; Rodesch, Simon et al. 1992). During this period, the placenta grows at a faster rate than the 
embryo. This low-oxygen environment in early pregnancy is also essential for normal embryonic and 
placental development as studies have shown that early onset of maternal blood flow into the IVS is 
associated with early pregnancy loss (Hustin, Jauniaux et al. 1990; Jauniaux, Greenwold et al. 2003; 
Jauniaux, Zaidi et al. 1994). 
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Near the end of the first trimester, endovascular trophoblastic plugs are progressively dislodged, 
exposing the developing placenta to maternal blood flow from ~10 weeks of gestation (Jaffe and Woods 
1993; Jauniaux, Jurkovic et al. 1992). Indeed, placental oxygen tension in the IVS increases nearly 3-
fold (>60mmHg, 8-9%) after 10-12 weeks gestation (Burton, Jauniaux et al. 1999; Rodesch, Simon et al. 
1992) exposing trophoblasts to increased oxygen tension at this time  and indicating that  maternal 
blood is flowing into the intervillous spaces (Jaffe and Woods 1993; Jauniaux, Jurkovic et al. 1992; 
Jauniaux, Watson et al. 2000).  
 
The exact mechanism by which trophoblasts sense oxygen tension is currently unclear however, 
several potential pathways have been identified. The most characterised mechanism in trophoblast 
involves the formation of the hypoxia-inducible factor (HIF) protein complex. HIF is a heterodimeric 
basic helix-loop-helix PAS transcription factor composed of an α and a β subunit. Both HIF subunits are 
constitutively expressed, although under normoxic conditions the α subunit is rapidly hydroxylated and 
subsequently targeted for proteolytic degradation (Ivan, Kondo et al. 2001; Jaakkola, Mole et al. 2001; 
Masson, Willam et al. 2001; Maxwell, Wiesener et al. 1999; Yu, White et al. 2001). Under hypoxic 
conditions, the absence of oxygen prevents hydroxylation and therefore degradation of the α subunit, 
which can then translocate from the cytoplasm to the nucleus and dimerise with the β subunit (Huang 
and Bunn 2003; Wang, Jiang et al. 1995a; Wang, Jiang et al. 1995b). This forms the active HIF complex 
which binds to the short DNA consensus sequence, the hypoxia response element (HRE, 5’ -RCGTG- 
3’) in the promoter region of various genes and induces their transcription (Zagorska and Dulak 2004). 
Among the variety of molecules whose expression is induced under low oxygen are those involved in 
glycolytic pathways and vasculogenesis. Studies have also demonstrated that the gene encoding 
insulin-like growth factor-II (IGF-II), which is important in fetal and placental growth, is also induced in 
some cell types by hypoxic exposure (Feldser, Agani et al. 1999; Kim, Bae et al. 1998; Steinbrech, 
Mehrara et al. 2000; Tucci, Nygard et al. 1998). 
 
IGF-II is expressed by the fetus and placenta during pregnancy and is particularly abundant in the EVT 
invading the maternal endometrium and spiral arteries in women (Han, Bassett et al. 1996; Ohlsson, 
Holmgren et al. 1989; Ohlsson, Larsson et al. 1989) and other species (Han and Carter 2000; Redline, 
Chernicky et al. 1993; Zhou and Bondy 1992). This spatial expression of IGF-II suggests a role for this 
protein in regulating trophoblast function. Indeed, IGF-II stimulates glucose and amino acid uptake 
(Kniss, Shubert et al. 1994), proliferation (Ohlsson, Holmgren et al. 1989), migration (Irving and Lala 
1995; McKinnon, Chakarborty et al. 2000; McKinnon, Chakraborty et al. 2001) and invasion (Hamilton, Chapter 3    Effect and interaction of IGF-II and oxygen 
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Lysiak et al. 1998) of cultured human trophoblast cell lines. Studies performed in genetically modified 
mice either completely deficient in Igf2 (Baker, Liu et al. 1993; DeChiara, Efstratiadis et al. 1990; Lopez, 
Dikkes et al. 1996) or with impaired placental Igf2 gene expression (Constancia, Hemberger et al. 2002) 
display reduced placental development with subsequent perturbations in fetal growth. 
 
IGF-II can bind to both types of IGF receptor, IGF1R and IGF2R, as well as the insulin receptor (InsR). 
The biological activities of IGF-II are primarily thought to be mediated through the IGF1R, which is a 
disulfide-linked heterotetrameric (α2β2) transmembrane glycoprotein with an extracellular ligand-binding 
α-subunit and intracellular β-subunit with tyrosine kinase activity (Nissley, Haskell et al. 1985). The InsR 
plays a role in embryonic development (Louvi, Accili et al. 1997) but its involvement in IGF-II effects on 
placental development is unclear. IGF2R is a single transmembrane receptor identical to the cation-
independent mannose-6-phosphate receptor, consisting of a large extracellular domain and a small 
cytoplasmic tail that lacks tyrosine kinase activity (Ludwig, Le Borgne et al. 1995). IGF2R is thought to 
primarily function as a clearance receptor for IGF-II and thereby modulates extracytoplasmic 
concentrations of IGF-II (Ludwig, Eggenschwiler et al. 1996; Ludwig, Le Borgne et al. 1995). However, 
recently, a role for IGF2R in mediating IGF-II effects on trophoblast invasion has been reported 
(Hamilton, Lysiak et al. 1998). In addition, studies in human monocytes have revealed the membrane 
bound IGF2R is capable of activating latent TGF-β1 (LTGF-β1) (Godar, Horejsi et al. 1999), an inhibitor 
of trophoblast invasion (Graham and Lala 1991; Graham and Lala 1992) via an interaction that involves 
the urokinase plasminogen activator receptor (uPAR).  
 
Therefore, we have proposed that interactions between oxygen concentration, IGF-II, and TGF-β1 
activation may be key to the regulation of placental development. The aims of this investigation were to 
examine the effect and interaction of oxygen concentration and exogenous IGF-II treatment on first 
trimester human placental growth, gene expression and TGF-β activation in vitro. To achieve this we 
employed a first trimester placental villous explant system, involving the culture of placental villi in 
serum-free media, on an artificial extracellular matrix (Matrigel) and exposing the explants to 1%, 5% or 
20% oxygen with or without exogenous IGF-II (6 treatments). 
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3.2  Results 
 
3.2.1.1  First trimester villous explant growth 
Villous explants were established from first trimester human placenta obtained from women undergoing 
elective termination of pregnancy at 7-12 weeks of gestation and morphological integrity and growth 
over the 6 days in culture were assessed in photomicrographs taken daily. EVT outgrowth from the 
distal end of the villous tips and their migration into the surrounding extracellular matrix (Matrigel) were 
observed over the culture period (Figure 3.1). Following only two days in culture, explants developed 
dense, three-dimensional outgrowths (cell columns) at the distal tips of villi (Figure 3.1b). Cells 
dissociated from the cell column (EVTs) and migrated away from the villous tips radially as individual 
cells (evc, Figure 3.1b). Cell columns aggregated with adjacent cell columns at 4 days of culture (cc, 
Figure 3.1d) and extensive migration of EVTs lead to the formation of looped outgrowth (L, Figure 3.1e) 
and/or dense balloon-like structures (not shown). By day 6 in culture it appeared that some cells that 
originally comprised cell columns, had detached and migrated away from the villous tip in clusters of 
cells deemed cell islands (i, Figure 3.1e).  
 
To confirm that outgrowing/migrating cells were trophoblasts, explants were frozen and 
immunohistochemically labelled for cytokeratin-7 and also for the expression of IGF-II (Figure 3.2). 
Antibodies against cytokeratins are commonly employed to identify cells of epithelial origin, while 
cytokeratin-7 identifies trophoblast (Blaschitz, Weiss et al. 2000; King, Thomas et al. 2000). In these 
explants, there being no attached decidua, the only epithelial cells will be trophoblasts. Cells that formed 
the outgrowths (cell columns) at the tips of villi characteristically displayed a vacuolated appearance 
with large nuclei, which was most obvious in the negative controls (Figure 3.2b). The STB, CTB and 
cells constituting the extravillous cell columns labelled for cytokeratin-7, whereas the villous 
mesenchyme was negative (Figure 3.2a). Matrigel, the ECM substrate used in the villous explant 
cultures, was also seen to non-specifically label (Figure 3.2a). IGF-II protein was localised to CTB and 


















Figure 3.1 Daily growth of human placental villous explants. First trimester (7 weeks 
gestation) human placental villous explants after 1 day (a), 2 days (b), 3 days (c), 4 days (d), 5 
days (e) and 6 days (f) in culture in serum-free media in 1% oxygen. Note the formation of cell 
columns (cc) at the tips of villi (v) and the detachment and migration away from villous tips of 
individual extravillous cells (evt) after only 2 days in culture (b). Cell columns began to aggregate 
with adjacent cell columns (cc) following 4 days of culture (d) and after 5 days in culture (e), 
extravillous cell migration was extensive and exhibited a loop-like appearance (L). Some cells that 
originally comprised cell columns, appeared to have detached and migrated away in clusters 
forming extravillous cell islands (i) after 6 days in culture (f). Photomicrographs taken with an 
inverted microscope with 4x objective.
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Figure 3.2 Cytokeratin-7 and IGF-II immunolabelling of villous explants. Trophoblast was 
identified in fresh-frozen first trimester (7 weeks gestation) human placental villous explants that 
had been cultured for 6 days using immunohistochemical labelling and counterstained with 
haematoxylin. Cells that were positive for cytokeratin-7 (a) or IGF-II (c) stained brown and 
negative control section shown (b). Cell column (cc), Matrigel (ma), mesenchyme (me). 
Photomicrographs taken with a brightfield microscope under 10x objective.
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3.2.1.2  The effect of gestational age on villous explant outgrowth in response to oxygen 
concentration 
To determine whether there was a differential response of first trimester placental villous explants to 
oxygen concentration with gestational age, villous explants of 7-12 weeks gestation were cultured in 
20%, 5% and 1% oxygen atmospheres. There was no effect of gestational age on the proportion of tips 
outgrowing in explants cultured in 20% oxygen. However, there was a negative correlation between 
gestational age and proportion of villous tips outgrowing in those exposed to 5% and 1% oxygen 
atmospheres (r = -0.50, P= 0.034 and r = -0.58, P= 0.003, respectively) (Figure 3.3a). Regardless of 
oxygen concentration, gestational age of the villous explants was negatively correlated with villous tip 
proliferation score (r = -0.51, P < 0.001) and migration score (r = -0.49, P < 0.001) (Figure 3.3b and c).  
 
To determine whether the gestational age of the placenta affected the responsiveness of explants to 
oxygen concentration, the percent difference of outgrowth for individual placental explants grown in 20% 
oxygen was compared with 5% and 1% explants (Figure 3.4). There was significant reduction in the 
proportion of tips outgrowing and extent of proliferation and migration from those tips in placentas from 
11 and 12 weeks of gestation in those cultured in 5% oxygen compared to 20% oxygen controls (Figure 
3.4a-c). In response to 1% oxygen atmospheres, there was significant reduction in the proportion of tips 
outgrowing and extent of proliferation in placenta at 10 weeks and migration from those tips at 9 weeks 
of gestation (Figure 3.4 d-f). Given the differential response of placenta at different gestational ages on 




3.2.1.3  Effect and interaction of oxygen and exogenous IGF-II on villous outgrowth at 7-8 
weeks of gestation 
To determine the effect and interaction of oxygen concentration and IGF-II on the formation of 
extravillous cytotrophoblast outgrowths, human first trimester villous explants obtained at 7-8 weeks of 
gestation were cultured under 20%, 5% and 1% oxygen atmospheres with and without the addition of 
17nmol IGF-II. The morphologies of the resultant outgrowth patterns were compared (Figure 3.5).  
 
Culture of explants under low oxygen atmospheres increased the proportion of tips outgrowing by 42% 
under 5% oxygen and by 58% under 1% oxygen compared with those cultured in 20% oxygen (mean ± 
SEM; 20% oxygen: 0.53 ± 0.03, 5% oxygen: 0.75 ± 0.04, 1% oxygen: 0.83 ± 0.03, both P < 0.001, 





































































































Figure 3.3 Association of gestational age and villous explant outgrowth under different 
oxygen concentrations. The proportion of villous tips bearing cell columns per explant (a) and 
the extent of proliferation (b) and migration (c) from those tips in response to 20%, 5% and 1% 
oxygen atmospheres. Each data point represents mean value of 8 explants per placenta (closed 
circles, 20% oxygen; open circles, 5% oxygen; closed triangles, 1% oxygen). Number of 
placentas per oxygen concentration = 23, thus giving a total 69 placentas. Regression lines for 
each oxygen concentration are displayed on the graph. Refer to text for r and P values.
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Figure 3.4 Effect of gestational age with the growth response of villous explants to oxygen 
concentration. Villous explant outgrowth in response to 5% oxygen (a-c) and 1% oxygen (d-
f), across gestational age was expressed as a percentage of the explants cultured in 20% oxygen 
atmospheres (as indicated by zero line). Growth responses were indicated by proportion of villous 
tips bearing cell columns per explant (a, d) and the extent of proliferation (b, e) and migration (c, 
f) from those tips. Figures represent the mean differential response within each placenta ± SEM. 
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(mean ± SEM = 0.72 ± 0.03 versus 0.53 ± 0.03, respectively, P < 0.001), whereas it did not affect tip 
outgrowth in explants cultured in 1% or 5% oxygen. The outgrowth seen in 20% oxygen explants with 
exogenous IGF-II was similar to that seen in 1% and 5% oxygen explants.  
 
By arbitrarily assessing the appearance of the EVTs as being round, dendriform or a mixture, 
dendriform being a phenotype attributed to migratory cells, it was found that there was a higher 
proportion of EVTs displaying a dendriform migratory phenotype in 5% and 1% oxygen explants 
compared with 20% oxygen (P < 0.047 and P < 0.001, Figure 3.5b). Addition of exogenous IGF-II to 
each of the explants had no effect on EVT appearance (Figure 3.5b). There was no effect of oxygen 
concentration or exogenous IGF-II on the extent of villous tip proliferation or migration (Figure 3.5c, d). 
 
 
3.2.1.4  Effect and interaction of oxygen and exogenous IGF-II on villous outgrowth at 9-13 
weeks of gestation 
To determine the effect and interaction of oxygen concentration and IGF-II on the formation of 
extravillous cytotrophoblast outgrowths, human first trimester villous explants obtained at 9-13 weeks of 
gestation were cultured in 20%, 5% and 1% oxygen atmospheres with and without the addition of 
17nmol IGF-II, and the morphology of the resultant outgrowth patterns were compared. 
 
There was no effect of oxygen concentration on any of the four villous outgrowth parameters assessed 
(Figure 3.6). In explants exposed to 20% oxygen, exogenous IGF-II increased the proportion of villous 
tips bearing cell columns by 22% (P = 0.047) and the proliferation (+31%, P = 0.04) and migration 
(+33%, P = 0.035) of trophoblast from those tips, without altering the phenotype of the EVTs (Figure 
3.6a, c, d).  
 
 
3.2.1.5  Effect of gestational age on villous explant outgrowth in response to IGF-II treatment 
Given there was an effect of exogenous IGF-II on outgrowth in explants cultured under 20% oxygen 
regardless of gestational age, and the gestational age affected explant growth in culture, we determined 
whether there was a differential response of explants to exogenous IGF-II treatment with gestational 
age. There was no effect of gestational age on the proportion of tips growing per explant in response to 
IGF-II treatment (Figure 3.7a). However, there was a clear difference in the proliferative response of 
explants to exogenous IGF-II between placenta at 7 and 8 weeks of gestation with those at 9, 10 and 12 
weeks (Figure 3.7b). There was also a dramatic increase in the migratory response of explants to  Figure 3.5 Effect and interaction of oxygen and IGF-II concentrations on villous explant 
outgrowth at 7-8 weeks of gestation. First trimester human villous explants were assessed for 
outgrowth and migratory behaviour on day 6 of culture under 1%, 5% or 20% oxygen without 
(0 IGF-II) and with the addition of 17nmol IGF-II (+ IGF-II). Villous tip outgrowth was expressed as the 
proportion of tips bearing cell columns per explant (a). Arbitrary scores were used to assess the 
extravillous cytotrophoblast phenotype as being round, dendriform or a mixture of the two (d:r) (b). 
Extent of proliferation observed at the tips of villi (c) and the extent of extravillous cytotrophoblast 
migration (d) were also recorded using arbitrary scores. Data are expressed as mean ± SEM. n = 8 
placentae, 8 wells/treatment/placenta. Compared with 20% oxygen no IGF-II, **P < 0.047 and 
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explant outgrowth at 9-13 weeks of gestation. First trimester human villous explants were 
assessed for outgrowth and migratory behaviour on day 6 of culture under 1%, 5% or 20% oxygen 
with and without the addition of 17nmol IGF-II. Villous tip outgrowth was expressed as the proportion 
of tips bearing cell columns per explant (a). Arbitrary scores were used to assess the extravillous 
cytotrophoblast phenotype as being round, dendriform or a mixture of the two (d:r) (b). Extent of 
proliferation observed at the tips of villi (c) and the extent of extravillous cytotrophoblast migration (d) 
were also recorded using arbitrary scores. Data are expressed as mean ± SEM. n = 8 placentae, 8 
wells/treatment/placenta. Different letters denote statistical difference, where a vs b, P < 0.047, as 
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exogenous IGF-II between placentas at 12 weeks of gestation compared with the 7-11 weeks (Figure 
3.7 c).  
 
 
3.2.1.6  Effect of oxygen and exogenous IGF-II on villous gene expression at 7-8 weeks of 
gestation 
To determine whether the effect of IGF-II and oxygen concentration on villous explant outgrowth at 7-8 
weeks of gestation coincided with alterations in gene expression, Igf2, Igf1r, Igf2r, Upar and Tgfβ1 
mRNA were quantitated relative to 18s rRNA using sequence-specific primers and Real Time RT-PCR. 
All five genes were expressed in villous explant cytotrophoblasts (Table 3.1) and produced the expected 
exponential curves of fluorescence. However, there was considerable variation in gene expression 
between samples, regardless of treatment group. 
 
Bands visualised after gel electrophoresis revealed a single cDNA product was amplified with each 
primer pair, all of which were consistent with the predicted sizes of 18s (91 bp), Igf2 (90 bp), Igf2r (88 
bp), Igf1r (142 bp), Upar (71 bp), Tgfβ1 (104 bp) (Figure 3.8). The expression of 18s rRNA did not vary 
significantly across the six treatments studied (data not shown). As ΔCT is inversely related to levels of 
mRNA expression, the abundance of Igf2 mRNA transcripts relative to 18s rRNA (mean ΔCT ± SEM = 
2.15 ± 0.3) was significantly higher than Igf1r (10.9 ± 3.3), Igf2r (11.9 ± 2.2), Upar (12.6 ± 3.4) and 
Tgfβ1 (10.4 ± 4.0) mRNA in explant cytotrophoblasts across all treatments (p <0.001, Table 3.1). 
Expression of all genes were normalised to the house-keeping gene, 18s rRNA and expressed as a 
percent of the mean value for the 20% oxygen without exogenous IGF-II treatment group. 
 
Culture under 1% oxygen increased the expression of Igf2 mRNA by 3.5-fold and 4-fold compared with 
20% (P=0.04) and 5% oxygen explants. However, this did not reach statistical significance with 5% 
oxygen explants (P = 0.065) (Figure 3.9a). Exogenous IGF-II did not affect the expression of Igf2 mRNA 
in explants cultured under 20% or 5% oxygen. However, there appeared to be a negative effect of IGF-II 
on gene expression in 1% oxygen explants, where the addition of exogenous IGF-II reduced Igf2 mRNA 
expression by nearly 65%, although this failed to reach statistical significance (P= 0.06, Figure 3.9 a).  
 
There was no effect of low oxygen concentration on Igf2r gene expression by villous explants compared 
with those cultured in 20% oxygen (Figure 3.9b). There was, however, a 9-fold difference in Igf2r mRNA 

















































































































































Figure 3.7 Association of gestational age with the growth response of placental villous 
explants to exogenous IGF-II. Villous explant outgrowth in response to exogenous IGF-II in 
20% oxygen atmospheres, across gestational age was expressed as a percentage of the 
explants cultured in the absence of exogenous IGF-II (exIGF-II, as represented by zero line). 
Growth responses were indicated by the proportion of villous tips bearing cell columns per 
explant (a) and the extent of proliferation (b) and migration (c) from those tips. Figures represent 
the mean differential response within each placenta ± SEM.
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Table 3.1 Real Time PCR assay characteristics 
Gene  Lowest Ct  Highest Ct  ΔCt*  Amplification 
efficiency (%) 
18s  14.7 19.8  -  76 
Igf2  16.6  25.7  2.15 ± 0.3  87 
Igf1r  21.9  29.9  10.9 ± 3.3  98 
Igf2r  26.0  33.0  11.9 ± 2.2  73 
Upar  24.2  32.8  12.6 ± 3.4  82 
Tgfβ1  21.86  36.2  10.4 ± 4.0  85 
Number of explants = 48, from each of 8 placentas). Ct = cycle threshold, ΔCt = 18s - gene of interest.  










Figure 3.8 PCR amplification products of sequence specific primers. Lanes 1 and 9 show 
molecular weight markers with size in base pairs (bp) denoted. Lanes 2-7 show, 18S (91 bp), 
IGF-II (90 bp), IGF2R (88 bp), IGF1R (142 bp), uPAR (71 bp), TGF-β1 (104 bp) PCR 
amplification products, respectively. Lane 8 shows representative no cDNA template control.
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in 1% oxygen explants (P = 0.003, Figure 3.9b). There was no effect of exogenous IGF-II on Igf2r gene 
expression. When comparing all treatment groups, Igf2r mRNA expression was increased 2-fold in 
explants grown in 1% oxygen compared with those exposed to 20% oxygen and treated with IGF-II (P = 
0.04, Figure 3.9b). 
 
There was no significant effect of oxygen concentration or exogenous IGF-II on Igf1r, Upar or Tgfβ1 
gene expression (Figure 3.9c-e). 
 
 
3.2.1.7  Effect of oxygen and exogenous IGF-II on placental villous explant IGF-II protein 
secretion at 7-8 weeks of gestation 
Culture of villous explants in 1% oxygen atmospheres increased IGF-II protein secretion by 10-fold 
compared with 20% oxygen explants (mean ± SEM = 9.85 ± 2.74 versus 0.98 ± 0.67 ng/ml, 
respectively, P < 0.005).  
 
 
3.2.1.8  Effect of oxygen concentration and exogenous IGF-II on TGFβ1 activation at 7-8 weeks 
of gestation  
As the TGF-β1 protein requires activation to have biological effects, the effects of oxygen concentration 
and exogenous IGF-II on TGFβ1 activation was determined in villous explant-conditioned media.  
 
Total TGF-β1 protein secretion (inactive + active) was unaltered by culture in 1% oxygen or exposure to 
exogenous IGF-II (Figure 3.10a), which was consistent with gene expression studies. Culture of villous 
explants in 1% oxygen atmospheres reduced the concentration of active TGF-β1 by 90%, compared 
with 20% oxygen explants (mean ± SEM = 0.88 ± 0.44 versus 7.12 ± 0.77 pg/ml, respectively, P < 
0.005, Figure 3.10b). There was no effect of IGF-II treatment on the concentration of active TGF-β1 in 
explants exposed to 1% oxygen (Figure 3.10b). However, exogenous IGF-II reduced the concentration 
of active TGF-β1 protein by 65% in explants cultured in 20% oxygen (mean ± SEM= 2.50 ± 0.46 versus 
7.12 ± 0.77 pg/ml, respectively, P < 0.005) (Figure 3.10b). Despite reductions in TGF-β1 activation with 
the addition of IGF-II to explants cultured under 20% oxygen atmospheres, concentrations of active 
TGF-β1 were still significantly higher than in 1% oxygen cultures (P < 0.05, Figure 3.10b).  
 
 Figure 3.9 Effect and interaction of oxygen and IGF-II concentrations on placental villous 
explant gene expression. Igf2 (a), Igf2r (b), Igf1r (c), Upar (c) and Tgfβ1 (c) gene expression 
were measured in cytotrophoblasts of first trimester (7-8 weeks gestation) human placental villous 
explants on day 6 of culture under 1%, 5% or 20% oxygen with and without the addition of 
17nmol IGF-II using Real-Time RT-PCR.  Data were normalised to the housekeeper, 18s rRNA, 
and each treatment expressed as a percentage of the mean value for the 20% oxygen, no 
exogenous IGF-II treatment group, using the 2-ΔΔCT method. Data are expressed as mean ±
SEM. n = 8 placentae, 8 wells pooled per treatment per placenta. Different letters denote 
statistically significant difference as determined by Mann-Whitney U Tests; a vs b, P < 0.04 and b 









































































































































Figure 3.10 Effect and interaction of oxygen and IGF-II concentration on villous explant 
TGF-β1 production and activation. Total (inactive + active, a) and active (b) TGF-β1 protein 
concentrations were determined in first trimester (7-8 weeks gestation) human villous explant-
conditioned media on day 6 of culture under 1% or 20% oxygen with and without the addition of 
17nmol IGF-II using a commercially available TGF-β1 ELISA. A four parameter logistic regression 
curve was used to determine the concentration of protein, after which, media blanks were 
subtracted from values. Data are expressed as mean pg / ml ± SEM. n = 12-13 placentas, 1 
representative well/treatment/placenta. Superscripts denote statistical significance determined 
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3.2.1.9  Correlations of gene expression and TGF-β1 activation with placental villous explant 
outgrowth at 7-8 weeks of gestation 
All villous outgrowth, gene expression and protein studies were undertaken in each placental sample. 
Therefore, we investigated whether there were any significant correlations between these parameters 
(Table 3.2). Igf2 and Igf2r gene expression were positively associated with villous proliferation (r = 0.43, 
P = 0.003 and r = 0.38, P = 0.008, respectively) and migration (r = 0.47, P = 0.001 and r = 0.39, P = 
0.007, respectively). Igf2 transcription was also positively correlated with the proportion of tips that were 
outgrowing per explant (r = 0.44, P = 0.003). In contrast, total TGFβ1 protein was negatively correlated 
with migratory phenotype (r = -0.25, P = 0.03) and active TGFβ1 was negatively correlated with villous 
tip outgrowth and migration (r = -0.59, P < 0.001 and r = -0.30, P = 0.034, respectively). There were no 
significant correlations between morphological parameters and Upar, Igf1r or Tgfβ1 gene expression or 
surprisingly, with IGF-II protein secretion. In placental villous conditioned media, IGF-II protein was 
negatively correlated with concentrations of active TGF-β1 protein (r = -0.42, P = 0.003). 
 
 
Table 3.2 Association of gene expression, TGF-β1 protein secretion and villous explant 
outgrowth 
  Tips growing  EVT phenotype Proliferation  Migration 
Igf2  0.44** 0.12  0.43** 0.47** 
Igf2r  0.17 -0.21 0.38* 0.39* 
Igf1r  0.15 0.17 -0.04 0.16 
Upar  -0.01  0.05 -0.05 0.09 
Tgfβ1  0.07 0.22 -0.21 0.16 
Active TGF-β1#  -0.59** -0.30*  -0.13  -0.12 
Total TGF-β1  0.09 -0.25* -0.05  0.16 
IGF-II# 0.23  0.03  0.19  0.28 
Table displaying correlation coefficients (r), which were significant at * P < 0.04 or ** P < 0.003, as 
determined by Pearson’s bi-variate correlation analyses. # Negatively correlated with each other, r = -
0.42 P = 0.003. Across all treatments, with n = 48 samples from 8 placenta. 
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3.3  Discussion  
The low-oxygen environment in which human placental development occurs during the first trimester of 
pregnancy is believed to be important in controlling EVT outgrowth (Caniggia and Winter 2002; 
Genbacev, Zhou et al. 1997) and is essential for pregnancy success (Hustin, Jauniaux et al. 1990; 
Jauniaux, Greenwold et al. 2003; Jauniaux, Zaidi et al. 1994). In the present study, we have 
demonstrated for the first time that this low oxygen environment during early pregnancy, stimulates 
human placental outgrowth, induces Igf2 gene expression and inhibits TGF-β1 activation. IGF-II 
appears to mimic the low oxygen response, as addition of exogenous IGF-II to placental explants 
cultured in 20% oxygen stimulates placental outgrowth and inhibits TGF-β1 activation. These suggest 
that prior to the onset of maternal blood flow to the intervillous space, IGF-II mediates the low oxygen 
response during early pregnancy to promote placental invasion. Later in pregnancy, when oxygen 
concentrations increase, placental invasion declines and differentiation of the placental exchange region 
occurs to increase functional capacity, potentially via TGF-β1 activity. 
 
Placental development requires spatially and temporally regulated invasion of the maternal decidua and 
its vasculature by EVTs. This process requires rapid changes in the expression repertoire of adhesion 
molecules by the villous cytotrophoblast, a highly organised and polarised epithelium, into a phenotype 
that is characteristic of endothelial cells and leukocytes and capable of invasion (epithelial to 
mesenchymal transformation). In the current study, culture of 7-8 weeks gestation placental explants in 
5% or 1% oxygen, which is similar to the assumed physiological oxygen environment at the feto-
maternal interface in vivo (Burton, Jauniaux et al. 1999; Rodesch, Simon et al. 1992), increased villous 
tip outgrowth and the proportion of EVTs displaying a migratory appearance, compared with 20% 
oxygen atmospheres. This data is in agreement with studies using isolated cytotrophoblast cells and 
villous explant culture systems demonstrating that oxygen can influence cell-matrix interactions, cell-cell 
associations, cell cycle progression and initial cellular differentiation along the invasive pathway. For 
instance, previous investigations of 5-8 week old villous explants exposed to hypoxia (2% oxygen; ~14 
mmHg) have demonstrated an inhibition of cytotrophoblast terminal differentiation into syncytium (Alsat, 
Wyplosz et al. 1996), increased trophoblast proliferation/outgrowth at tips of anchoring villi (Caniggia 
2000; Genbacev, Joslin et al. 1996) through direct impacts on cell cycle regulatory proteins (Genbacev, 
Zhou et al. 1997), increased HLA-G and α5 integrin expression (Iwaki, Yamamoto et al. 2004; Kilburn, 
Wang et al. 2000) and the activities of MMP-2 (Caniggia, Lye et al. 1997; Caniggia, Taylor et al. 1997) 
and focal adhesion kinase (MacPhee, Mostachfi et al. 2001; Seko, Takahashi et al. 1999).  Chapter 3    Effect and interaction of IGF-II and oxygen 
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In the present study, there was no effect of 5% or 1% oxygen on proliferation or migration scores, 
despite a higher proportion of EVTs displaying a migratory, dendriform phenotype in explants exposed 
to low oxygen phenotype. This suggests that low oxygen initiates the first stages of the extravillous 
differentiation pathway, but may not be sufficient for trophoblast completion of the invasion path. 
Additionally, our data may indicate that the explants were already at their maximal outgrowth capacity 
given that the extended culture period of six days without media change.  
 
Independent of oxygen concentration, the extent of villous tip proliferation and migration declined 
progressively with gestational age of the tissue, suggesting that trophoblast is innately programmed to 
proliferate and invade optimally in early stages of gestation, when maternal blood perfusion of the 
placenta is minimal. Indeed, other investigators have shown that exposure to hypoxia stimulates first 
trimester immortalised human trophoblast invasion by more than 40% and is associated with reduced 
secretion of tissue inhibitors of matrix metalloproteinases, TIMP-1 and TIMP-2 and increased uPAR 
(and therefore uPA cell surface-associated activity) expression compared with high (20% oxygen) 
(Canning, Postovit et al. 2001; Graham, Fitzpatrick et al. 1998). More quantitative methods to measure 
proliferation and migration in response to oxygen rather than arbitrarily scoring placental villous explants 
are required to confirm and supplement the current observations. This may involve measuring tritiated 
thymidine analogue uptake by villous explants in response to low oxygen concentration or measuring 
distance and area of resultant explant outgrowth using Video Image Analysis software on 
photomicrographs.  
 
In the present study, exposure of 7-8 weeks gestation villous explants to low oxygen atmospheres 
almost completely abolished activation of TGF-β1. Explant synthesis of total and active TGF-β1 protein 
was negatively correlated with villous tip outgrowth. This is consistent with previous investigations 
demonstrating that TGF-β1 is negative regulator of first trimester trophoblast cell proliferation (Graham 
and Lala 1992), migration (Irving and Lala 1995) and invasion (Graham and Lala 1991; Graham and 
Lala 1992) in vitro. TGF-β1 reduces trophoblast migration and invasion by increasing the expression of 
TIMPs (Graham and Lala 1991; Khoo, Bechberger et al. 1998), plasminogen activator inhibitor (PAI)-1 
(Graham 1997), promotes intercellular adhesion by increasing E-cadherin expression (Karmakar and 
Das 2004), promotes extracellular matrix deposition (Chen, Yang et al. 2005; Feinberg, Kliman et al. 
1994) and reduces uPA (Graham and Lala 1991) and MMP-9 activation (Meisser, Chardonnens et al. 
1999). Furthermore, expression of the TGF-β superfamily transmembrane protein, endoglin also inhibits Chapter 3    Effect and interaction of IGF-II and oxygen 
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human trophoblast outgrowth and may be necessary for the inhibitory effects of TGF-β (Caniggia, 
Taylor et al. 1997). Interestingly, the endoglin gene contains a functional hypoxia response element 
(HRE) (Sanchez-Elsner, Botella et al. 2002). However, whether endoglin expression was altered by 
oxygen concentration in the current study has yet to be established. 
 
In the current study, the mechanisms by which hypoxia decreases activation of TGF-β1 protein did not 
involve inhibition of Tgfβ1 transcription nor total protein synthesis. This is in contrast to Tgfβ3 gene 
regulation by hypoxia in placental villous explants (Caniggia 2000). Enzymatic activation of TGF-β1 in 
vivo is mediated by glycosidases, serine proteases and thrombospondin-1 (Gleizes, Munger et al. 1997; 
Munger, Harpel et al. 1997). Studies in human monocytes and more recently in endothelial cells have 
also revealed that activation of TGF-β1 occurs on the IGF2R. Upon binding of LTGF-β1 to the IGF2R 
(due to M6P residues in the latency-associated peptide), IGF2R simultaneously complexes with the 
uPAR on the cell surface (Godar, Horejsi et al. 1999; Leksa, Godar et al. 2005). The binding of uPA to 
uPAR allows uPA to cleave plasminogen into plasmin, the latter of which cleaves the latency-associated 
peptide and allows release of biologically active TGF-β1 (Godar, Horejsi et al. 1999; Leksa, Godar et al. 
2005). Previous studies have failed to demonstrate an effect of oxygen concentration on TGF-β1 
activation in human fibroblast cultures isolated from term placenta (Chen, Yang et al. 2005). This may 
reflect differences in the composition of culture media used in our villous explant system. Our media is 
supplemented with plasminogen, which is required for activation of TGF-β1 by the IGF2R complex 
(Godar, Horejsi et al. 1999; Leksa, Godar et al. 2005) and is secreted by trophoblasts as they invade in 
vivo (Graham, Postovit et al. 2000). Additionally, fibroblasts may not express all components of the 
IGF2R-uPAR complex. 
 
To elucidate the effects of hypoxia on TGF-β1-IGF2R-uPAR activation complex, we quantified the 
expression of Upar, Igf2r and Igf1r genes. Alterations in the expression of the latter may have indirectly 
influenced IGF2R ligand occupancy. All three genes were expressed by outgrowing trophoblast in our 
explants. In addition, there was a trend for increased Igf2r transcription in explants exposed to 1% 
oxygen atmospheres compared with 20% but this failed to reach significance. There was no effect of 
oxygen concentration on explant expression of Upar mRNA. These are in contrast to previous findings, 
which demonstrated an induction of this gene in response to hypoxia in the transformed cell line, HTR-
8/SVneo (Graham, Fitzpatrick et al. 1998). A lack of an effect of oxygen availability on gene expression 
may have been due to differences in study design and inherent differences in trophoblast populations 
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expression may have been diluted as analyses were performed on pooled samples of RNA per 
placenta, per treatment and we observed significant variations in growth of individual explants within 
treatments and between patients. Additionally, the heterogeneous nature of the outgrowing trophoblasts 
used for analysis may have been responsible for the considerable variation in gene expression across 
treatments. Isolating certain trophoblast populations in our explants, ie those that constitute the cell 
column or those that have detached and are migrating and invading could provide more informative 
data on gene expression. 
 
Alternatively, differences in the length of hypoxic exposure may underlie the inconsistencies between 
the current and previous studies. Previous studies only acutely exposed their cells to hypoxia – for a 
duration of 24 hours. However, in the current study, explants were exposed to prolonged hypoxia, that 
is, for 6 days. It is well established that acute and chronic hypoxic exposure can have different effects 
on transcription and cellular function (Uchida, Rossignol et al. 2004). Further mRNA analyses of 
outgrowing trophoblasts from explants after different lengths of hypoxic exposure may help to elucidate 
this. 
 
Importantly, in the current investigation, explants prepared from placentas at 7-8 weeks of gestation and 
exposed to 1% oxygen, displayed increased Igf2 gene expression and protein secretion, compared to 
those exposed to 20% oxygen atmospheres. Addition of exogenous IGF-II appeared to inhibit 
endogenous Igf2 transcription in explants exposed to 1% oxygen atmospheres. This negative feedback 
has been demonstrated in differentiating myoblasts, where it appears to operate through the IGF1R 
(Magri, Benedict et al. 1994). As there was no effect of exogenous IGF-II on explant endogenous Igf2 
transcription in 5% or 1% oxygen atmospheres, this negative feedback may operate in a concentration 
dependent manner. 
 
Although a defined HRE (HIF-1 binding site) in the upstream region of the Igf2 gene remains to be 
identified, other investigators have reported that Igf2 is induced by hypoxia in some cell types, including 
mouse embryonic fibroblasts, rat osteoblasts and astrocytes, human hepatocarcinoma (HepG2) and 
bovine pulmonary endothelial cells (Feldser, Agani et al. 1999; Kim, Bae et al. 1998; Steinbrech, 
Mehrara et al. 2000; Tucci, Nygard et al. 1998). In the current study, IGF-II secretion was negatively 
correlated with explant activation of TGF-β1 and IGF-II treatment of villous explants incubated in 20% 
oxygen atmospheres inhibited TGF-β1 activation (to a similar extent to that seen in 1% oxygen 
explants). This suggested that IGF-II may mediate the low oxygen response on TGF-β1 activation. Chapter 3    Effect and interaction of IGF-II and oxygen 
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The mechanism for IGF-II inhibition of TGF-β1 activation is predicted to involve competitive interaction 
between these two factors with IGF2R. Although the IGF2R binding sites for LTGF-β1 (mannose-6 
phosphate site) and IGF-II are distinct, IGF2R-IGF-II interaction induces a conformational change in the 
structure of IGF2R, which causes the LTGF-β1 binding site to become inaccessible (Leksa, Godar et al. 
2005). Furthermore, other studies performed in the laboratory have supported the notion that IGF-II has 
a greater affinity for IGF2R than LTGF-β1 (Roberts, CT unpublished). Given that IGF2R and uPAR are 
expressed by trophoblast (confirmed in this study), which also up-regulate IGF-II synthesis in 1% 
oxygen atmospheres, IGF-II is likely to saturate the IGF2R, thereby preventing TGF-β1 activation. This 
is especially likely since Igf1r transcription was not affected by oxygen. 
 
In vivo, IGF-II is highly expressed by the human placenta but declines by late gestation (Han, Bassett et 
al. 1996). IGF-II is most highly expressed by EVTs deep in the decidua or within and surrounding 
maternal uterine spiral arterioles and lowest in cells of the villus (Han, Bassett et al. 1996; Ohlsson, 
Holmgren et al. 1989; Ohlsson, Larsson et al. 1989). These suggest that although invading trophoblasts 
encounter a gradient of increasing oxygen concentration as they approach the maternal vasculature, 
they continue to synthesise IGF-II. Additionally, IGF-II expression in the placenta remains high (Han, 
Bassett et al. 1996) following flow of maternal blood into the intervillous space (Jaffe and Woods 1993; 
Jauniaux, Jurkovic et al. 1992; Jauniaux, Watson et al. 2000) and elevated local oxygen concentrations 
((Burton, Jauniaux et al. 1999; Rodesch, Simon et al. 1992), suggesting little regulatory effect of oxygen 
on IGF-II synthesis in vivo. Despite the in vitro findings of the current work, this would suggest that, in 
vivo, IGF-II synthesis is not solely regulated by oxygen availability. Interestingly, IGF-II has been 
demonstrated to increase HIF-1α protein expression, HIF-1 DNA binding activity, and transactivation of 
target genes under normoxic atmospheres in vitro (Feldser, Agani et al. 1999; Zelzer, Levy et al. 1998). 
Therefore, IGF-II may extend HIF actions in the placenta, including effects on Igf2 gene expression in 
trophoblasts as they invade the decidua and subsequent to maternal blood perfusion of the placenta.  
 
As IGF-II inhibited TGF-β1 activation, a negative regulator of trophoblast function, exogenous IGF-II 
would be expected to increase villous explant outgrowth. In the current investigation, treatment of villous 
explants cultured in 20% oxygen with IGF-II, also increased villous tip outgrowth. Regardless of the 
gestational age of placental villous explants, exogenous IGF-II increased the proportion of villous tips 
outgrowing and in explants greater than 9 weeks of gestation, stimulated trophoblast proliferation and 
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treatment in explants at 7-8 weeks of gestation cultured in 20% oxygen, resembled outgrowth seen in 
explants exposed to low oxygen atmospheres, suggesting that IGF-II may mediate the growth 
promoting effects of low oxygen availability. This is consistent with previous studies that demonstrated 
the positive effects of exogenous IGF-II on first trimester placental trophoblast DNA synthesis and 
proliferation (Ohlsson, Holmgren et al. 1989), EVT cell migration (Irving and Lala 1995; McKinnon, 
Chakarborty et al. 2000; McKinnon, Chakraborty et al. 2001) and invasion (Hamilton, Lysiak et al. 1998) 
in vitro. Interestingly, IGF-II also promotes differentiation of murine trophoblast into invasive cells, by 
transforming ectoplacental cone cells (early trophoblast stem cells) into invasive trophoblast giant cells 
in vitro (Kanai-Azuma, Kanai et al. 1993).  
 
The effects of IGF-II on placental explant outgrowth under 20% oxygen atmospheres may have been 
mediated through any of the three cell surface receptors, IGF1R, IGF2R and InsR (Abu-Amero, Ali et al. 
1998; Desoye, Hartmann et al. 1997; Fang, Furesz et al. 1997; Holmes, Porter et al. 1999; Jones, 
Hartmann et al. 1993; Milio, Hu et al. 1994; Ohlsson, Holmgren et al. 1989), which are expressed by 
human placental trophoblast. IGF1R-InsR hybrids are also expressed by the human placenta (Soos, 
Field et al. 1993), however their contribution to IGF-II effects in our explant system are unknown. We 
predict that IGF-II stimulation of trophoblast proliferation in our explants occurred via IGF1R, which 
activates the insulin receptor substrate-1-dependent intracellular signalling pathways (Jones and 
Clemmons 1995). Additionally, in the presence of abundant IGF-II, InsR has been demonstrated to 
mediate IGF-II mitogenic effects (Morrione, Valentinis et al. 1997). Importantly, it has been reported that 
IGF-II promotion of invasion is independent of IGF1R in vitro (Hamilton, Lysiak et al. 1998). As IGF-II 
preferentially binds to IGF2R (Jones and Clemmons 1995), the latter may play a dominant role in IGF-II 
actions on explant outgrowth.  
 
As well as its established role in IGF-II clearance, several reports indicate that IGF2R also functions in 
IGF-II signalling (Groskopf, Syu et al. 1997; Ikezu, Okamoto et al. 1995; Ikushima, Munakata et al. 
2000; McKinnon, Chakarborty et al. 2000; McKinnon, Chakraborty et al. 2001; Minniti, Kohn et al. 1992; 
Nishimoto 1993; Tsuruta, Eddy et al. 2000; Zhang, Tally et al. 1997). Interaction of IGF-II with IGF2R, 
can stimulate an intracellular signalling pathway using a Gi-coupled receptor (Ikezu, Okamoto et al. 
1995; Murayama, Okamoto et al. 1990) and mitogen activated protein kinase (MAPK) (Groskopf, Syu et 
al. 1997; Ikezu, Okamoto et al. 1995; McKinnon, Chakarborty et al. 2000; McKinnon, Chakraborty et al. 
2001; Nishimoto 1993), inducing cell differentiation, migration and invasion. Furthermore, activation of 
plasmin on uPAR-IGF2R complex can activate latent MMPs, which are also involved in cellular 
migration and invasion. Consistent with this, exogenous IGF-II increased MMP-2 and MMP-9 activity in Chapter 3    Effect and interaction of IGF-II and oxygen 
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first trimester primary trophoblast cultures (Hills, Elder et al. 2004). Indeed, in the current study, Igf2 and 
Igf2r gene expression were positively correlated with villous tip outgrowth, and are both abundantly 
expressed by EVT at the invading front (Han, Bassett et al. 1996; Ohlsson, Holmgren et al. 1989), 
further supporting a role for IGF2R in mediating IGF-II regulation of trophoblast migration and invasion. 
Interestingly, exogenous IGF-II increased the proliferation and migration response by 60-70% in 
explants exposed to 20% oxygen atmospheres in placenta from 12 weeks gestation. This is likely to 
reflect a stimulation in growth of explants that are otherwise not growing well as there was a decline in 
outgrowth with gestational age. Certainly, IGF-II has well documented roles in the promotion of cell 
survival and protection from apoptosis (Jones and Clemmons 1995). 
 
Despite the positive effects of low oxygen availability on explant outgrowth from placenta at 7-8 weeks 
of gestation, culture of explants from greater than 9 weeks of gestation in low oxygen atmospheres 
reduced the proportion of villous tips outgrowing. This observation presumably reflected a state of 
hypoxic stress, as it is believed that endovascular trophoblast plugs, which initially occlude the maternal 
spiral arteries, gradually disperse from 10 weeks of gestation, allowing maternal arterial blood to flow 
into the intervillous space and increased oxygen tension to 8-9% (Jaffe, Jauniaux et al. 1997; Jauniaux, 
Hempstock et al. 2003; Jauniaux, Jurkovic et al. 1992). Comparison of explant outgrowth in response to 
5% or 1% oxygen with 20% oxygen, revealed there was a significant effect of oxygen tension in 
placenta of 11 weeks and 10 weeks gestation, respectively. This was shown as a gradual decline in the 
effect of oxygen concentration as gestational age increased, supporting the concept that placenta 
becomes exposed to increasing oxygen concentrations late in the first trimester of pregnancy in vivo. 
Furthermore, the change in responsiveness to low oxygen atmospheres in explants greater than 10 
weeks gestation in 1% oxygen is consistent with the observation that endovascular trophoblastic plugs 
dissociate at this time (Burton, Jauniaux et al. 1999; Jaffe, Jauniaux et al. 1997; Jauniaux, Hempstock 
et al. 2003; Jauniaux, Jurkovic et al. 1992; Jauniaux, Watson et al. 2001; Rodesch, Simon et al. 1992). 
The decline in explant outgrowth in placenta less than 11 weeks of gestation in 5% oxygen is also 
expected, as this concentration of oxygen is still lower than that reported for the intervillous space in 
vivo, which is 8-9% oxygen at this time (Rodesch, Simon et al. 1992). 
 
In later gestation, the placenta undergoes dramatic remodelling and differentiation to increase its 
functional efficiency and support the demands of the growing fetus. These changes  result from 
developmentally regulated periods of villous arborization, branching and non-branching angiogenesis 
and trophoblast terminal differentiation into syncytium (Kaufmann, Mayhew et al. 2004), the latter of 
which is specialised for hormone synthesis. These all result in increased surface area of Chapter 3    Effect and interaction of IGF-II and oxygen 
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syncytiotrophoblast for placental exchange between the maternal and fetal circulations. Perturbations in 
the normal pattern of placental development will lead to a placenta with altered function and may 
compromise the pregnancy (Mayhew, Charnock-Jones et al. 2004). Interestingly, TGF-β1 promotes 
terminal differentiation of trophoblast into syncytium (Graham, Lysiak et al. 1992) by increasing 
cadherin-11 cell surface expression (Getsios, Chen et al. 1998). Thus, we hypothesize that later in 
pregnancy, when IGF-II synthesis declines (Han, Bassett et al. 1996) and the placenta is well 
oxygenated, trophoblast activation of TGF-β1 might provide a means for functional morphogenesis of 
the placental villous tree. Certainly, TGF-β plays dominant roles in regulating the development and 
patterning (by determining the number of branches, branch angles, and morphological features of the 
epithelial stalk) of other organs composed of epithelial trees, including the mammary gland (Ewan, 
Shyamala et al. 2002; Pollard 2001; Silberstein 2001), lung (Karihaloo, Nickel et al. 2005) and kidney 
(Bartram and Speer 2004; Bush, Sakurai et al. 2004; Davies and Fisher 2002; Karihaloo, Nickel et al. 
2005). Trophoblast activation of TGF-β1 in precise positions on the chorionic villous tree may therefore 
modify the morphogenesis and complexity of the arborizing structure in late pregnancy.  
 
In conclusion, the current and previous studies have indicated that oxygen availability at the feto-
maternal interface “fine-tunes” trophoblast behaviour by influencing the balance of IGF-II expression 
and TGF-β1 activation. We propose that early in pregnancy, prior to the onset of maternal blood flow to 
the intervillous space, the hypoxic environment stimulates IGF-II synthesis, which promotes trophoblast 
villous outgrowth and invasion of the maternal decidua by direct effects on trophoblast function and 
inhibiting molecules secreted by the decidua, namely TGF-β1, which act to inhibit this process. This 
promotes circumferential growth of the placenta and allows adequate invasion and subsequent 
remodelling of the maternal vasculature. Later in pregnancy, when oxygen levels increase and IGF-II 
synthesis declines, TGF-β1 sequestered in the decidua can act on trophoblast to promote terminal 
differentiation of EVTs, which is required for functional capacity. It is possible that alterations in the 
expression of IGF-II, TGF-β1 or components of the IGF2R-uPAR complex may contribute to the overall 
shape of the villous tree and thus influence functional capacity and pregnancy outcome.  
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4.1  Introduction 
Intrauterine growth restriction (IUGR) is an important obstetric and neonatal condition that affects 
approximately 6% of Australian births (Laws and Sullivan 2004). It is associated with increased fetal and 
neonatal mortality and morbidity, and neurological handicap in children (Fitzhardinge 1985; Kramer 
1990; Kramer, Olivier et al. 1990; Low, Handley-Derry et al. 1992; Smith, Smith et al. 1998). 
Furthermore, IUGR is also associated with increased risk of poor health in offspring in adult life, 
including atherosclerosis (Martyn, Gale et al. 1998), coronary heart disease (Barker 1995), hypertension 
(Barker, Bull et al. 1990), insulin resistance, non-insulin dependent diabetes (Barker 1998; Barker and 
Clark 1997) and elevated plasma cholesterol (Barker, Martyn et al. 1993) in the offspring later in adult 
life. All of these are major public health concerns as they significantly contribute to the premature death 
and poor health of individuals in the Western world. Despite extensive investigations, the precise 
pathological events responsible for the development of IUGR have not been elucidated and therefore, 
currently there are no effective preventative treatments. A better understanding of the regulation of fetal 
growth may provide insight into the pathophysiology of IUGR, which is important not only for 
reproduction but for the long-term programming of adult health. 
 
Fetal growth is dependent on maternal supply of nutrients and oxygen. To ensure a continuous delivery 
of nutrients to the fetus despite intermittent food intake, the maternal body undergoes several 
physiological changes during pregnancy which, in turn, are influenced by maternal factors including diet 
and hormonal milieu (Butte 2005; Owens 1991). The placenta is critical to these processes, as it forms 
the functional interface between the maternal and fetal circulations. It mediates all interactions between 
the mother and fetus, including transport of nutrients and oxygen from the mother to the fetus. The 
placenta may also indirectly influence the supply of substrate to the fetus through its elaboration of 
peptide and steroid hormones, secreted into the maternal and fetal circulations, which influence 
metabolism and alter nutrient utilization and substrate partitioning between the mother and fetus (Butte 
2000; Catalano 1999; Ryan and Enns 1988). Thus, the placenta has the unique ability to alter the 
pattern of fetal development and affect pregnancy outcome. 
 
The syncytiotrophoblast is the transporting epithelium of the placenta and maternal to fetal exchange of 
substrate is mediated by transporter systems embedded in the maternal facing, microvillous membrane 
(MVM) and the fetal facing, basal membrane (BM). Glucose and amino acids are the main substrates 
utilized by the fetus and thus it is not surprising that human IUGR fetuses display reduced plasma 
concentrations of both these substrates (Cetin, Corbetta et al. 1990; Cetin, Radaelli et al. 2001; Chapter 4    Acute effects of IGF treatment 
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Economides and Nicolaides 1989) and significant reductions in placental nutrient transport capacity 
(Jansson and Powell 2006). For instance, System A sodium-dependent transporters are responsible for 
mediating the uptake and transfer of neutral amino acids, including alanine, glycine, glutamine and 
serine (McGivan and Pastor-Anglada 1994). The activities of System A transporters are reduced in 
IUGR pregnancies and correlate with severity of growth restriction (Glazier, Cetin et al. 1997; Jansson, 
Ylven et al. 2002; Mahendran, Donnai et al. 1993), suggesting that alterations in placental transport 
capacity represent an important mechanism for influencing/regulating fetal growth. Importantly, these 
studies also demonstrate that System A transporter activity perturbations were localised specifically to 
the syncytiotrophoblast MVM, and not BM. This implies that factors in the maternal circulation perfusing 
the placenta, have the potential to alter placental amino acid uptake and transfer through regulation of 
System A transporters on MVM.  
 
Transport of glucose by the placenta occurs by facilitated carrier diffusion, primarily through glucose 
transporter (GLUT)-1. GLUT-1 is primarily localised to MVM (Jansson, Wennergren et al. 1993; 
Tadokoro, Yoshimoto et al. 1996; Takata, Kasahara et al. 1992), suggesting that placental glucose 
delivery across the BM is the rate-limiting step (Illsley 2000). In contrast to System A amino acid 
transport, and despite fetal hypoglycaemia, glucose transport activity is unaltered in placenta from 
human IUGR pregnancies (Jansson, Wennergren et al. 1993; Jansson, Ylven et al. 2002; Kainulainen, 
Jarvinen et al. 1997). Interestingly, the capacity for the placenta to deliver glucose is increased in BM of 
placenta from pregnancies complicated by insulin-dependent diabetes mellitus associated with 
increased fetal growth (Gaither, Quraishi et al. 1999; Jansson, Wennergren et al. 1999), but is unaltered 
in gestational diabetes, which is also associated with accelerated growth of the fetus (Jansson, 
Ekstrand et al. 2001). This work suggests that, glucose transporters are responsive to stimulation in 
early pregnancy and affect subsequent fetal growth. Further studies on the regulation of placental 
metabolism and maternal and fetal utilization of substrate may help to elucidate the mechanisms 
involved in placental transfer in pregnancies associated with fetal growth restriction. Certainly, factors on 
either side of the placenta may have impacts on placental metabolism and nutrient transfer and 
partitioning and thus, regulate fetal growth.  
 
The insulin-like growth factors (IGFs) may be such factors, as they are abundantly expressed by the 
fetus and mother in most species (Fowden 2003; Murphy, Smith et al. 2006), with IGF-II also copiously 
synthesized by the placenta (Han and Carter 2000) Both IGFs play dominant roles in the regulation of 
fetal growth (Baker, Liu et al. 1993; DeChiara, Efstratiadis et al. 1990; Liu, Baker et al. 1993) and may 
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partitioning during pregnancy. IGF-I and IGF-II are anabolic polypeptides, expressed in most tissues, 
and circulate around the body in association with IGF-binding proteins (IGFBPs). IGFBPs affect the 
bioavailability of IGF-I and IGF-II (Jones and Clemmons 1995) and are considered to regulate the 
endocrine actions of IGFs, as they localise IGFs to specific cell types and modulate both IGF binding to 
receptors and growth promoting actions (Kelley, Oh et al. 1996; Wetterau, Moore et al. 1999). IGFs can 
bind to two types of IGF receptor, IGF1R and IGF2R, as well as the insulin receptor (InsR) with different 
affinities and effects. During pregnancy, substantial changes in the abundance of IGFs and IGFBPs in 
the maternal circulation occur (Donovan, Giudice et al. 1991; Gargosky, Moyse et al. 1990; Hills, 
English et al. 1996; Nason, Binder et al. 1996; Sohlstrom, Katsman et al. 1998b; Travers, Madon et al. 
1990; Wilson, Bennett et al. 1982), which further suggest an important regulatory role for the IGFs in 
pregnancy. 
 
Studies performed in vitro in human placental trophoblasts have demonstrated that IGFs have the ability 
to influence glucose and amino acid transport across the placenta (Bloxam, Bax et al. 1994; Karl 1995; 
Kniss, Shubert et al. 1994; Yu, Iwashita et al. 1998). These may have been due to direct impacts on 
nutrient transporter expression. Certainly, IGF-I induces gene and protein expression of Slc2a1 and 
Slc2a3 (genes that encode GLUT-1 and GLUT-3) in bovine chromaffin cells, in vitro (Fladeby, Skar et al. 
2003) and equine articular chondrocytes (Phillips, Ferraz et al. 2005). Exogenous IGF-I also promotes 
the re-distribution/translocation of GLUT-1, GLUT-3 and GLUT-4 from their intracellular storage sites, to 
the cell surface in muscle cell lines, which resulted in increased glucose uptake and transfer (Bilan, 
Mitsumoto et al. 1992a; Bilan, Mitsumoto et al. 1992b; Wilson, Mitsumoto et al. 1995). Interestingly, in 
mice where the Igf2 P0 transcript, responsible for placental IGF-II synthesis, has been deleted, System 
A amino acid uptake by the placenta was up-regulated in early pregnancy (Constancia, Hemberger et 
al. 2002) and placental glucose transport enhanced throughout gestation (Constancia, Angiolini et al. 
2005). This may have been an adaptive mechanism to increase fetal growth in spite of reduced 
development and passive permeability of the placenta in these mice (Constancia, Hemberger et al. 
2002; Sibley, Coan et al. 2004). 
 
IGFs appear to also modify placental substrate transfer through impacts on placental structure. 
Certainly, diminished circulating concentrations of both IGFs in undernourished guinea pig mothers 
(Roberts, Kind et al. 2002; Roberts, Sohlstrom et al. 2001a; Roberts, Sohlstrom et al. 2001b; Sohlstrom, 
Katsman et al. 1998b) or reduced placental synthesis of IGF-II in Igf2 P0 mice (Constancia, Hemberger 
et al. 2002), increased thickness of the barrier for transport and reduced the surface area across which 
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capacity of the placenta to deliver substrate to the fetus and may explain the development of fetal 
growth restriction. These studies indicate that placental transport alterations can contribute directly to 
the growth of the fetus and are likely to involve factors including IGF-I and IGF-II. In a more recent 
investigation undertaken in guinea pigs, maternal administration of IGF-I and IGF-II during early to mid 
pregnancy increased fetal and placental growth in mid gestation, with IGF-II also increasing maternal 
interscapular fat mass (Sohlstrom, Fernberg et al. 2001). It is not known whether the anabolic effects 
seen in response to IGF treatment are a consequence of altered placental nutrient transport and 
substrate partitioning between the mother and fetus.  
 
The aim of this study was to investigate how IGF-I or IGF-II supplementation to the mother during early 
to mid pregnancy, exerts acute effects on maternal growth and body composition and fetal and 
placental growth. The acute effects of such a treatment on placental transfer of glucose and amino 
acids and nutrient utilization in the mother and fetus, were also examined. To do this, pregnant female 
guinea pigs were treated from day 20 of pregnancy (term ~70 days) with IGF-I, IGF-II (both   
1 mg/kg/day) or vehicle. On day 35 of pregnancy, whilst the treatment was still occurring, transfer of the 
non-metabolisable radioanalogues [3H]-methyl-D-glucose (MG) and [14C]-amino-isobutyric acid (AIB) in 
vivo was measured, just prior to maternal death. Circulating fetal and maternal metabolites were 
quantitated and fetal and placental weights and maternal body composition were also recorded. This 
project was part of a shared cohort of animals used for Prue Standen’s honours work analyses. 
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4.2  Results 
 
4.2.1.1  Acute effect of maternal IGF treatment on the circulating concentration of IGFs and 
IGFBPs 
To determine the concentration of IGFs we achieved in the maternal circulation in response to this 
treatment, size exclusion HPLC (at pH 2.5) and specific RIAs were performed on maternal plasma. 
Exogenous IGF-I increased maternal plasma IGF-I by 340% (P = 0.001) and reduced that of IGF-II by 
45% (P = 0.008, Figure 4.1a). Exogenous IGF-II did not alter plasma IGF-I concentrations but increased 
plasma IGF-II by 240% (P = 0.004, Figure 4.1a). Total apparent IGFBP activity in maternal plasma was 
not altered by exogenous maternal IGF (Figure 4.1b). Maternal IGF-I treatment increased the ratio of 
IGF-I to IGFBPs in plasma by 230% (P = 0.004), while IGF-II increased the ratio of IGF-II to IGFBPs in 
plasma by 125% (P = 0.04, Figure 4.1c). 
 
Western-ligand blot analysis of pooled maternal plasma samples (Figure 4.1d) revealed distinct ~46-
kDa, ~30-kDa and ~28-kDa bands, which  were identified as IGFBP-3, IGFBP-2 and IGFBP-1, 
respectively, on the basis of their apparent molecular mass. Additionally, a faint band corresponding to 
17kDa was seen, which was identified as IGFBP-4. IGFBP-3 was the most abundant binding protein in 
all treatment groups, followed by  IGFBP-2, -1 and -4 (Figure 4.1d). IGF-I treatment increased the 
plasma levels of IGFBP-3, -2 and –1. IGF-II treatment did not alter plasma IGFBP-3 concentration, but it 
increased plasma IGFBP-2 concentration and reduced that of IGFBP-1 (Figure 4.1d). 
 
 
4.2.1.2  IGF receptor protein localization in the guinea pig placenta on day 35 of pregnancy 
To establish that IGF1R and IGF2R are expressed by the guinea pig placenta during the IGF treatment, 
immuno-labelling was performed on guinea pig placenta recovered from vehicle treated mothers killed 
on day 35 of pregnancy (Figure 4.2). IGF1R and IGF2R were ubiquitously expressed by the guinea pig 
placenta, with profuse cytoplasmic staining observed in trophoblast and fetal endothelium of the 
labyrinth and trophoblast of the interlobium (Figure 4.2a, c). Both IGF receptor proteins were 
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Figure 4.1 Acute effect of exogenous maternal IGF in early to mid pregnancy on plasma 
IGF-I, IGF-II and IGFBP concentrations in the mother. The effect of exogenous maternal IGFs
on maternal circulating IGF-I, IGF-II (a) and total IGFBP concentrations (b) and bioavailability of 
IGFs in the circulation indicated by IGF to IGFBP ratios (c) during treatment on day 35 of 
pregnancy, as determined by HPLC and RIAs. Western ligand blot of IGFBPs in pooled maternal 
plasma (d) from; vehicle (lane 1), IGF-I (lane 2) and IGF-II (lane 3) treated animals on day 35 of 
gestation with molecular masses (kDa) shown (left of blot). Data are from 3-9 mothers per 
treatment and values are expressed as means ± SEM. Asterisks denote statistically significant 
difference compared to the vehicle group, P < 0.034, determined by general linear model 
univariate ANOVA with Bonferroni Post Hoc Tests. 
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Figure 4.2 Localisation of IGF receptors in the guinea pig placenta in mid-pregnancy. 
Representative mid-sagittal serial sections of placenta on day 35 of pregnancy immuno-labelled 
for the type 1 (a and b) and type 2 (c and d) IGF receptors. Representative negative control 
placental section displayed (e and f). Two asterisks indicate maternal blood sinusoids and single 
asterisks indicate maternal blood spaces. Scale bars = 400μm (a, c, e) and 40μm (b, d, f). 
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4.2.1.3  Acute effect of maternal IGF treatment on maternal body composition 
Maternal exogenous IGF-I and IGF-II did not affect maternal weight gain over the time of treatment in 
mid-pregnancy (data not shown). Maternal IGF-I treatment increased the absolute and relative weights 
of the maternal kidneys (+16%, P < 0.001 and +15%, P = 0.024, respectively) and spleen (+40%, P = 
0.005 and +38%, P = 0.038), compared to vehicle (Table 4.1). Maternal IGF-II elevated the absolute 
weight of the heart (+13%, P = 0.58), however its fractional weight was unaltered (Table 4.1) 
 
 
4.2.1.4  Acute effect of maternal IGF treatment on litter composition, fetal growth and placental 
weight 
Maternal treatment with IGF-I or IGF-II did not alter litter size or composition on day 35 of pregnancy 
(Figure 4.3a). Maternal IGF-I supplementation increased the weights of the fetus (+11%, P = 0.048) and 
placenta (+13%, P = 0.036) compared to vehicle (Figure 4.3 b, c). IGF-II treatment of the mother did not 
alter placental or fetal weights. There was no acute effect of maternal IGF supplementation on the fetal 
weight to placental weight ratio (data not shown). 
 
 
4.2.1.5  Acute effect of maternal IGF treatment on uptake of methyl glucose and amino 
isobutyric acid by the placenta 
Treating the mother with IGF-I during early to mid pregnancy increased total placental MG uptake 
(+42%, P = 0.036) and AIB uptake per gram and total placenta (+51%, P = 0.003 and +68%, P = 0.005, 
respectively), compared to vehicle treated mothers in mid-gestation (Figure 4.4). Placenta from mothers 
treated with IGF-I had higher total AIB uptake compared with those treated with IGF-II (+61%, P = 
0.014) (Figure 4.4).  
 
 
4.2.1.6  Acute effect of maternal IGF treatment on uptake of methyl glucose and amino 
isobutyric acid by the fetus 
Treating the mother with IGF-I during early to mid pregnancy increased per gram and total fetal MG 
content (+48%, P = 0.012 and +59%, P = 0.004, respectively) and per gram and total fetal AIB uptake 
(+68%, P = 0.005 and +90%, P = 0.004, respectively), compared to vehicle treated mothers in mid-
gestation (Figure 4.5). There was no acute effect of exogenous maternal IGF-II on uptake of either 
radio-labelled substrate by the fetus. 
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Table 4.1 Acute effect of maternal IGF treatment in early to mid pregnancy on maternal body 
composition  
 Vehicle  IGF-I  IGF-II 
Number of dams  8  9  9 
Weight at d35  747 ± 16  788 ± 15  753 ± 15 
Net body mass**  700 ± 30  735 ± 23  688 ± 31 
Uterus* (g)  47 ± 5  53 ± 5  37 ± 5 
Adrenals (g) 
     (% Body weight)‡ 
0.33 ± 0.02 
0.05 ± 0.00 
0.35 ± 0.01 
0.05 ± 0.00 
0.36 ± 0.01 
0.05 ± 0.00 
Kidneys (g) 
     (% Body weight)‡ 
4.54 ± 0.1a 
6.5 ± 0.03a 
5.28 ± 0.1b 
7.5 ± 0.02b 
4.84 ± 0.1ab 
6.8 ± 0.02a 
Spleen (g) 
     (% Body weight)‡ 
1.51 ± 0.1a 
0.21 ± 0.02a 
2.11 ± 0.1b 
0.29 ± 0.02a 
1.57 ± 0.1ab 
0.22 ± 0.02a 
Pancreas (g) 
     (% Body weight)‡ 
1.98 ± 0.2 
0.28 ± 0.03 
2.13 ± 0.2 
0.29 ± 0.03 
2.07 ± 0.2 
0.29 ± 0.03 
Liver (g) 
     (% Body weight)‡ 
25.5 ± 1.0 
3.6 ± 0.1 
26.6 ± 0.9 
3.6 ± 0.1 
25.1 ± 0.9 
3.5 ± 0.1 
Lung (g) 
     (% Body weight)‡ 
4.21 ± 0.3 
0.60 ± 0.04 
3.93 ± 0.3 
0.54 ± 0.03 
3.98 ± 0.3 
0.56 ± 0.03 
Brain (g) 
     (% Body weight)‡ 
4.20 ± 0.4 
0.60 ± 0.05 
4.32 ± 0.4 
0.59 ± 0.05 
4.65 ± 0.3 
0.66 ± 0.05 
Heart (g) 
     (% Body weight)‡ 
2.01 ± 0.1a 
0.30 ± 0.01 
2.19 ± 0.1ac 
0.31 ± 0.01 
2.28 ± 0.1c 
0.30 ± 0.01 
Ovaries (g) 
     (% Body weight)‡ 
0.17 ± 0.08 
0.02 ± 0.00 
0.16 ± 0.07 
0.02 ± 0.00 
0.26 ± 0.07 
0.05 ± 0.00 
Stomach (g) 
     (% Body weight)‡ 
7.14 ± 0.6 
1.4 ± 0.2 
7.04 ± 0.6 
0.97 ± 0.2 
6.55 ± 0.6 
0.85 ± 0.2 
S. intestine (g) 
     (% Body weight)‡ 
15.3 ± 1.3 
2.4 ± 0.2 
15.3 ± 1.3 
1.7 ± 0.2 
15.9 ± 1.3 
2.2 ± 0.2 
L. intestine (g) 
     (% Body weight)‡ 
7.99 ± 0.8 
1.1 ± 0.2 
9.95 ± 0.8 
1.7 ± 0.2 
7.31 ± 0.8 
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Caecum (g) 
     (% Body weight)‡ 
10.2 ± 0.5 
1.6 ± 0.1 
10.6 ± 0.5 
1.4 ± 0.1 
10.3 ± 0.5 
1.4 ± 0.1 
Total GIT (g) 
     (% Body weight)‡ 
45.0± 1.6 
6.2 ± 0.2 
43.0± 1.6 
5.8 ± 0.3 
40.0 ± 1.6 
5.5 ± 0.2 
M.soleus (g) 
     (% Body weight)‡ 
0.17 ± 0.02 
0.02 ± 0.00 
0.20 ± 0.2 
0.03 ± 0.00 
0.16 ± 0.02 
0.02 ± 0.00 
M.biceps (g) 
     (% Body weight)‡ 
0.42 ± 0.01 
0.06 ± 0.00 
0.43± 0.01 
0.06 ± 0.00 
0.40 ± 0.01 
0.06 ± 0.00 
M.triceps (g) 
     (% Body weight)‡ 
2.13 ± 0.1 
0.30 ± 0.01 
2.26 ± 0.1 
0.31 ± 0.01 
2.09 ± 0.1 
0.29 ± 0.01 
M.gastroc (g) 
     (% Body weight)‡ 
2.13 ± 0.1 
0.27 ± 0.01 
2.04 ± 0.1 
0.28 ± 0.01 
2.09 ± 0.1 
0.26 ± 0.01 
Perirenal fat (g) 
     (% Body weight)‡ 
5.3 ± 0.5 
0.74± 0.07 
5.72 ± 0.5 
0.79 ± 0.07 
6.3 ± 0.5 
0.87 ± 0.07 
Retro fat (g) 
     (% Body weight)‡ 
7.65 ± 0.5 
1.2 ± 0.1 
7.95 ± 0.5 
0.85 ± 0.1 
7.90±0.5 
1.2±0.06 
Inter fat (g) 
     (% Body weight)‡ 
9.73 ± 0.8 
1.1 ± 0.06 
10.2 ± 0.8 
1.1 ± 0.05 
9.36 ± 0.8 
1.1 ± 0.05 
Skin (g) 
     (% Body weight)‡ 
109 ± 5 
15 ± 0.6 
122 ± 5 
17 ± 0.6  
118 ± 5 
17 ± 0.6 
Carcass (g) 
     (% Body weight)‡ 
382 ± 8 
54 ± 0.8 
397 ± 8 
54 ± 0.8  
389 ± 8 
55 ± 0.8 
Data expressed as means ± SEM. *Uterus and contents. **Net body mass is weight at post-mortem minus 
the uterus and contents. ‡ Tissue weight calculated as a percentage of net body mass. GIT, 
gastrointestinal tract; Inter fat, interscapular fat; L. intestine, large intestine; M.gastroc, M.gastrocnemius; 
Retro fat, retroperitoneal fat; S. intestine, small intestine. Different superscripts denote difference between 
groups, a vs b, P < 0.05 (significant), a vs c P = 0.058 (not significant), as determined by General Linear 







































































Figure 4.3 Acute effect of maternal IGF treatment in early to mid pregnancy on litter 
composition and fetal and placental weights. Mothers treated from day 20 of pregnancy with 
vehicle, IGF-I or IGF-II, were killed during the treatment on day 35 of pregnancy. Total litter size, 
viable and resorbing fetuses were enumerated (a) and fetal (b) and placental weights (c) were 
recorded. Data represents the mean ± SEM (a) and estimated marginal mean ± SEM, controlled 
for the number of viable pups per litter (b, c). Different superscripts denote statistical significance 
difference between groups as determined by a Linear Mixed Model Repeated Measures with 
Sidak Post Hoc test, using the mother as the subject and the fetus as a repeated measure; a vs
b, p < 0.05. The number of implantation sites and mothers per group are vehicle: 27 and 8, 
respectively, IGF-I: 31 and 8, respectively and IGF-II: 20 and 9, respectively.
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Figure 4.4 Acute effect of maternal IGF treatment in early to mid pregnancy on placental 
uptake of substrate. Placental uptake of [3H]-methyl-D-glucose (MG, a) and [14C]-
aminoisobutyric acid (AIB, b). Data are expressed as estimated marginal mean DPM ± SEM, 
controlling for the number of viable pups per litter. Different superscripts denote statistically 
significant difference between groups as determined by a Linear Mixed Model Repeated 
Measures with Sidak Post Hoc test, using the mother as the subject and the fetus as a repeated 
measure, a vs b, p < 0.05. The number of placenta and mothers per group are vehicle: 27 and 8, 
respectively, IGF-I: 31 and 8, respectively and IGF-II: 20 and 9, respectively.
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Figure 4.5  Acute effect of maternal IGF treatment in early to mid pregnancy on fetal 
utilization of substrate. Fetal uptake of [3H]-methyl-D-glucose (MG, a) and [14C]-aminoisobutyric 
acid (AIB, b). Data are expressed as estimated marginal mean DPM ± SEM, controlling for the 
number of viable pups per litter. Different superscripts denote statistically significanct difference 
between groups as determined by a Linear Mixed Model Repeated Measures with Sidak Post 
Hoc test, using the mother as the subject and the fetus as a repeated measure, a vs b, p < 0.05. 
The number of fetuses and mothers per group are vehicle: 27 and 8, respectively, IGF-I: 31 and 
8, respectively and IGF-II: 20 and 9, respectively.
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4.2.1.7  Acute effect of maternal IGF treatment on circulating methyl glucose and amino 
isobutyric acid in the mother 
There was no acute effect of maternal IGF treatment on the circulating concentrations of MG or AIB in 
the mother (Figure 4.6a). 
 
 
4.2.1.8  Acute effect of maternal IGF treatment on uptake of methyl glucose by the mother 
Uptake of methyl glucose by individual maternal organs and tissues are displayed in Table 4.2. When 
tissues were analysed individually, there was no significant effect of maternal IGF treatment on the 
uptake of MG per gram of tissue (Table 4.2). However, maternal IGF-I supplementation increased total 
spleen uptake of MG compared with vehicle and IGF-II treated mothers (+97%, P = 0.012, +65%, P = 
0.043, respectively). 
 
When all tissues were combined, there was no acute effect of maternal IGF treatment on MG uptake per 
gram of tissue (Figure 4.6b). However, IGF-I increased total uptake of MG by muscle (+23%, P = 0.015) 
(Figure 4.6 c).  
 
 
4.2.1.9  Acute effect of maternal IGF treatment on uptake of amino isobutyric acid by the 
mother  
Uptake of amino isobutyric acid by individual maternal organs and tissues are displayed in Table 4.3. 
Exogenous IGF-I treatment acutely increased per gram and total AIB uptake by the maternal brain 
(+77%, P = 0.007; +85%, P = 0.004, respectively) and spleen (+52%, P = 0.035; +222%, P = 0.004, 
respectively) (Table 4.3). Uptake (DPM / g) of AIB by the maternal triceps was increased by maternal 
IGF-I and IGF-II (+35 and +40%, both P = 0.078) and maternal IGF-I increased total uptake by maternal 
gastrocnemius (+29%, P = 0.07) but these failed to reach statistical significance. 
 
When all tissues were combined, there was no acute effect of maternal IGF treatment on AIB uptake per 
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Table 4.2 Acute effect of maternal IGF treatment in early to mid pregnancy on methyl glucose 
uptake in the mother 
 Vehicle  IGF-I  IGF-II 
Number   7  9  9 
Brain         (DPM / gram) 
                  (total DPM) 
151 ± 21 
632 ± 104 
182 ± 17 
792 ± 93 
194 ± 19 
896 ± 94 
Heart         (DPM / gram) 
                  (total DPM) 
334 ± 69 
673 ± 143 
228 ± 68 
490 ± 127 
274 ± 62 
629 ± 128 
Liver          (DPM / gram) 
                  (total DPM) 
269 ± 38 
6653 ± 1004 
338 ± 34 
8894 ± 895 
312 ± 34 
7940 ± 903 
Lungs        (DPM / gram) 
                  (total DPM) 
595 ± 150 
2165 ± 536 
548 ± 128 
2123 ± 458 
507 ± 123 
1988 ± 440 
Kidneys     (DPM / gram) 
                  (total DPM) 
442 ± 125 
1962 ± 639 
470 ± 117 
2472 ± 597 
698 ± 120 
3492 ± 616 
Spleen       (DPM / gram) 
                  (total DPM) 
166 ± 25a 
238 ± 53a 
226 ± 23b 
469 ± 48b 
178 ± 23ab 
285 ± 48a 
Triceps      (DPM / gram) 
                  (total DPM) 
73 ± 7 
155 ± 18 
93 ± 7 
209 ± 16 
89 ± 7 
189 ± 16 
Gastroc.     (DPM / gram) 
                  (total DPM) 
71 ± 6 
134 ± 13 
85 ± 6 
175 ± 12 
83 ± 6 
156 ± 12 
Interscap.   (DPM / gram) 
                  (total DPM) 
43 ± 3 
392 ± 42 
41 ± 3 
420 ± 37 
42 ± 3 
401 ± 37 
Perirenal    (DPM / gram) 
                  (total DPM) 
112 ± 22 
532 ± 95 
84 ± 20 
450 ± 84 
103 ± 20 
576 ± 85 
Retroperit. (DPM / gram) 
                  (total DPM) 
65 ± 26 
459 ± 212 
70 ± 21 
553 ± 175 
88 ± 21 
693 ± 177 
Data expressed as estimated marginal means ± SEM adjusted for the number of viable fetuses per litter. 
Different superscripts denote difference between groups, a vs b, P < 0.05 (significant); a vs c P = 0.07 (not 
significant), as determined by General Linear Univariate ANOVA with Bonferoni Post Hoc Tests. 
 Figure 4.6 Acute effect of maternal IGF treatment in early to mid pregnancy on maternal 
utilization of substrate. Plasma (a) and tissue content of [3H]-methyl-D-glucose, (MG, b and c) and 
[14C]-aminoisobutyric acid, (AIB, d and e). Uptake expressed per gram (b and d) of tissue or total (c
and e). Values are expressed as mean DPM ± SEM from 8-9 mothers per treatment. Different 
superscripts denote statistically significant difference between groups determined by Univariate 
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Table 4.3 Acute effect of maternal IGF treatment in early to mid pregnancy on amino isobutyric 
acid uptake in the mother 
 Vehicle  IGF-I  IGF-II 
Number   7  9  9 
Brain         (DPM / gram) 
                  (total DPM) 
3.1 ± 0.5a 
13 ± 2a 
5.5 ± 0.5b 
24 ± 2b 
4.5 ± 0.5a 
20 ± 2ab 
Heart         (DPM / gram) 
                  (total DPM) 
104 ± 16 
207 ± 33 
78 ± 14 
168 ± 29 
91 ± 14 
205 ± 30 
Liver          (DPM / gram) 
                  (total DPM) 
296 ± 67 
6951 ± 1427 
354 ± 59 
9114 ± 1271 
293± 60 
7271 ± 1282 
Lungs        (DPM / gram) 
                  (total DPM) 
338 ± 130 
1217 ± 485 
403 ± 111 
1568 ± 415 
282 ± 107 
1104 ± 398 
Kidneys     (DPM / gram) 
                  (total DPM) 
229 ± 36 
1962 ± 639 
247 ± 34 
2472 ± 597 
244 ± 35 
3492 ± 616 
Spleen       (DPM / gram) 
                  (total DPM) 
160 ± 22a 
228 ± 56a 
243 ± 20b 
507 ± 50b 
182 ± 20a 
307 ± 50a 
Triceps      (DPM / gram) 
                  (total DPM) 
20 ± 2a 
44 ± 6 
27 ± 2c 
61 ± 6 
28 ± 2c 
58 ± 6 
Gastroc.     (DPM / gram) 
                  (total DPM) 
19 ± 2 
35 ± 3a 
22 ± 2 
45 ± 3c 
21 ± 2 
39 ± 3ac 
Interscap.   (DPM / gram) 
                  (total DPM) 
11 ± 1 
104 ± 13 
10 ± 1 
104 ± 11 
11 ± 1 
108 ± 11 
Perirenal    (DPM / gram) 
                  (total DPM) 
26 ± 10 
136 ± 52 
23 ± 9 
125 ± 46 
40 ± 9 
216 ± 47 
Retroperit. (DPM / gram) 
                  (total DPM) 
16 ± 5 
114 ± 40 
12 ± 4 
96 ± 32 
21 ± 4 
171 ± 33 
Data expressed as estimated marginal means ± SEM adjusted for the number of viable fetuses per litter. 
Different superscripts denote difference between groups, a vs b, P < 0.05 (significant) and a vs c P < 
0.078 (not significant), as determined by General Linear Univariate ANOVA with Bonferoni Post Hoc 
Tests. 
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4.2.1.10   Acute effect of maternal IGF treatment on circulating metabolites in the mother 
There was no acute effect of maternal IGF treatment on the circulating concentrations of glucose, free 
fatty acids, amino acids, triglycerides or cholesterol in the mother (Figure 4.7a), as determined by 
enzymatic and colorimetric assays. There were no significant correlations of maternal circulating 




4.2.1.11   Acute effect of maternal IGF treatment on circulating hormones in the mother 
To determine whether treatment of the mother during early to mid pregnancy with IGFs altered maternal 
circulating estradiol (Figure 4.7b) and progesterone (Figure 4.7c), their concentrations were determined 
using RIAs. There was a trend for increased circulating estradiol (+150%) and progesterone 
concentrations (+53%), in mid pregnancy following exogenous maternal IGF-II, however these also did 
not reach statistical significance (P = 0.08). There were no significant correlations of maternal circulating 
hormone concentrations with maternal body composition or circulating metabolite concentrations or with 



























































Figure 4.7 Acute effect of maternal IGF treatment in early to mid pregnancy on maternal 
circulating metabolite and hormone concentrations. Plasma concentrations of amino acids 
(AA), cholesterol (Chol), free fatty acids (FFA), glucose (Gluc) and triglycerides (Trig) (a), as well 
as estradiol (b) and progesterone (c) in the mother, were determined. Data are from 6-8 mothers 
per treatment and values are expressed as mean ± SEM.
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4.3  Discussion 
The results of the current study indicate that maternal IGF-I treatment from early pregnancy, increases 
placental glucose and System A amino acid transfer and fetal uptake, while enhancing maternal muscle 
substrate utilization in mid pregnancy. Furthermore, maternal administration of IGF-I also increased 
placental and fetal growth and altered maternal body composition. By contrast, IGF-II treatment did not 
affect mid-gestational placental glucose and System A amino acid transport and substrate partitioning 
between the mother and fetus. IGF-II also did not alter fetal, placental nor maternal growth in the current 
study, despite increased fetal and placental growth a few days following treatment in a similar study 
previously performed in guinea pigs (Sohlstrom, Fernberg et al. 2001).  
 
It is well established that human pregnancies complicated by IUGR display altered activity and/or 
expression of placental nutrient and ion transporters (Jansson and Powell 2000; Jansson and Powell 
2006). In the current study, exogenous maternal IGF-I increased the activity of the System A amino acid 
transporters in mid pregnancy, as measured by AIB uptake per gram and total placental weight, and 
fetal AIB content. Indeed, System A transporter activity on the MVM of the syncytiotrophoblast is 
reduced in human placenta from IUGR pregnancies (Glazier, Cetin et al. 1997; Jansson, Ylven et al. 
2002; Mahendran, Donnai et al. 1993) and down-regulated in IUGR induced by maternal protein 
restriction in rats (Malandro, Beveridge et al. 1996) and uterine artery ligation in guinea pigs (Jansson 
and Persson 1990). Additionally, there is a positive association of System A transport and fetal growth 
in human pregnancy (Dicke and Henderson 1988; Mahendran, Donnai et al. 1993). Furthermore, partial 
inhibition of System A activity by administration of meAIB to pregnant rats results in IUGR (Cramer, 
Beveridge et al. 2002), clearly highlighting the importance of system A transport functionality for fetal 
growth. Work performed in rats more recently has demonstrated that, reductions in System A activity 
precede the development of IUGR (Jansson, Pettersson et al. 2006), suggesting that alterations in 
placental transport are the cause of alterations in fetal growth. Indeed in the current study, elevated 
maternal plasma IGF-I also increased fetal and placental weights.  
 
In addition to effects on amino acid transfer in the current study, elevated maternal IGF-I treatment 
increased overall placental uptake of glucose. Interestingly, IGF-I did not alter glucose uptake per gram 
of placenta, suggesting that placental glucose metabolism is unaltered and that increased total placental 
uptake is due to increased placental mass observed with the treatment. Nevertheless, placental supply 
of glucose to the fetus is increased as indicated by elevated MG concentrations in fetuses. Indeed, 
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and System A amino acids per gram of fetal tissue. This increase may have been related to indirect 
effects of maternal IGF-I on transplacental substrate transport, as amino acid and glucose are potent 
stimulators of insulin release from the fetal pancreas, which regulates fetal growth. Concomitantly, 
maternal exogenous IGF-I accelerated fetal growth on day 35 (current study), with both IGF-I and IGF-II 
increasing fetal weight on day 40 (Sohlstrom, Fernberg et al. 2001). This is consistent with reported 
reductions in maternal plasma IGF-I concentrations from 20 weeks to delivery in human pregnancies 
complicated by IUGR (Holmes, Montemagno et al. 1997). 
 
The cellular mechanisms responsible for increased placental transport in IGF-I treated mothers remain 
to be established. It is hard to determine whether increased glucose and amino acid supply were 
caused by an alteration in the concentration gradient between the fetal and maternal circulations, which 
is known to influence substrate partitioning between the mother and fetus, as fetal plasma could not be 
recovered at this gestational age. However, this seems unlikely, as the circulating concentrations of 
amino acids and glucose, as well as other metabolites in the mother, were unaltered by either IGF 
treatment on day 35 (current study) or on day 40 of pregnancy (Sohlstrom, Fernberg et al. 2001). 
Instead, we speculate that maternal IGFs may have exerted an endocrine influence over the placenta, 
as we found abundant IGF1R and IGF2R immunoreactivity in trophoblast, particularly on the surface 
facing maternal blood spaces. If this is the case, maternal exogenous IGF-I may have increased 
placental transport by altering placental blood flow through its vasorelaxant effects, as previously 
demonstrated in vitro (Siler-Khodr and Forman 1993; Siler-Khodr, Forman et al. 1995) and in vivo 
(Schini-Kerth 1999; Yang, Chao et al. 2006). 
 
Alternatively, IGF-I effects on placental substrate transfer may have been mediated through direct 
stimulation of transporter activity or expression, particularly in the case of System A amino acid 
transport, which was increased per gram of placenta. The System A amino acid transporters are 
encoded by the Slc38 gene family and give rise to three isoforms, SNAT1, SNAT2 and SNAT4, which 
are expressed by the placenta of humans (Desforges, Lacey et al. 2006; Wang, Huang et al. 2000), rats 
(Mackenzie and Erickson 2004) and mice (Constancia, Angiolini et al. 2005). It was recently 
demonstrated that restriction of protein intake by pregnant rats, which reduced maternal circulating  
IGF-I, decreased SNAT2 protein expression and System A activity, resulting in IUGR (Jansson, 
Pettersson et al. 2006). Furthermore, IGF-I over-abundance in growth hormone transgenic mice, altered 
placental expression of other amino acid transporters (Matthews, Beveridge et al. 1999). Unfortunately, 
no study has characterized the expression of amino acid transporters in the guinea pig and thus, future Chapter 4    Acute effects of IGF treatment 
Amanda N Sferruzzi-Perri  126 
research endeavours should be directed at identifying them and determining the effect of IGF 
supplementation on their abundance and activity.  
 
In addition to direct effects on placental transporter expression, IGF-I may enhance the function of the 
System A transporters, leading to increased uptake by the placenta and increased delivery of substrate 
(AIB) to the fetus. The function of the System A transporters depends on the activity of the placental 
sodium-proton exchanger and the sodium-potassium-ATPase pump, both of which are reduced on the 
MVM of placenta in pregnancies complicated by IUGR (Glazier, Cetin et al. 1997; Johansson, Glazier et 
al. 2002; Johansson, Karlsson et al. 2003). Insulin is known to stimulate the sodium-proton exchanger in 
red blood cells (Ceolotto, Conlin et al. 1997) and other tissues (Sweeney and Klip 1998) as well as the 
sodium-potassium ATPase pump (Ewart and Klip 1995). Thus, it would be interesting to know whether 
IGF-I altered either of these, as these would be expected to enhance System A transporter activity.  
 
An additional mechanism, by which IGF-I may elicit its effects on placental transfer, may be through the 
mammalian target of rapamycin (mTOR). mTOR is a serine/threonine kinase, which amongst other cell 
functions, controls cell metabolism and growth through its impacts on transcription and translation and 
nutrient uptake in many cell types (Regnault, Friedman et al. 2005). mTOR has been suggested to act 
as the nutrient sensor, as it responds to amino acid and glucose sufficiency, energy availability, stress, 
hypoxia and hormonal stimulation in numerous cell types (Kim, Sarbassov et al. 2002). In the presence 
of high nutrient levels, mTOR activates cell protein synthesis, growth and function, whilst in 
environments of nutrient deprivation, mTOR is inactive and the cell undergoes catabolic breakdown 
(Levine, Feng et al. 2006). IGFs activate gene expression, protein synthesis (James and Zomerdijk 
2004) and glucose transport (Fladeby, Skar et al. 2003) via the mTOR signaling pathway in several cell 
types. Recently, mTOR was identified in human placental tissue (Kim, Sarbassov et al. 2002). As IGF 
abundance is modulated by factors such as nutrition, metabolic state and stress, elevated maternal 
plasma IGF-I concentration in the current study, may have signaled to the placenta, through activation 
of mTOR, that the maternal environment is beneficial and to increase substrate supply to the fetus and 
stimulate fetal growth. Analysis of mTOR and its downstream effectors (such as 4E-binding protein-1 
and S6-kinase) in the placenta of IGF treated animals may help elucidate the mechanisms involved.  
 
In addition to acute effects on the fetus and placenta, exogenous maternal IGF-I enhanced MG and AIB 
uptake by the maternal muscle and spleen. Neither IGF affected maternal weight gain during the 
treatment. However, maternal IGF-I also increased the absolute and fractional weights of the maternal 
spleen and kidneys and IGF-II tended to increase the weight of the maternal heart. These alterations, Chapter 4    Acute effects of IGF treatment 
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particularly at the level of nutrient uptake per gram of maternal organ, suggest improved metabolism 
and thus, functional capacity, which are likely to enhance maternal blood filtration and flow to the uterus 
and thereby, accelerate conceptus growth. This is consistent with the current findings of increased fetal 
and placental growth on day 35 with IGF-I and with either IGF treatments on day 40 (Sohlstrom, 
Fernberg et al. 2001).  
 
In contrast to IGF-I, IGF-II treatment did not alter placental transport, fetal or maternal substrate 
utilization nor fetal or placental growth on day 35 of pregnancy. It is possible that, perhaps analysis on 
day 35 of gestation was simply too early to see an effect of maternal IGF-II on the fetus and placenta. 
Indeed, rapid growth of the guinea pig fetus occurs between gestation days 30 and 45 (Kaufmann 1969; 
Kaufmann and Davidoff 1977) and IGF-II increased fetal and placental growth on day 40 (Sohlstrom, 
Fernberg et al. 2001). In the Igf2 P0 knock out mouse, effects of this genotype on placental 
development, transport and fetal growth, were not apparent until after mid gestation (from gestational 
day 14 and onwards, term = day 20) (Baker, Liu et al. 1993; Constancia, Hemberger et al. 2002; 
DeChiara, Efstratiadis et al. 1990). It would be interesting to examine placental gene expression or 
placental invasion of the uterus, to determine what molecular events are taking place in response to 
maternal IGF-II treatment, which result in enhanced fetal and placental growth on day 40 (Sohlstrom, 
Fernberg et al. 2001). Certainly, maternal IGF-II treatment tended to increase circulating estradiol and 
progesterone concentrations in the mother, in the current study, suggestive of enhanced placental 
steriodogenesis.  
 
It is also possible to speculate that the lack of effects of IGF-II on the placenta, fetus and mother may 
have been related to the extent to which concentrations in the maternal plasma were elevated for the 
dose administered. In the current study, although the dose of IGF-I and IGF-II administered was the 
same (1mg/kg/day), the percent increase in circulating IGFs achieved was different due to the greater 
abundance of IGF-II in normal pregnancy sera. We achieved a 340% increase in circulating IGF-I, while 
that of IGF-II was increased by just 240%. Furthermore, although the concentration of free IGF to 
IGFBP ratio in the maternal plasma, and hence bioavailable IGF, was also increased by maternal IGF 
treatment, the extent to which bioavailable IGF-II was increased compared to vehicle, was almost half 
that of IGF-I in the IGF-II treated mother. Therefore, the dose of IGF-II administered to the mother may 
have been too low to exert any acute growth/metabolic effects. To elicit similar effects to those of IGF-I, 
it may be necessary to elevate circulating and bioavailable IGF-II to a similar level relative to that of IGF-
I. Moreover, it is thought that IGF-I is more potent than IGF-II at inducing amino acid uptake by cultured 
placental trophoblasts (Karl 1995). This also suggests that IGF impacts on substrate uptake occur via Chapter 4    Acute effects of IGF treatment 
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the IGF1R, which IGF-I has greater affinity than IGF-II. IGF-II effects are expected to be distributed 
across IGF2R, IGF1R and InsR, which it can bind. 
 
Interestingly, maternal IGF-I treatment increased the concentration of IGFBP-3, IGFBP-2 and IGFBP-1 
in the maternal circulation. This was surprising as neither IGF treatments altered the maternal circulating 
total IGFBP binding capacity, in the current study. This difference may reflect reduced sensitivity in 
measurement of the latter, which was determined indirectly as the interference of the IGFBPs in the IGF 
radioimmunoassay, as previously utilized by others (Francis, McNeil et al. 1989; Francis, Owens et al. 
1989; Owens, Johnson et al. 1990). Nevertheless, elevated concentrations of IGFBPs in the IGF-I 
treated mother, are expected to prolong the extracellular half-life of IGF-I by preventing its proteolysis 
(Jones and Clemmons 1995). 
 
Work performed in guinea pigs has shown that the abundance and ratio of IGFs to IGFBP in the 
maternal circulation are important predictors of placental growth. For instance, Roberts and colleagues 
have demonstrated that, maternal circulating IGFBP-1 concentrations in mid pregnancy correlate 
negatively with maternal blood space volume in the exchange region of the placenta (labyrinth) 
(Roberts, Kind et al. 2002). Also a greater availability of IGF-I, reflected by increased IGF-I to IGFBP-3 
and IGFBP-1 ratios in these studies, was correlated positively with the development of the placental 
labyrinth in late pregnancy. Work performed by Prue Standen in the laboratory, has assessed placental 
structure in the same cohort of guinea pigs as the present study, in response to IGF treatment on day 
35 of gestation. Interestingly, her work has suggested that exogenous maternal IGF-I may change the 
shape of the placenta in mid gestation. IGF-I treatment of the mother reduced the total mid-sagittal 
cross-sectional area of the placenta by 17% (Standen et al., in preparation), which was largely due to a 
22% reduction in the area dedicated for exchange. Despite this, IGF-I did not alter its volume or cellular 
structure (Standen et al., in preparation). It is postulated that elevated maternal IGF-I may have induced 
placental trophoblast proliferation instead of differentiation into invasive cells, which is required for 
expansion of the placental exchange region. Alternatively, a 45% reduction in maternal circulating IGF-II 
in IGF-I treated mothers, may have indirectly led to altered placental labyrinthine development, as IGF-II 
has an established role in placental development (Constancia, Hemberger et al. 2002; Roberts, 
Sohlstrom et al. 2001b; Sibley, Coan et al. 2004) (refer to Chapter 3). This suggests that systemic IGF-I 
and modulation of its bioavailability by IGFBP-1 and IGFBP-3 or reduced plasma IGF-II abundance 
within the mother may have influenced placental growth and transporter function.  
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In conclusion, we have shown that increased maternal circulating IGF-I concentrations from early 
pregnancy, acutely increases maternal substrate utilization and placental glucose and System A amino 
acid transfer to the fetus, enhancing fetal and placental growth. While IGF-II does not induce immediate 
effects on the fetus, placenta or mother, in the current study on day 35 of gestation, this treatment has 
been reported to have anabolic effects a few days later (Sohlstrom, Fernberg et al. 2001). Further 
studies are clearly required to determine whether the effects of IGF-I in the present study, as well as 
IGF-II in a previous study (Sohlstrom, Fernberg et al. 2001), are sustained until term, after cessation of 
treatment. These promise to advance our understanding of the endocrine regulation of fetal growth by 
the IGFs through the placenta, acting as a nutrient sensor, and the mother supporting the process of 
pregnancy. This may ultimately help understand the pathophysiology of pregnancies complicated by 
growth restriction. 
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5.1  Introduction 
The placenta is a multifunctional organ that forms the interface between the fetal and maternal 
circulations. It is essential for fetal growth as it supplies the developing fetus with oxygen and nutrients, 
transporting them from the mother into the umbilical circulation. Abnormalities in placental structural 
development can impair placental function, reducing substrate supply to the fetus and may result in 
intrauterine growth restriction (IUGR) (Khong, De Wolf et al. 1986). It is estimated that placental 
dysfunction accounts for 70-80% of growth restricted newborns (Regnault, de Vrijer et al. 2002a), 
currently affecting 6% of pregnancies in developed countries (Laws and Sullivan 2004) and up to 40% in 
developing countries (Albertsson-Wikland, Wennergren et al. 1993). IUGR is associated with perinatal 
morbidity and mortality and increases the risk of poor health in childhood and adult life (Barker 1998; 
Barker 2004a; Barker 2004c). In addition, impaired placental trophoblast invasion of the maternal 
uterine vasculature and/or poor placental function are implicated in other major pregnancy 
complications, miscarriage (Khong, Liddell et al. 1987), preeclampsia (Khong 2000; Khong, De Wolf et 
al. 1986), placental abruption (Dommisse and Tiltman 1992), preterm labour (Kim, Bujold et al. 2003; 
Kim, Chaiworapongsa et al. 2002) and stillbirth (Khong, De Wolf et al. 1986; Robertson, Brosens et al. 
1967). Therefore, it is imperative that we understand the factors essential for regulating placental 
functional development to identify causes of such diseases and as a basis for the development of 
therapeutics. 
 
The insulin-like growth factors (IGF)-I and IGF-II, have been implicated in placental structural and 
functional development. Igf2 over-expression in mice causes placental and fetal overgrowth (Ferguson-
Smith, Cattanach et al. 1991), while Igf2 gene deletion reduces placental weight by 17% on day 13.5 
and 25% on day 16.5 of gestation, with a fetal weight reduction of 40% from day 16.5 (term=19 days) 
(Baker, Liu et al. 1993; DeChiara, Efstratiadis et al. 1990). In addition, placental amino acid transporter 
expression is altered by Igf2 deficiency in mice (Matthews, Beveridge et al. 1999). Ablation of the 
placental specific Igf2 promoter (P0) in mice, reduces placental weight and adversely affects placental 
structural differentiation and transport capacity with reduced fetal weight evident two days later 
(Constancia, Hemberger et al. 2002; Sibley, Coan et al. 2004). The latter reduction in fetal weight was 
comparable to that induced by global Igf2 gene ablation, suggesting that the effects of Igf2 deficiency on 
fetal growth are mediated by actions on the placenta in mice. 
 
In contrast, Igf1 gene ablation in mice does not alter placental weight but reduces fetal weight, indicating 
that IGF-I is important in the fetus (Baker, Hardy et al. 1996; Liu, Baker et al. 1993). IGF-I may modulate Chapter 5    Sustained effects of IGF treatment 1 
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placental nutrient capacity since IGF-I administration to pregnant rats, or increased endogenous 
expression in pregnant mice, increases the weight of the fetus but not that of the placenta (Gluckman 
and Harding 1992). IGF-I stimulates glucose and amino acid uptake in cultured human placental 
trophoblasts (Bloxam, Bax et al. 1994; Karl 1995; Kniss, Shubert et al. 1994; Yu, Iwashita et al. 1998) 
and promotes placental nutrient uptake and metabolism when infused into fetal sheep (Bloomfield, Zijl 
et al. 2002; Harding, Liu et al. 1994; Liechty, Boyle et al. 1996). Moreover, exposure to IGF-I inhibits 
release of vasoconstrictors, such as thromboxane B2 and prostaglandin F2 α, in human term placental 
explants (Siler-Khodr and Forman 1993; Siler-Khodr, Forman et al. 1995), which may increase placental 
blood flow and delivery of nutrients for the growth of the fetus.  
 
The placenta is exposed to IGFs from multiple sources, including those produced locally and those 
circulating within the fetus and mother. Maternally derived IGFs may have a major influence on 
placental development, particularly in women and in guinea pigs where circulating IGFs are substantial 
(Gargosky, Moyse et al. 1990; Sohlstrom, Katsman et al. 1998b). Indeed, the IGF axis in guinea pigs is 
very similar to that of humans (Keightley and Fuller 1996), whereas rats and mice do not have 
circulating IGF-II postnatally. The placenta in guinea pigs is more similar to the human placenta than 
that of other non-primate species being haemomonochorial, although it is labyrinthine rather than villous 
in structure. The guinea pig placenta is comprised of a labyrinth, which contains both fetal capillaries 
and maternal blood sinuses and provides the means for exchange between the two circulations and an 
interlobium which is comprised of syncytiotrophoblast and maternal blood sinuses, and is the site where 
much of the metabolic activity of the placenta is thought to occur (Kaufmann 1969; Kaufmann and 
Davidoff 1977). In the human placenta, exchange and endocrine functions are performed in the 
placental villi (Gude, Roberts et al. 2004). In addition, placental trophoblast cells in guinea pigs are 
highly invasive and, like those in humans, engage in interstitial and endovascular invasion of the 
decidua. They remodel the uterine spiral arterioles to permit the large increase in blood flow to the 
placenta (Moll, Espach et al. 1983; Nanaev, Chwalisz et al. 1995a) that is essential for placental growth 
and subsequent function and therefore fetal growth. 
 
In the guinea pig, major structural determinants of placental function are strongly predicted by maternal 
IGF-II concentration in mid pregnancy and by maternal IGF-I in late pregnancy (Roberts, Kind et al. 
2002; Roberts, Sohlstrom et al. 2001b). Furthermore, in this species, food restriction reduces maternal 
plasma IGF concentrations (Sohlstrom, Katsman et al. 1998b) which correlate with delayed structural 
and functional maturation of the placenta and with reduced fetal growth (Roberts, Sohlstrom et al. Chapter 5    Sustained effects of IGF treatment 1 
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2001a). The structural defects in the placenta in food restricted guinea pigs are similar to those seen in 
placentas from women with preeclampsia (Roberts, Sohlstrom et al. 2001a). In addition, reduced 
maternal plasma IGF-I in pregnant women is associated with placental dysfunction and small for 
gestational age (Larsen, Main et al. 1996; Stefanidis, Solomou et al. 1998) or growth restricted infants 
(Holmes, Montemagno et al. 1997). 
 
Consistent with these adaptive changes in maternal IGFs regulating placental development, maternal 
supplementation with IGF-I or IGF-II in early to mid pregnancy in the guinea pig increases placental and 
fetal weights by mid gestation (Sohlstrom, Fernberg et al. 2001) (Chapter 4). We therefore suggest that 
the increased maternal production of both IGFs in early pregnancy is an important adaptation to 
pregnancy, which promotes placental functional development and consequently fetal growth. Whether 
anabolic effects of an increased abundance of maternal IGFs in early pregnancy on the placenta would 
persist into late gestation and affect the fetus is currently unknown. Furthermore, in contrast to IGF-I, 
which binds almost exclusively to the type 1 IGF receptor (IGF1R) and mediates its effects on fetal 
growth (Baker, Liu et al. 1993), IGF-II cross-reacts with both IGF receptors (IGF1R and IGF2R) and the 
insulin receptor (InsR), hindering the identification of the receptor potentiating IGF-II actions. Therefore, 
the aims of this study were to 1) determine the effects of maternal IGF-I and IGF-II supplementation in 
early to mid pregnancy on placental development and fetal growth and viability near term and 2) 
determine the role of IGF2R in mediating IGF-II influences on fetal and placental growth. The latter aim 
was undertaken using, [Leu27]-IGF-II (Leu27-IGF-II), an IGF-II analogue which selectively interacts with 
IGF2R (Sakano, Enjoh et al. 1991). 
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5.2  Results 
 
5.2.1.1  Sustained effects of exogenous IGF treatment to the mother on maternal body 
composition and weight gain during pregnancy  
Pregnant guinea pigs were infused with IGF-I, IGF-II, Leu27-IGF-II (each 1mg/kg/day) or vehicle (0.1M 
acetic acid) subcutaneously from days 20 to 38 of pregnancy and killed on day 62 (term = 69 days). 
This treatment elevated maternal circulating IGF-I and IGF-II concentrations by 2.4 and 3.4 fold, 
respectively (Chapter 4, p 109). 
 
To determine whether exogenous IGFs affected the mother, maternal weight gain and body composition 
analyses were performed. Both exogenous maternal IGF-I, IGF-II and Leu27-IGF-II did not alter maternal 
weight gain during or following IGF treatment (Figure 5.1), nor total body and lean body mass near term 
(Table 5.1). IGF-I reduced maternal interscapular fat depot weight (-25%, P = 0.028) and the fractional 
weights of the perirenal (-32%, P = 0.05), retroperitoneal (-33%, P = 0.037) and interscapular fat (-28%, 
P = 0.01, Table 5.1). IGF-I reduced the absolute and fractional weights of the combined adipose depot 
weights in the mother by ~30%, (P = 0.016 and P = 0.007, respectively). Leu27-IGF-II reduced the 
absolute and fractional weights of the maternal retroperitoneal fat (-34%, P = 0.04 and -32%, P = 0.02, 
respectively) and the absolute weight of the maternal interscapular fat (-18%, P = 0.05). IGF-II treatment 
tended to increase the absolute weight of the spleen (+31%, P = 0.056) but did not affect any other 
tissue or organ weight in absolute or relative to body weight terms (Table 5.1). 
 
 
5.2.1.2  Sustained effects of exogenous maternal IGF treatment on maternal circulating 
hormone concentrations 
To determine whether treatment of the mother during early to mid pregnancy with IGFs altered maternal 
circulating estradiol (Figure 5.2a) and progesterone (Figure 5.2b) near term, specific 
radioimmunoassays were performed. Treating the mother during early to mid pregnancy with IGF-I 
doubled circulating maternal estradiol concentrations in late pregnancy although did not reach 
significance (P = 0.078). IGF-I treatment did not alter late pregnancy circulating progesterone 
concentration. Both exogenous maternal IGF-II and Leu27-IGF-II during early to mid pregnancy did not 































Figure 5.1 Sustained effect of maternal IGF treatment in early to mid pregnancy on 
maternal weight gain during pregnancy. Female guinea pigs were weighed three times weekly 
during the study to determine an average weekly weight, from one week before mating and 
during pregnancy up until kill. Mini osmotic pumps were inserted on day 20 of pregnancy and 
delivered vehicle (n = 7), IGF-I (n = 7), IGF-II (n = 9) or Leu27-IGF-II (n = 4) for 18 days. Term, 
which is ~67-70 days of pregnancy, is denoted on the graph. Values are expressed as means ±
SEM. Repeated measures ANOVA was performed and found no significant effect of treatment. 
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Table 5.1 Sustained effect of maternal IGF treatment in early to mid pregnancy on maternal body 
composition  
 Vehicle  IGF-I  IGF-II  Leu27-IGF-II 
Number of dams  7  7  9  4 
Weight at d62  978 ± 23  1012 ± 34  971 ± 36  982 ± 49 
Net body mass**  736 ± 21  761 ± 62  725 ± 19  691 ± 36 
Lean body mass†  711 ± 19  744 ± 62  702 ± 18  671 ± 48 
Adrenals (g) 
     (% Body weight)‡ 
55 ± 0.06  
0.07 ± 0.00 
56 ± 0.06 
0.07 ± 0.00 
54 ± 0.06 
0.07 ± 0.00 
64 ± 0.06 
0.09 ± 0.00 
Kidneys (g) 
     (% Body weight)‡ 
4.66 ± 0.2 
6.3 ± 0.03 
4.85 ± 0.2 
6.5 ± 0.03 
4.94 ± 0.2 
6.8 ± 0.03 
4.74 ± 0.2 
6.9 ± 0.04 
Spleen (g) 
     (% Body weight)‡ 
1.29 ± 0.1a 
0.17 ± 0.01 
1.32 ± 0.1a 
0.17 ± 0.02 
1.69 ± 0.1c 
0.23 ± 0.01 
1.25 ± 0.2a 
0.18 ± 0.02 
Pancreas (g) 
     (% Body weight)‡ 
1.89 ± 0.3 
0.26 ± 0.03 
2.12 ± 0.2 
0.28 ± 0.03 
2.13 ± 0.2 
0.29 ± 0.03 
1.92 ± 0.3 
0.28 ± 0.04 
Liver (g) 
     (% Body weight)‡ 
26.6 ± 1.3 
3.9 ± 0.2 
26.5 ± 1.2 
3.5 ± 0.2 
26.8 ± 1.1 
3.6 ± 0.2 
27.1 ± 1.6 
3.9 ± 0.2 
Lung (g) 
     (% Body weight)‡ 
4.35 ± 0.4 
0.58 ± 0.06 
3.84 ± 0.4 
0.51 ± 0.06 
4.40 ± 0.3 
0.60 ± 0.05 
5.14 ± 0.5 
0.77 ± 0.08 
Brain (g) 
     (% Body weight)‡ 
3.95 ± 0.1 
0.53 ± 0.02 
4.12 ± 0.1 
0.56 ± 0.03 
4.12 ± 0.1 
0.56 ± 0.02 
3.96 ± 0.1 
0.58 ± 0.03 
Heart (g) 
     (% Body weight)‡ 
2.16 ± 0.2 
0.29 ± 0.03 
2.06 ± 0.2 
0.27 ± 0.03 
2.51 ± 0.2 
0.34 ± 0.03 
2.36 ± 0.3 
0.34 ± 0.04 
Uterus* (g) 
     (% Body weight)‡ 
231 ± 38 
0.32 ± 0.06 
250 ± 35 
0.36 ± 0.05 
221 ± 33 
0.30 ± 0.05 
291 ± 47 
0.42 ± 0.08 
Ovaries (g) 
     (% Body weight)‡ 
0.13 ± 0.01 
0.02 ± 0.00 
0.16 ± 0.01 
0.02 ± 0.00 
0.13 ± 0.01 
0.02 ± 0.00 
0.13 ± 0.01 
0.02 ± 0.00 
Stomach (g) 
     (% Body weight)‡ 
7.44 ± 0.7 
0.68 ± 0.3 
5.80± 0.7 
0.56 ± 0.3 
6.33 ± 0.6 
0.87 ± 0.3 
6.58 ± 0.9 
0.95 ± 0.3 
S. intestine (g) 
     (% Body weight)‡ 
17.9 ± 1.3 
2.4 ± 0.02 
17.6 ± 1.2 
2.3 ± 0.01 
14.6± 1.1 
2.0 ± 0.02 
17.1 ± 1.6 
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L. intestine (g) 
     (% Body weight)‡ 
8.51 ± 1.3 
1.2 ± 0.2 
8.25± 1.2 
1.1 ± 0.2 
10.28 ± 1.1 
1.4 ± 0.2 
6.93 ± 1.6 
1.0 ± 0.2 
Caecum (g) 
     (% Body weight)‡ 
11.2 ± 0.9 
1.5 ± 0.1 
10.9 ± 0.8 
1.5 ± 0.1 
10.0 ± 0.8 
1.3 ± 0.1 
11.4 ± 1.1 
1.7 ± 0.2 
Total GIT (g) 
     (% Body weight)‡ 
45.0± 3.1 
6.1 ± 0.4 
42.6± 2.3 
5.7 ± 0.3 
41.2 ± 2.2 
5.7 ± 0.3 
42.0 ± 2.5 
6.1 ± 0.4 
M.soleus (g) 
     (% Body weight)‡ 
0.17 ± 0.03 
0.02 ± 0.00 
0.18 ± 0.3 
0.02 ± 0.00 
0.17 ± 0.03 
0.02 ± 0.00 
0.19 ± 0.04 
0.03 ± 0.00 
M.biceps (g) 
     (% Body weight)‡ 
0.44 ± 0.03 
0.06 ± 0.00 
0.48± 0.03 
0.06 ± 0.00 
0.44 ± 0.03 
0.06 ± 0.00 
0.46 ± 0.04 
0.07 ± 0.00 
M.triceps (g) 
     (% Body weight)‡ 
2.13 ± 0.10 
0.29 ± 0.01 
2.26 ± 0.98 
0.30 ± 0.01 
2.33 ± 0.09 
0.32 ± 0.01 
2.24 ± 0.13 
0.33 ± 0.01 
M.gastroc (g) 
     (% Body weight)‡ 
1.94 ± 0.10 
0.26 ± 0.01 
1.99 ± 0.09 
0.26 ± 0.01 
1.97 ± 0.08 
0.27 ± 0.01 
1.88 ± 0.12 
0.27 ± 0.01 
Perirenal fat (g) 
     (% Body weight)‡ 
5.27 ± 0.8a 
0.71 ± 0.1a 
3.50 ± 0.5b 
0.48 ± 0.08b 
4.72 ± 0.4ab 
0.66 ± 0.05ab 
5.17 ± 0.94a 
0.72 ± 0.12a 
Retro fat (g) 
     (% Body weight)‡ 
8.96 ± 0.9a 
1.2 ± 0.1a 
6.27 ± 0.8b 
0.85 ± 0.1b 
8.47±0.6ab 
1.2±0.06a 
5.87 ± 1.1b 
0.82 ± 0.12b 
Inter fat (g) 
     (% Body weight)‡ 
10.85 ± 0.9a 
1.5 ± 0.1a 
8.11 ± 0.6b 
1.1 ± 0.08b 
9.95 ± 0.4ab 
1.4 ± 0.06a 
8.94 ± 1.1b 
1.3 ± 0.13ab 
Total fat (g) 
     (% Body weight)‡ 
25.2 ± 2.2a 
3.4 ± 0.27a 
17.9 ± 2.1b 
2.4 ± 0.25b  
23.4 ± 1.9ab 
3.2 ± 0.23a 
20.0± 2.7ab 
2.8 ± 0.33ab 
Skin (g) 
     (% Body weight)‡ 
112 ± 7.8 
15 ± 1.1 
111 ± 6.6 
15 ± 0.9  
115 ± 6.2 
16 ± 0.9 
102 ± 8.7 
15 ± 1.3 
Carcass (g) 
     (% Body weight)‡ 
418 ± 16 
56.6 ± 2.0 
383 ± 15 
51.1 ± 1.9  
395 ± 14 
54.0 ± 1.7 
371 ± 19 
53.8 ± 2.5 
Data expressed as means ± SEM. *Uterus and contents. **Net body mass is weight at post-mortem 
minus the uterus and contents. †Lean body mass is net body mass minus total fat. ‡Tissue weight 
calculated as a percentage of net body mass. GIT, gastrointestinal tract; Inter fat, interscapular fat;  
L. intestine, large intestine; M.gastroc, M.gastrocnemius; Retro fat, retroperitoneal fat; S. intestine, small 
intestine. Different superscripts denote difference between groups, a vs b, P < 0.05 (significant),   




























Figure 5.2 Sustained effect of exogenous maternal IGFs in early to mid pregnancy on 
circulating hormone concentrations in the mother. Estradiol (a) and progesterone (b) plasma 
concentrations were determined. Data are from vehicle (n = 7), IGF-I (n = 7), IGF-II (n = 9) and 
Leu27-IGF-II (n = 4) treated mothers and values are expressed as means ± SEM. Data was 
analysed by a General Linear Univariate ANOVA with Bonferoni Post Hoc Tests.
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5.2.1.3  Sustained effects of maternal IGF treatment on the development of the placental 
exchange region (labyrinth) 
IGF treatment in early to mid pregnancy did not alter placental weight in late gestation, compared with 
vehicle (Table 5.2). Placentae from IGF-II treated mothers were 18-19% heavier than those from 
mothers treated with IGF-I and Leu27-IGF-II (P = 0.034 and P = 0.05, respectively).  
 
To elucidate whether exogenous IGF affected placental structure, the two regions of the guinea pig 
placenta, the labyrinth and interlobium, were identified by Masson’s Trichrome staining. Exogenous  
IGF-II increased placental labyrinthine cross-sectional area by 28% (P = 0.005) but not that of the 
interlobium (Figure 5.3a-d, Table 5.2). Leu27-IGF-II treatment tended to reduce the cross-sectional area 
of the interlobium (P = 0.07), while neither IGF-II nor Leu27-IGF-II treatment altered the total placental 
cross-sectional area (Table 5.2). The ratio of labyrinth to interlobium was increased by IGF-II (+37%,  
P = 0.054) and Leu27-IGF-II (+39%, P = 0.017). IGF-II and Leu27-IGF-II treatments both increased the 
proportion of the placenta comprised of labyrinth (both +9%, P < 0.003) and reduced that composed of 
the interlobium (both -24%, P < 0.003) (Table 5.2). IGF-II also increased the volume of placental 
labyrinth (+28%, P = 0.027) but did not alter that of the interlobium, while Leu27-IGF-II treatment reduced 
the volume of the interlobium (-33%, P = 0.01, Table 5.2). Maternal IGF-I treatment did not alter any 
placental parameter (Table 5.2). 
 
To examine placental labyrinthine development in response to earlier maternal IGFs, structural 
components of the placental labyrinth, fetal trophoblast, maternal blood spaces and fetal capillaries, 
were identified using double-label immunohistochemistry and haematoxylin and eosin counter-staining 
and structural correlates of placental function were quantified using video image analysis (Figure 5.3e). 
Maternal Leu27-IGF-II treatment increased the proportion of the labyrinth composed of trophoblast and 
maternal blood spaces (+22%, P = 0.014 and +40%, P = 0.0003, respectively), while reducing that of 
fetal capillaries (-60%, P < 0.0001), however neither IGF-I nor IGF-II treatment had an effect (Figure 
5.4a). Both IGF-II and Leu27-IGF-II treatments increased the volume of trophoblast (+29%, P = 0.015 
and +27%, P = 0.014, respectively) and that of maternal blood spaces (+46%, P = 0.035 and +40%, P = 
0.003, respectively) within the placental labyrinth (Figure 5.4b).  
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Table 5.2 Sustained effect of maternal IGF treatment in early to mid pregnancy on placental 
structure 
 Vehicle  IGF-I  IGF-II  Leu27-IGF-II 
Number  of  dams  7 7 9 4 
Placental weight (g)  4.63 ± 0.29ab 4.11  ± 0.24a 4.84  ± 0.22b 4.07  ± 0.33a 
Cross-sectional area labyrinth (mm2)  98.9 ± 3.8a 112.3  ± 8.9a 126.6  ± 8.3b 108.8  ± 8.4ab 
Cross-sectional area interlobium (mm2)  35.6 ± 2.8  32.6 ± 4.3  30.4 ± 2.6  25.8 ± 2.9 
Total cross-sectional area (mm2)  136 ± 14  145 ± 11  157 ± 12  135 ± 10 
Labyrinth : Interlobium  3.10 ± 0.43a  3.89 ± 0.44a  4.23 ± 0.35c  4.31 ± 0.33b 
Proportion labyrinth (%)  73.6 ± 1.2a 77.6  ± 1.1ab 80.5  ± 1.1b 80.6  ± 1.4b 
Proportion interlobium (%)  26.4 ± 1.2a 22.4  ± 1.1ab 19.5  ± 1.1b 19.4  ± 1.5b 
Volume labyrinth (cm3)  3.34 ± 0.25a 3.26  ± 0.23a 4.26  ± 0.23b 3.44  ± 0.21 
Volume interlobium (cm3)  1.21 ± 0.09a 0.95  ± 0.09ab 1.03  ± 0.08ab 0.81  ± 0.1b 
Data are expressed as mean ± SEM with 1-3 placentae per dam randomly selected for histological 
analysis. Different superscripts denote differences between groups, a vs b, P < 0.039 (significant) and a 
vs c, P = 0.054 (not significant). Statistical analyses were performing using Linear Mixed Model 
Repeated Measures with Sidak Post Hoc Tests, using the mother as the subject and the fetus as the 
repeated measure. 
 Figure 5.3 Photomicrographs demonstrating sustained effect of exogenous maternal IGF 
treatment in early to mid pregnancy on placental structure. Representative mid-sagittal sections 
of near term placentae stained with Masson’s Trichrome to distinguish labyrinth and interlobium layers 
from mothers that had been treated with vehicle (a),) IGF-I (b IGF-II (c) or Leu27-IGF-II (d) during early 
to mid pregnancy. L, labyrinth; i, interlobium. Scale bars = 400 μm. Representative mid-sagittal 
section of near term placenta double-immunolabelled with haematoxylin and eosin counter-staining 
shown (d) to reveal structural components of the placental labyrinth, including fetal trophoblast (thin 

























































































Figure 5.4 Sustained effect of exogenous maternal IGFs in early to mid pregnancy on 
structural correlates of placental exchange function. Proportions (a) and volumes (b) of fetal 
trophoblast, maternal blood spaces and fetal capillaries in the placental labyrinth (exchange 
region), as well as the total surface area of syncytiotrophoblast for exchange (c). Data are from n 
= 1-3 placentae from each mother (n = 4-9 dams per treatment). Values are expressed as means 
± SEM. Different superscripts denote statistically significant differences, P < 0.05, as determined 
by a Linear Mixed Model Repeated Measures with Sidak Post Hoc test, using the mother as the 
subject and the fetus as a repeated measure. 
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Treatment of the mother with Leu27-IGF-II also reduced the volume of labyrinthine fetal capillaries  
(-40%, P = 0.017, Figure 5.4b). The total surface area of trophoblast functioning in exchange was also 
increased by IGF-II and Leu27-IGF-II treatments (+39%, P = 0.037 and +277%, P < 0.0001, Figure 5.4c). 
Leu27-IGF-II treatment reduced syncytiotrophoblast barrier thickness, compared to vehicle and both 
IGF-I and IGF-II treatments (vehicle: 4.7 ± 0.2μm, IGF-I: 4.8 ± 0.2 μm; IGF-II: 4.4 ± 0.2 μm and Leu27-
IGF-II: 2.1 ± 0.3 μm, P < 0.001). Maternal IGF-I treatment did not affect any placental labyrinthine 
structural parameter measured. 
 
 
5.2.1.4  Sustained effects of exogenous maternal IGFs on litter size and fetal survival 
Maternal IGF treatment did not affect total litter size (Table 5.3). However, IGF-I, IGF-II and Leu27-IGF-II 
treatment reduced the number of resorptions (-77%, P = 0.009, -60%, P = 0.01, -100%, P = 0.033, 
respectively) and increased the number of viable fetuses (+25%, P = 0.011, +23%, P = 0.019, +27%,  
P = 0.05, respectively) near term (Table 5.3). There was no effect of treatment on the ratio of females to 
males (Table 5.3).  
 
 
5.2.1.5  Sustained effects of exogenous maternal IGFs on fetal growth  
Maternal IGF-I and IGF-II treatment in early to mid pregnancy increased fetal weight near term by 17% 
(P = 0.002) and 11% (P = 0.042), respectively (Table 5.4). Maternal IGF-I, IGF-II and Leu27-IGF-II 
treatments, significantly skewed the fetal weight distribution to the right (all P < 0.0005, Figure 5.5a). 
The percentage of fetuses heavier than 81 grams was 5% in controls, 37% in IGF-I, 19% in IGF-II and 
9% in Leu27-IGF-II treated animals (Figure 5.5a). IGF-I treatment increased fetal crown-rump length by 
9% (P = 0.014), as well as abdominal circumference by 10% (P = 0.05). IGF-I increased the fetal weight 
to placental weight ratio by 29% compared with vehicle and IGF-II treatment groups (vehicle: 14.82 ± 
0.86; IGF-I: 19.14 ± 0.73; IGF-II: 16.18 ± 0.65; Leu27-IGF-II: 17.72 ± 0.92, P < 0.001 and P = 0.007). 
Fetal weight correlated positively with placental weight across all treatments (r = 0.27, P = 0.026) and 
within IGF-I, IGF-II and Leu27-IGF-II treatment groups (r = 0.44, P = 0.042; r = 0.51, P = 0.005 and  
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Table 5.3 Sustained effect of maternal IGF treatment in early to mid pregnancy on litter 
composition  
 Vehicle  IGF-I  IGF-II  Leu27-IGF-II 
Dams 7  7  9  4 
Fetuses 19  22  30  13 
F / M*  9 / 10  12 / 10  14 / 16  9 / 4 
Total Litter   3.42 ± 0.1  3.36 ± 0.1  3.67 ± 0.1  3.46 ± 0.2 
Number viable  2.73 ± 0.2a 3.42  ± 0.2b 3.37  ± 0.1b 3.46  ± 0.2b 
Number resorbing  0.68 ± 0.1a 0.09  ± 0.1b 0.27  ± 0.1b 0.00  ± 0.00b 
Data are expressed as mean ± SEM. *F = females, M = males. Different superscripts denote significant 
differences between groups, a vs b P < 0.05. Statistical analyses were performing using Linear Mixed 
Model Repeated Measures with Sidak Post Hoc Tests, using the mother as the subject and the fetus as 



































































Figure 5.5 Sustained effect of maternal IGF treatment in early to mid pregnancy on fetal 
weight distribution (a) and the association of fetal and placental weights (b). Regression 
curves are displayed for vehicle, IGF-I, IGF-II and Leu27-IGF-II treated animals. Each fetus per 
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Overall, fetal weight correlated positively with both the mid-sagittal cross-sectional area and the 
estimated total volume of the placental labyrinth (r = 0.638, P = 0.001 and r = 0.61, P < 0.0001, 
respectively), as well as with the volumes of trophoblast and fetal capillaries in the placental labyrinth  
(both r = 0.51, P = 0.001).  
 
 
5.2.1.6  Sustained effects of exogenous maternal IGFs on fetal body composition 
Maternal IGF-I treatment increased fetal carcass weight (+19%, P = 0.002), increased the combined 
weights of fetal kidneys (+20%, P = 0.028), caecum (+24%, P = 0.027), total gastrointestinal tract 
(+13.5%, P = 0.049) and the combined fetal fat depots (+16%, P = 0.028) (Table 5.4). Conversely, IGF-I 
reduced the fractional weights of the fetal spleen (-24%, P = 0.001), liver (-12.5%, P = 0.002) and brain 
(-18.5%, P = 0.004) (Table 5.4). Both IGF-I and IGF-II increased the weights of the fetal retroperitoneal 
fat (+24%, P = 0.004; +18%, P = 0.031, respectively), combined muscle mass (+22%, P = 0.008; +19%, 
P = 0.024, respectively) and the triceps absolute (+29%, P = 0.001; +24% P = 0.01, respectively) and 
relative weights (both +16%, P < 0.03, Table 5.4). Compared to vehicle, Leu27-IGF-II increased the total 
weight of the gastrointestinal tract (+15%, P = 0.048) and reduced the fractional weight of the fetal liver 
compared with the vehicle treatment group (-16%, P = 0.004). Leu27-IGF-II increased the absolute and 
fractional weights of the fetal perirenal (+20%, P = 0.05; +17%, P = 0.033, respectively), interscapular 
(+23%, P = 0.025; +20%, P = 0.05, respectively), retroperitoneal (+21%, P = 0.05; +22%, P = 0.05, 
respectively) and combined fat depots (+25.5%, P = 0.01; +19%, P = 0.033, respectively). There was no 
effect of treatment on the fetal liver weight to brain weight ratio (estimated marginal mean ± SEM; 
vehicle: 1.51 ± 0.1; IGF-I: 1.52 ± 0.7; IGF-II: 1.53 ± 0.08; Leu27-IGF-II: 1.35 ± 0.9). Body composition of 
male and female fetuses was similar and was similarly affected by maternal IGF and Leu27-IGF-II 
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Table 5.4 Sustained effect of maternal IGF treatment in early to mid pregnancy on fetal weight and 
body composition  
  Vehicle IGF-I  IGF-II  Leu27-IGF-II 
Fetal weight (g)  66.62 ± 2.40a 77.75  ± 1.96b 74.03  ± 1.69b 70.66  ± 2.77ab 
Crown-rump length (cm)  14.00 ± 0.34a 15.28  ± 0.28b 14.77  ± 0.24ab 13.87  ± 0.43ab 
Abdominal circ. (cm)  8.82 ± 0.28a 9.69  ± 0.23b 9.01  ± 0.20ab 9.23  ± 0.28ab 
Head width (cm)  6.81 ± 0.46  7.07 ± 0.39  7.20 ± 0.37  7.20 ± 0.51 
Adrenals (g) 
           (% Body weight) 
0.055 ± 0.01 
0.08 ± 0.00 
0.028 ± 0.01 
0.05 ± 0.00 
0.036 ± 0.01 
0.05 ± 0.00 
0.026 ± 0.01 
0.04 ± 0.00 
Kidneys (g) 
          (% Body weight) 
0.59 ± 0.04a 
0.89 ± 0.04 
0.71 ± 0.03b 
0.92 ± 0.03 
0.67 ± 0.03ab 
0.91 ± 0.03 
0.56 ± 0.04a 
0.79 ± 0.04 
Spleen (g) 
          (% Body weight) 
0.11 ± 0.01 
0.17 ± 0.01a 
0.10 ± 0.01 
0.13 ± 0.01b 
0.11 ± 0.01 
0.15 ± 0.01ab 
0.91 ± 0.04 
0.13 ± 0.06ab 
Pancreas (g) 
          (% Body weight) 
0.10 ± 0.01 
0.15 ± 0.01 
0.10 ± 0.01 
0.13 ± 0.01 
0.11 ± 0.01 
0.16 ± 0.01 
0.10 ± 0.01 
0.14 ± 0.02 
Liver (g) 
          (% Body weight) 
3.71 ± 0.18 
5.6 ± 0.2a 
3.77 ± 0.14 
4.9 ± 0.1b 
3.84 ± 0.13 
5.2 ± 0.1ab 
3.34 ± 0.20 
4.7 ± 0.02b 
Lungs (g) 
          (% Body weight) 
1.33 ± 0.05 
1.9 ± 0.1 
1.42 ± 0.04 
1.9 ± 0.04 
1.31 ± 0.04 
1.9 ± 0.04 
1.36 ± 0.06 
1.9 ± 0.1 
Brain (g) 
          (% Body weight) 
2.49 ± 0.07 
3.8 ± 0.2a 
2.51 ± 0.06 
3.1 ± 0.1b 
2.52 ± 0.05 
3.5 ± 0.1ab 
2.56 ± 0.07 
3.7 ± 0.1ab 
Heart (g) 
          (% Body weight) 
0.47 ± 0.03 
0.69 ± 0.03 
0.47 ± 0.02 
0.62 ± 0.03 
0.50 ± 0.02 
0.71 ± 0.03 
0.42 ± 0.03 
0.59 ± 0.04 
Uterus (g) 
          (% Body weight) 
0.12 ± 0.04 
0.2 ± 0.1 
0.13 ± 0.03 
0.2 ± 0.1 
0.17 ± 0.03 
0.2 ± 0.1 
0.20 ± 0.07 
0.3 ± 0.1 
Testes (g) 
          (% Body weight) 
0.07 ± 0.02 
0.09 ± 0.00 
0.09 ± 0.02 
0.12 ± 0.00 
0.08 ± 0.01 
0.11 ± 0.00 
0.06 ± 0.02 
0.09 ± 0.00 
Stomach (g) 
          (% Body weight) 
0.54 ± 0.04 
0.77 ± 0.05 
0.50 ± 0.03 
0.66 ± 0.04 
0.54 ± 0.03 
0.76 ± 0.04 
0.54 ± 0.05 
0.76 ± 0.06 
S.intestine (g) 
          (% Body weight) 
1.79 ± 0.1 
2.6 ± 0.1 
1.94 ± 0.1 
2.6 ± 0.1 
1.73 ± 0.1 
2.4 ± 0.1 
1.82 ± 0.1 
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L.intestine (g) 
          (% Body weight) 
0.73 ± 0.06 
1.1 ± 0.2 
0.83 ± 0.05 
1.1 ± 0.2 
0.86 ± 0.05 
1.2 ± 0.2 
1.06 ± 0.2 
1.5 ± 0.2 
Caecum (g) 
          (% Body weight) 
0.37 ± 0.03a 
0.56 ± 0.03 
0.46 ± 0.02b 
0.59 ± 0.02 
0.40 ± 0.02ab 
0.54 ± 0.02 
0.39 ± 0.03ab 
0.6 ± 0.03 
Total GI tract (g) 
          (% Body weight) 
3.33 ± 0.14a 
5.0 ± 0.1 
3.78 ± 0.11b 
4.9 ± 0.1 
3.59 ± 0.10ab 
4.9 ± 0.1 
3.82 ± 0.20b 
5.4 ± 0.2 
M.soleus (g) 
          (% Body weight) 
0.027 ± 0.003 
0.03 ± 0.00 
0.027 ± 0.002 
0.04 ± 0.00 
0.024 ± 0.002 
0.03 ± 0.00 
0.027 ± 0.004 
0.04 ± 0.00 
M.gastroc (g) 
          (% Body weight) 
0.13 ± 0.01 
0.19 ± 0.00 
0.15 ± 0.01 
0.20 ± 0.00 
0.14 ± 0.01 
0.20 ± 0.00 
0.14 ± 0.01 
0.20 ± 0.00 
M.biceps (g) 
          (% Body weight) 
0.04 ± 0.03 
0.06± 0.00 
0.04 ± 0.02 
0.06± 0.00 
0.04 ± 0.02 
0.06± 0.00 
0.04 ± 0.04 
0.06± 0.00 
Triceps (g) 
          (% Body weight) 
0.17 ± 0.01a 
0.25 ± 0.01a 
0.22 ± 0.01b 
0.29 ± 0.008b 
0.21 ± 0.01b 
0.29 ± 0.007b 
0.20 ± 0.01ab 
0.28 ± 0.009ab 
Total muscle (g) 
          (% Body weight) 
0.36 ± 0.21a 
0.56 ± 0.02 
0.44 ± 0.16b 
0.57 ± 0.02 
0.43 ± 0.15b 
0.55 ± 0.01 
0.40 ± 0.02ab 
0.56 ± 0.02 
Perirenal fat (g) 
          (% Body weight) 
0.81 ± 0.03a 
1.2 ± 0.03b 
0.85 ± 0.03ab 
1.1 ± 0.03b 
0.83 ± 0.03ab 
1.2 ± 0.03b 
0.97 ± 0.05b  
1.4 ± 0.06b 
Interscap fat (g) 
          (% Body weight) 
1.03 ± 0.05a 
1.5 ± 0.06a 
1.09 ± 0.04ab  
1.4 ± 0.05a 
1.06 ± 0.04a 
1.4 ± 0.05a 
1.27 ± 0.07b 
1.8 ± 0.1b 
Retro fat (g) 
          (% Body weight) 
0.63 ± 0.04a 
0.9 ± 0.04 
0.78 ± 0.03b 
1.0 ± 0.03 
0.74 ± 0.03b 
1.0 ± 0.03 
0.76 ± 0.04b 
1.1 ± 0.04b 
Total fat (g) 
         (% Body weight) 
2.39 ± 0.11a 
3.6 ± 0.1a 
2.77 ± 0.09b 
3.6 ± 0.1a 
2.72 ± 0.08ab 
3.7 ± 0.09a 
3.0 ± 0.1b 
4.3 ± 0.1b 
Carcass (g) 
         (% Body weight) 
48.68 ± 2.0a 
73 ± 0.8 
58.01 ± 1.6b 
75 ± 0.6 
53.98 ± 1.5ab 
74 ± 0.6 
53.00 ± 2.2ab 
74 ± 0.8 
Data expressed as estimated marginal means ± SEM adjusted for the number of viable fetuses per litter. 
Different superscripts denote significant difference between groups, a vs b, P < 0.05. Statistical analyses 
were performed using Linear Mixed Model Repeated Measures with Sidak Post Hoc Tests, using the 
mother as the subject, the fetus as the repeated measure and the number of viable pups as the covariate. 
Abdominal circ = Abdominal circumference, Gastro = gastrocnemius, Interscap = interscapular fat, 
L.intestine = large intestine, Retro fat = retroperitoneal fat, S.intestine = small intestine. Chapter 5    Sustained effects of IGF treatment 1 
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5.3  Discussion  
The present study demonstrates for the first time that administration of IGF-II to the mother in early to 
mid pregnancy increases placental structural and functional capacity by increasing the volume and 
surface area of the exchange region of the placenta near term, while IGF-I has no effect on the 
placenta. IGF-I, in contrast, reduced maternal adiposity late in pregnancy, while IGF-II did not affect 
maternal body composition. Importantly, however, maternal treatment with either IGF in early to mid 
pregnancy substantially reduced fetal resorptions and increased fetal viability and weight near term. 
This suggests that maternal IGF abundance, particularly that of IGF-II, during the period of early 
placental growth and development may in part determine the margin of safety between placental 
capacity to deliver, and fetal demand for, substrates throughout pregnancy. Importantly, administration 
of Leu27-IGF-II, an analogue of IGF-II with markedly reduced affinity for IGF1R and InsR, suggest that 
the impacts of IGF-II on the fetus are secondary to effects on the placenta, which are mediate 
predominantly through IGF2R. 
 
In the current study, administration of 1mg/kg/day IGFs has been demonstrated to increase the 
abundance of bio-available maternal circulating IGF-II and IGF-I by 2.4 to 3.4-fold, during early to mid 
pregnancy (Chapter 4, p 109). Similar IGF treatment of guinea pigs during early to mid-pregnancy 
increased placental weight at mid-gestation (Sohlstrom, Fernberg et al. 2001), which was not sustained 
to near term in the current study. Importantly, however, the functional capacity of the placenta, as 
indicated by the mid-sagittal cross-sectional area, proportion and volume of the region devoted to 
exchange (labyrinth) were increased late in gestation, by prior maternal IGF-II treatment. Furthermore, 
although the composition of the exchange region of the placenta was unaltered by earlier maternal IGF 
treatment, the total volume of trophoblast and maternal blood spaces, as well as the total surface area 
of placenta functioning in exchange, were increased by IGF-II. As the labyrinth expands at the expense 
of the interlobium in the second half of pregnancy in the guinea pig (Kaufmann and Davidoff 1977; 
Roberts, Sohlstrom et al. 2001a), together these changes placental structure following earlier 
exogenous maternal IGF-II, are suggestive of a more mature placenta and would be expected to 
increase placental transport capacity. In contrast, maternal exogenous IGF-I had no effect on structural 
correlates of placental function.  
 
Rapid placental structural differentiation and growth occurs in early to mid gestation in all eutherian 
mammals. In humans and guinea pigs, trophoblasts invade deeply within the uterus and its arterioles, 
extensively remodelling them, to permit increased maternal blood flow to the placenta (Hees, Moll et al. Chapter 5    Sustained effects of IGF treatment 1 
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1987; Lyall 2005; Moll, Espach et al. 1983; Pijnenborg, Bland et al. 1981; Pijnenborg, Robertson et al. 
1981; Pijnenborg, Vercruysse et al. 2006). This ensures delivery of oxygen and nutrients to the 
placenta, and subsequently to the fetus. The sustained effects of maternal IGF-II supplementation in 
early to mid pregnancy on the placenta reported here are the converse of those observed following 
specific deletion of IGF-II within the placenta. IGF-II is abundantly expressed by invasive trophoblasts of 
human (Han, Bassett et al. 1996), mouse (Redline, Chernicky et al. 1993), rat (Zhou and Bondy 1992) 
and guinea pig placenta (Han, Carter et al. 1999). Ablation of placenta specific Igf2 gene expression (P0 
transcript) in mice reduced the surface area for exchange, increased the exchange barrier thickness 
and also impaired nutrient transport capacity of the placenta (Constancia, Hemberger et al. 2002; 
Sibley, Coan et al. 2004). 
 
Reduced maternal circulating IGF-II in mid-pregnancy, as a result of under-nutrition in guinea pigs 
(Sohlstrom, Katsman et al. 1998b), is associated with similar consequences to those of placental Igf2 
gene deletion (Sibley, Coan et al. 2004), with a delay and impairment in the functional maturation of the 
placenta and with reduced fetal growth in both mid and late gestation (Roberts, Sohlstrom et al. 2001b). 
Together these findings indicate that maternal circulating IGF-II may act in an endocrine fashion to 
modulate placental development, in addition to any autocrine / paracrine effects of locally produced IGF-
II. We suggest that exposure to increased circulating maternal IGF-II in early to mid pregnancy may 
provide a foundation of increased placental trophoblast proliferation and invasion of the uterus and its 
vasculature, which leads to increased volumes of both trophoblast and maternal blood spaces in the 
placental labyrinth in late gestation. This would be expected to increase maternal blood flow to the 
placenta and enhance growth of the area devoted to exchange improving placental transfer of oxygen 
and nutrients to the fetus from the mother. Hence, maternal IGF-II supplementation presumably 
increased fetal growth and viability predominantly by these actions on the placenta.  
 
Supplementing the mother during early to mid pregnancy with either IGF had a sustained positive effect 
on fetal weight, length and girth near term, which is consistent with the anabolic effects on the fetus 
seen at mid-pregnancy following similar treatment in the guinea pig (Sohlstrom, Fernberg et al. 2001). 
The increased fetal weight observed with maternal IGF treatment appears to be substantially due to 
increased muscle mass overall and proportionately for selected muscles, and perhaps enhanced fetal 
bone growth as indicated by increased carcass weights. This may be metabolically beneficial in later life 
because muscle is an important site for insulin-induced glucose uptake. Indeed, fetal growth restriction 
in the guinea pig, induced by maternal food restriction and accompanied by reductions in circulating 
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mass, increased adiposity in the fetus near term (Kind, Roberts et al. 2005) and with increased blood 
pressure and impaired glucose and cholesterol homeostasis in adult offspring (Kind, Clifton et al. 2003; 
Kind, Clifton et al. 1999; Kind, Simonetta et al. 2002). 
 
The present study suggests that increased maternal IGF-I and IGF-II abundances during early to mid 
pregnancy, promote fetal growth and viability near term by multiple mechanisms. In addition to direct 
effects of IGF-II on placental structural development, which in the current study were positively 
associated with fetal weight, the IGFs may increase nutrient transporter expression (Bloxam, Bax et al. 
1997; Karl 1995; Kniss, Shubert et al. 1994; Yu, Iwashita et al. 1998) and/or placental vasodilation 
(Siler-Khodr and Forman 1993; Siler-Khodr, Forman et al. 1995), which would allow for more substrate 
to be delivered to the fetus for its growth. The IGFs may also influence placental metabolism and 
function, which, in turn may drive major physiological adaptations to pregnancy in the mother, including 
the development of insulin resistance to divert nutrients to the conceptus (Butte 2000; Catalano, Drago 
et al. 1995; Catalano and Hollenbeck 1992). This has been attributed to placental production of 
hormones including estrogen, progesterone and placental lactogen (Butte 2000; Ryan and Enns 1988) 
that reduce maternal insulin secretion (Butte 2000; Picard, Wanatabe et al. 2002) and antagonise the 
effects of insulin on maternal tissues, including fat deposition (Ryan and Enns 1988). Treatment of the 
mother with IGF-II enhanced placental weight in mid-pregnancy (Sohlstrom, Fernberg et al. 2001) and 
was accompanied by elevated maternal circulating estradiol and progesterone concentrations (Chapter 
4, p 122), although these were not significant. This would be expected to amplify insulin resistance and 
other adaptations such as fat deposition in the mother. Consistent with this, exogenous IGF-II during 
early to mid pregnancy in guinea pigs increased maternal interscapular adiposity at mid-pregnancy 
(Sohlstrom, Fernberg et al. 2001) near term. These increased maternal adipose stores were restored to 
normal by late pregnancy in the current study, which may have further enhanced nutrient availability for 
the fetus, either directly or indirectly. This suggests that IGF-II acts on the placenta to increase fetal 
growth, by sustainedly promoting placental development but may additionally enhance maternal 
physiological adaptation to pregnancy. 
 
The mechanism by which increased maternal IGF-I abundance in early to mid pregnancy sustainedly 
promotes fetal growth is less clear. The enhanced placental weight at mid gestation by prior maternal 
IGF-I treatment (Sohlstrom, Fernberg et al. 2001) (Chapter 4, p 112), which is no longer apparent in late 
gestation, may have had persistent effects on the fetus that increased fetal growth near term. In 
addition, unlike IGF-II, IGF-I did not increase maternal fat deposition in mid pregnancy (Sohlstrom, 
Fernberg et al. 2001) and in fact reduced fat depot weights near term. This is consistent with the lipolytic Chapter 5    Sustained effects of IGF treatment 1 
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effect of administered IGF-I in non-pregnant sheep (Lewis, Molan et al. 1988). Reduced adiposity may 
reflect increased mobilization and/or reduced deposition during pregnancy, which may have increased 
substrate availability in the maternal circulation for fetal growth. This has been observed in growth 
hormone treated pigs, where maternal circulating IGF-I concentration was elevated and associated with 
reductions in maternal backfat depots (Gatford, Owens et al. 2000). Another possible explanation is that 
larger fetuses of IGF-I treated dams may signal to the mother via nutrient sensors in the fetal circulation 
(such as IGFs and insulin), to influence placental metabolism and increase mobilisation of maternal 
adipose tissue stores late in pregnancy.  
 
These different IGF effects may reflect their distinct interactions with various receptors, since IGF-I 
binds with high affinity to the IGF1R but negligibly to IGF2R. In contrast, IGF-II binds to both these 
receptors, as well as to the insulin receptor (InsR). The guinea pig placenta ubiquitously expressed both 
IGF receptor proteins in mid pregnancy (Chapter 4, p 109). More importantly, however, at the time of 
IGF treatment, IGF1R and IGF2R were localised to the apical surface of trophoblasts, within large 
maternal blood vessels and blood spaces of the labyrinth permitting endocrine and exogenous IGFs to 
act directly within the placenta. In addition, insulin binding sites have previously been identified in 
trophoblast of the guinea pig placenta (Kelly, Posner et al. 1974; Posner 1974). This pattern of 
expression is consistent with the localisation of all three receptors to placental trophoblasts in humans 
and rats (Abu-Amero, Ali et al. 1998; Fang, Furesz et al. 1997; Jones, Hartmann et al. 1993; Korgun, 
Dohr et al. 2003; Milio, Hu et al. 1994; Ohlsson, Holmgren et al. 1989; Zhou and Bondy 1992) and 
abundant expression of IGF1R and IGF2R in invasive trophoblast populations within the human decidua 
and its vasculature (Fang, Furesz et al. 1997). 
 
The specific effects of IGF-II on the placenta, which were not evident in IGF-I treated animals, suggest 
that IGF-II actions on the placenta may be mediated by the InsR, which has been implicated in 
mediating IGF-II effects on fetal growth (Louvi, Accili et al. 1997) or by the IGF2R, which it binds with 
much greater affinity than the IGF1R (Jones and Clemmons 1995). In the current study we have 
attempted to discriminate the contribution of IGF2R in mediating IGF-II effects on placental development 
and fetal growth using Leu27-IGF-II, an analogue of IGF-II that has significantly reduced binding capacity 
for the IGF1R and InsR (80 and 220-fold lower affinity, respectively (Sakano, Enjoh et al. 1991) and only 
slightly decreased affinity for the IGF binding proteins (Bach, Hsieh et al. 1993). Unexpectedly, placental 
weight was different between Leu27-IGF-II and IGF-II treated mothers. However, there was no effect of 
treatment on placental weight compared with vehicle treated controls. Importantly, analysis of placental Chapter 5    Sustained effects of IGF treatment 1 
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structure revealed that many of the effects seen on placental labyrinthine development with maternal 
IGF-II treatment, were mirrored by Leu27-IGF-II administration. Like IGF-II, Leu27-IGF-II increased 
labyrinth proportion and volume, while reducing the weight of the interlobium. It certainly seemed that 
Leu27-IGF-II was more potent than IGF-II at promoting labyrinthine development, as seen by increased 
volume densities of trophoblast and maternal blood spaces, increased total surface area of trophoblast 
for exchange and reduction in the thickness of the barrier for diffusion. This is consistent with effects of 
IGF-II being mediated through IGF2R to promote trophoblast migration and invasion (McKinnon, 
Chakarborty et al. 2000), and uterine angiogenesis and vascular remodelling (Herr, Liang et al. 2003).  
 
In contrast, the effects of maternal IGF-I treatment are likely to have been mediated by the IGF1R, 
particularly since this treatment also reduced IGF-II in the mother. Interestingly, the effects of IGF-I on 
maternal and fetal body composition were similar to those seen in Leu27-IGF-II, but not IGF-II treated 
mothers. For instance, mothers that had been treated with Leu27-IGF-II during early to mid pregnancy, 
also displayed reduced retroperitoneal and interscapular adiposity near term. This may have been 
indirectly due to an increased interaction of endogenous maternal circulating IGF-II with IGF1R in the 
Leu27-IGF-II treated animals because of the selective interaction of Leu27-IGF-II with IGF2R. Other IGF 
analogues with greater specificity for the IGF1R and InsR may be helpful in elucidating these effects 
further. 
 
In conclusion, increased maternal IGF-II in early pregnancy sustainedly promotes placental structural 
and functional capacity and fetal growth and viability, while IGF-I appears to act through the mother to 
enhance fetal growth to near term. This suggests sustained major and complementary roles in placental 
and fetal growth for increased circulating IGFs in the mother in early pregnancy.  











Chapter 6 :     Sustained effects of 
maternal IGF treatment on placental 
transport and nutrient partitioning 




 Chapter 6    Sustained effects of IGF treatment 2 
Amanda N Sferruzzi-Perri  154 
6.1  Introduction 
The relationship between maternal intake and utilization of substrates during pregnancy and their supply 
to the conceptus determines pregnancy success and life-long health of offspring (Redmer, Wallace et 
al. 2004). Adequate nutrients must be delivered to the growing placenta and fetus, as well as to the 
mother, to meet the energy requirements needed to maintain maternal health and her capacity to 
support the conceptus. To ensure the latter during normal pregnancy, the mother undergoes a number 
of physiological changes in her appetite, body composition, cardiovascular function, energy 
consumption and metabolism (Owens 1991). The placenta is central to these processes, as it is not only 
the organ responsible for the exchange of substrates between the mother and fetus, but also 
synthesises a number of steroid and peptide hormones, secreted into the maternal circulation, that 
modulate maternal physiology and adaptation to pregnancy. 
 
Impaired supply of nutrients to the fetus causes intrauterine growth restriction (IUGR) (Cetin, Corbetta et 
al. 1990; Cetin, Radaelli et al. 2001), which currently affects 6% of Australian births (Laws and Sullivan 
2004) and up to 40% in developing countries (Albertsson-Wikland, Wennergren et al. 1993). IUGR is 
associated with perinatal morbidity and mortality (Fitzhardinge 1985; Low, Handley-Derry et al. 1992) 
and increases the risk of poor health in childhood and adult life (Barker 1998). Understanding the 
factors essential for regulating nutrient partitioning during pregnancy may help to identify the causes of 
IUGR and possibly the development of novel therapeutics. 
 
The insulin-like growth factors (IGFs) are implicated as major factors influencing nutrient partitioning 
between the mother and fetus. Substantial pregnancy associated changes in maternal circulating IGF-I 
and IGF-II occur in several species (Donovan, Giudice et al. 1991; Gargosky, Moyse et al. 1990; Hills, 
English et al. 1996; Nason, Binder et al. 1996; Sohlstrom, Katsman et al. 1998b; Travers, Madon et al. 
1990; Wilson, Bennett et al. 1982), with IGF-II, in particular, also highly expressed in the placenta (Han 
and Carter 2000). While maternal IGFs do not cross the placenta in physiologically significant quantities 
(Brown and Thorburn 1989), they may act on the placenta and maternal tissues to regulate nutrient 
allocation between the mother, placenta and fetus in various ways (Wallace, Da Silva et al. 1997).  
 
Maternal IGF-I may improve or maintain nutrient transfer to the fetus by enhancing placental transport 
and modification of nutrients or by increasing substrate availability in the mother for transfer to the fetus, 
as seen in the pregnant ewe (Harding, Liu et al. 1994). This may also be the case in women, as IGF-I 
stimulates glucose and amino acid uptake in cultured human placental trophoblasts (Bloxam, Bax et al. Chapter 6    Sustained effects of IGF treatment 2 
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1994; Karl 1995; Kniss, Shubert et al. 1994; Yu, Iwashita et al. 1998). Furthermore, IGF-I inhibits the 
release of vasoconstrictors in term human placental villous explants (Siler-Khodr and Forman 1993; 
Siler-Khodr, Forman et al. 1995), which may increase placental blood flow and delivery of nutrients 
during pregnancy. However, there is also evidence to suggest that IGF-I may promote maternal 
anabolism over fetal growth. IGF-I administration in the second half of pregnancy increased maternal 
weight gain near term but did not alter fetal and placental growth in rats (Gargosky, Owens et al. 1991). 
In addition, elevated maternal circulating IGF-I induced by over nourishing the singleton-bearing 
adolescent sheep, correlated with increased maternal tissue accretion at the expense of the fetus and 
placenta (Wallace, Aitken et al. 1996; Wallace, Da Silva et al. 1997). 
 
IGF-II may also act locally to modulate placental development and transport function as occurs in mice. 
Indeed, placental amino acid transporter expression is altered by Igf2 deficiency in mice (Matthews, 
Beveridge et al. 1999) and ablation of the trophoblast specific Igf2 promoter (P0), reduces placental 
weight and adversely affects placental structural differentiation and transport capacity (Constancia, 
Hemberger et al. 2002; Sibley, Coan et al. 2004). In the Igf2 P0 mutant placenta, passive diffusion of 
inert hydrophilic solutes is reduced, while System A amino acid (Constancia, Hemberger et al. 2002; 
Sibley, Coan et al. 2004) and glucose (Constancia, Angiolini et al. 2005) transport are transiently up-
regulated, apparently via direct impacts on placental transporter gene expression (Constancia, Angiolini 
et al. 2005). 
 
In guinea pigs and humans, maternal circulating concentrations of IGFs are substantial (Gargosky, 
Moyse et al. 1990; Sohlstrom, Katsman et al. 1998b) and may have major influences on nutrient 
partitioning during pregnancy. Indeed, we have shown in the guinea pig that increasing concentrations 
of IGF by infusion of IGF-I or IGF-II into the mother during early to mid pregnancy enhanced fetal growth 
(largely due to increased muscle mass) and survival near term, but possibly in part via different 
mechanisms (Chapter 5). In the IGF-I treated mother, the nutritional requirements of the conceptus 
appeared to take priority over those of the mother, as maternal adipose stores were depleted in late 
pregnancy (without altering placental development), possibly increasing substrate availability for the 
conceptus (Chapter 5). In contrast, IGF-II treatment in early to mid pregnancy did not affect maternal 
body composition but enhanced development of the placental exchange region in late gestation, 
suggestive of improved placental functional capacity (Chapter 5). Additionally, IGF supplementation 
increased concentrations of steroid hormones in the maternal circulation, which may have modified 
maternal physiological responses to pregnancy and, in turn, nutrient partitioning (Chapter 5). 
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The aim of this study was to dissect the mechanisms underlying maternal IGF influences in early to mid 
pregnancy on substrate availability to, and hence growth of, the fetus near term. To achieve this, we 
measured placental uptake and transfer of non-metabolisable radioanalogues of glucose ([3H]-methyl-D-
glucose, MG) and amino acids ([14C]-amino-isobutyric acid, AIB), as well as circulating metabolite 
concentrations in the fetus and mother, on day 62 of pregnancy, just prior to term (term = 69 days). In 
light of our previous report of differences in fetal and maternal body composition near term in response 
to earlier maternal IGF treatment (Chapter 5), we also determined MG and AIB uptake by several fetal 
and maternal tissues. Furthermore, due to differences in maternal body composition between IGF-I and 
IGF-II treatment, we also aimed to elucidate the role of type 2 IGF receptor (IGF2R) in mediating IGF-II 
influences on nutrient uptake during pregnancy by maternal administration of Leu27-IGF-II, an IGF-II 
analogue selective for IGF2R (Sakano, Enjoh et al. 1991).  
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6.2  Results  
 
6.2.1.1  Sustained effect of exogenous maternal IGF treatment on litter composition and fetal 
and placental weights 
Some of the data in this chapter were common to those in chapter 5. Data in this chapter has been 
restricted to animals used in placental transport studies. Litters from mothers that had been treated with 
IGF-I and Leu27-IGF-II during early to mid pregnancy had a greater number of viable fetuses (+30%,  
P = 0.001; +40%, P = 0.002, respectively) and fewer resorptions (-84%, P = 0.007; -100%, P = 0.01, 
respectively) compared with vehicle treated mothers, near term (Table 6.1). However, total litter size 
was unaffected by earlier maternal IGF treatment (Table 6.1). Maternal IGF-I treatment increased fetal 
weight near term (+10%, P = 0.05) but there was no effect of treatment on placental weight (Table 6.1). 
 
 
6.2.1.2  Sustained effects of exogenous maternal IGF on placental uptake of methyl glucose 
and amino isobutyric acid  
Treating the mother with IGF-I during early to mid pregnancy increased placental MG uptake compared 
to vehicle treated mothers near term in per gram and total placenta terms (+78%, P = 0.001 and +70%, 
P = 0.004, respectively) (Figure 6.1a). Placentae from mothers treated with IGF-I had higher MG uptake 
per gram of placenta compared with those treated with IGF-II (P = 0.019). 
 
Earlier maternal IGF treatment did not alter placental uptake of AIB on a per gram of tissue or whole 
tissue basis (Figure 6.1b). Leu27-IGF-II increased AIB uptake per gram of placenta, compared with 
vehicle and IGF-II treated animals (+65%, P= 0.05; +46%, P = 0.058, respectively), without an alteration 
in total placental AIB uptake (Figure 6.1b). 
 
 
6.2.1.3  Sustained effects of exogenous maternal IGF on fetal plasma methyl glucose and 
amino isobutyric acid concentrations 
Maternal IGF-I, IGF-II and Leu27-IGF-II treatment during early to mid pregnancy increased the 
concentration of fetal plasma MG near term (+50%, P = 0.002; +41%, P = 0.012; +89%, P < 0.0001, 
respectively) (Figure 6.2a). Additionally, exogenous maternal Leu27-IGF-II increased the concentration  
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Table 6.1 Sustained effect of maternal IGF treatment in early to mid pregnancy on litter 
composition and fetal dimensions  
  Vehicle IGF-I  IGF-II  Leu27-IGF-II 
Dams 8  9  6  4 
Fetuses 20  30  18  13 
Female / Male  9 / 10  12 / 10  14 / 16  9 / 4 
Total Litter   3.1 ± 0.1  3.4 ± 0.1  3.3 ± 0.1  3.5 ± 0.2 
Number viable  2.5 ± 0.2a 3.3  ± 0.1b 3.0  ± 0.2ab 3.5  ± 0.2b 
Number resorbing  0.61 ± 0.1a 0.10  ± 0.01b 0.25  ± 0.1ab 0.0  ± 0.0b 
Fetal weight**  69.7 ± 2.4a 76.8  ± 1.9b 71.1  ± 2.6ab 72.0  ± 2.8ab 
Placenta weight**  4.26 ± 0.2  4.26 ± 0.1  4.28 ± 0.2  4.07 ± 0.2 
Data are expressed as mean ± SEM or ** estimated marginal mean ± SEM after adjusting for the 
number of viable pups per litter. Linear Mixed Model Repeated Measures with Sidak Post Hoc Tests, 
using the mother as the subject, the fetus as the repeated measure and the number of viable pups as 
the covariate (when required). Different superscripts denote significant differences between groups, a vs 
























































Figure 6.1 Sustained effect of maternal IGF treatment in early to mid pregnancy on 
placental tissue uptake of substrate. Placental uptake of [3H]-methyl-D-glucose (MG, a) and 
[14C]-aminoisobutyric acid (AIB, b) per gram and total tissue. Data are from all placentae obtained 
from mothers treated with vehicle (mothers = 6), IGF-I (mothers = 7), IGF-II (mothers = 6) or 
Leu27-IGF-II (mothers = 4). Values are expressed as estimated marginal mean DPM ± SEM. 
Different superscripts denote a statistically significant difference between treatments, a vs b P < 
0.05, as determined by a Linear Mixed Model Repeated Measures with Sidak Post Hoc test, 
using the mother as the subject, the fetus as the repeated measure and the number of viable 
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Figure 6.2 Sustained effect of maternal IGF treatment in early to mid pregnancy on fetal 
substrate utilization. Fetal concentrations of [3H]-methyl-D-glucose (MG) and [14C]-
aminoisobutyric acid (AIB) in plasma (a) and tissues (c and  d). Values are expressed as 
estimated marginal mean DPM / ml ± SEM (a) and estimated marginal mean total DPM ± SEM 
(c and d). Data are from all fetuses obtained from mothers treated with vehicle (mothers = 6), 
IGF-I (mothers = 7), IGF-II (mothers = 6) or Leu27-IGF-II (mothers = 4). Different superscripts 
denote statistically significant difference, P < 0.048, as determined by a Linear Mixed Model 
Repeated Measures with Sidak Post Hoc test, using the mother as the subject, the fetus as the 
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of AIB in fetal plasma near term, compared with vehicle (+240%, P = 0.024), IGF-I (+290%, P < 0.0001) 
and IGF-II (+238%, P < 0.0001) treatment groups (Figure 6.2a). 
 
Across all treatments, fetal plasma MG was positively correlated with fetal weight (r = 0.29, P = 0.031) 
and crown-rump length (r = 0.28, P = 0.036). Across all treatments, placental MG uptake per gram of 
tissue and total uptake was positively correlated with fetal plasma MG concentrations (r = 0.92,   
P < 0.001 and r = 0.92, P < 0.0001). Total placental uptake of MG was additionally positively associated 
with fetal weight (r = 0.91, P <0.0001). 
 
 
6.2.1.4  Sustained effects of exogenous maternal IGF treatment on fetal tissue methyl glucose 
uptake  
Early to mid pregnancy maternal IGF-I increased MG uptake per gram by fetal spleen (+42%, P = 0.05) 
perirenal fat (+49%, P = 0.043), lung (+63%, P = 0.037), liver (+36%, P = 0.037) and kidney (+51%, P = 
0.001) and total MG uptake of retroperitoneal fat (+74%, P = 0.002), perirenal fat (+85%, P = 0.003), 
lung (+84%, P = 0.013), liver (+49%, P = 0.041), kidney (+81%, P < 0.001), heart (+88%, P = 0.043), 
gastrocnemius (+99%, P = 0.015) and triceps (+77%, P = 0.036) compared to vehicle near term (Table 
6.2).  
 
Early to mid pregnancy maternal IGF-II increased MG uptake per gram by fetal lung (+50%, P = 0.043) 
and liver (+34%, P = 0.037) and total MG uptake by lung (+52%, P = 0.016), liver (+43%, P = 0.05), 
gastrocnemius (+49%, P = 0.049) and triceps (+44%, P = 0.05) compared to vehicle near term (Table 
6.2). Early to mid pregnancy treatment of the mother with Leu27-IGF-II increased total MG uptake (DPM) 
by fetal triceps (+69%, P = 0.045) (Table 6.2). 
 
MG uptake by the fetal kidney in total (DPM) and relative per gram terms were 23% and 39% greater 
with maternal IGF-I treatment compared with IGF-II, respectively (P = 0.049 and P = 0.018). Total MG 
uptake by the fetal retroperitoneal fat was 42% greater following maternal IGF-I treatment compared 
with IGF-II (P = 0.025) (Table 6.2). For all treatment groups, the uptake of MG per gram of tissue was 
greatest in the fetal kidney and lowest in the retroperitoneal fat, except for the Leu27-IGF-II animals 
where uptake was lowest in the interscapular fat (Table 6.2). 
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Table 6.2 Sustained effect of maternal IGF treatment in early to mid pregnancy on fetal tissue 
methyl glucose uptake  
  Vehicle IGF-I  IGF-II  Leu27-IGF-II 
Number mums   6  7  6  4 
Number of fetuses  17  18  16  13 
Brain    (DPM / gram) 
                (total DPM) 
150 ± 20 
369 ± 49 
191 ± 18 
496 ± 45 
179 ± 17 
462 ± 42 
176 ± 28 
449 ± 69 
Heart     (DPM / gram) 
               (total DPM) 
147 ± 30 
62 ± 16a 
220 ± 25 
116 ± 14b 
176 ± 24 
84 ± 13ab 
177 ± 29 
78 ± 16ab 
Liver     (DPM / gram) 
               (total DPM) 
154 ± 17a 
559 ± 82a 
209 ± 17b 
833 ± 81b 
206 ± 14b 
799 ± 69b 
184 ± 18ab 
687 ± 89ab 
Lungs    (DPM / gram) 
               (total DPM) 
118 ± 21a 
159 ± 33a 
192 ± 20b 
293 ± 30b 
177 ± 18b 
241 ± 28b 
140 ± 22ab 
197 ± 34ab 
Kidneys (DPM / gram) 
               (total DPM) 
187 ± 17a 
102 ± 14a 
282 ± 16b 
184 ± 13b 
229 ± 14a 
132 ± 12a 
234 ± 19ab 
137 ± 16ab 
Spleen   (DPM / gram) 
               (total DPM) 
115 ± 15a 
18 ± 3 
164 ± 13b 
19 ± 3 
147 ± 13ab 
15 ± 3 
133 ± 15ab 
13 ± 3 
M.Tric (DPM / gram) 
               (total DPM) 
72 ± 11 
13 ± 3a 
102 ± 12 
23 ± 3b 
98 ± 10 
18 ± 2b 
110 ± 13 
22 ± 3b 
M. Gast (DPM / gram) 
               (total DPM) 
101 ± 17 
12 ± 3a 
154 ± 15 
25 ± 3b 
128 ± 14 
19 ± 2b 
124 ± 17 
17 ± 3ab 
Inters    (DPM / gram) 
               (total DPM) 
94 ± 23 
84 ± 19 
78 ± 22 
80 ± 18 
66 ± 19 
69 ± 16 
56 ± 22 
70 ± 18 
Periren  (DPM / gram) 
               (total DPM) 
65 ± 10a 
45 ± 9a 
97 ± 9b 
86 ± 8b 
71 ± 8ab 
58 ± 7a 
75 ± 10ab 
75 ± 10ab 
Retro  (DPM / gram) 
             (total DPM) 
55 ± 8 
35 ± 5a 
76 ± 7 
61 ± 5b 
62 ± 7 
43 ± 4a 
67 ± 8 
47 ± 6ab 
Data expressed as estimated marginal means ± SEM adjusted for the number of viable fetuses per litter.  
M.Gast, gastrocnemius; M.Tric, triceps, Inters, interscapular fat; Periren, perirenal fat; Retro, 
retroperitoneal fat. Superscripts denote significant difference between groups, a vs b, P < 0.05, as 
determined by Linear Mixed Model Repeated Measures with Sidak Post Hoc Tests, using the mother as 
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Maternal IGF-I treatment increased MG uptake per gram by fetal visceral tissues by 38% (mean DPM / 
gram ± SEM; vehicle: 735 ± 69, IGF-I: 1016 ± 65; IGF-II: 936 ± 61, Leu27-IGF-II: 857 ± 77, P = 0.014) 
and combined internal organs and tissues by 34% (mean DPM / gram ± SEM; vehicle: 1271 ± 132, 
IGF-I: 1705 ± 118; IGF-II: 1540 ± 111, Leu27-IGF-II: 1495 ± 141, P = 0.05). Maternal IGF-I treatment 
increased total MG uptake by fetal fat (+45%, P = 0.046) and muscle (76%, P = 0.027) and IGF-I and 
IGF-II increased total MG uptake by fetal visceral tissues (+51%, P = 0.009 and 39%, P = 0.05 
respectively) and combined internal organs and tissues (+49%, P = 0.007, +31%, P = 0.048) (Figure 
6.2b). There was no significant effect of Leu27-IGF-II on combined fetal tissue uptake of MG (total DPM). 
Across all treatments, placental MG uptake was positively correlated with fetal plasma and tissue MG 
counts (data not shown). 
 
Placental MG transfer capacity (total fetal tissue counts divided by placental weight) was increased by 
earlier maternal IGF-I (+50%, P = 0.029), IGF-II (+28%, P = 0.033) or Leu27-IGF-II (+28%, P = 0.047) 
treatments (mean ± SEM; vehicle: 349 ± 43, IGF-I: 506 ± 39; IGF-II: 446 ± 36, Leu27-IGF-II: 446 ± 46). 
 
 
6.2.1.5  Sustained effects of exogenous maternal IGF on fetal tissue amino isobutyric acid 
uptake  
Compared to vehicle, maternal IGF-I and Leu27-IGF-II treatment during early to mid pregnancy 
increased AIB uptake per gram by the fetal heart (+56%, P = 0.033; +61%, P = 0.048, respectively), 
which was also true in total uptake terms for IGF-I (+80%, P = 0.036) (Table 6.3). Leu27-IGF-II also 
increased per gram and total uptake of AIB by the fetal lungs compared with vehicle (+73%, P = 0.031; 
+80%, P = 0.02, respectively) and IGF-II (+58%, P = 0.044; +69%, P = 0.027, respectively) treated 
animals (Table 6.3). There was no effect of maternal IGF-I or IGF-II treatment on AIB uptake by other 
fetal tissues (on a per gram or total tissue basis) (Table 6.3). The uptake of AIB per gram of tissue was 
lowest in the brain for all animals and greatest in the fetal liver in vehicle, IGF-I and IGF-II animals and 
the fetal kidney for Leu27-IGF-II (Table 6.3).  
 
Maternal IGF-I treatment increased AIB uptake (DPM / gram) by fetal visceral tissues combined by 41% 
(mean DPM / gram ± SEM; vehicle: 96 ± 12, IGF-I: 135 ± 12; IGF-II: 101 ± 11; Leu27-IGF-II: 133 ± 14, 
P = 0.05) and fetal muscle AIB by 59% compared with IGF-II (mean DPM / gram ± SEM; vehicle: 38 ± 
5.9, IGF-I: 51 ± 5.6; IGF-II: 32 ± 5.3; Leu27-IGF-II: 44 ± 6.9, P = 0.05). Maternal IGF-I treatment 
increased total AIB uptake into fetal visceral tissues compared with vehicle and IGF-II (+43%, P = 0.046  Chapter 6    Sustained effects of IGF treatment 2 
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Table 6.3 Sustained effect of maternal IGF treatment in early to mid pregnancy on fetal tissue 
amino isobutyric acid uptake  
  Vehicle IGF-I  IGF-II  Leu27-IGF-II 
Number mums   6  7  6  4 
Number of fetuses  17  18  16  13 
Brain    (DPM / gram) 
                (total DPM) 
2.4 ± 0.4 
6.2 ± 1.2 
2.7 ± 0.4 
5.8 ± 0.9 
2.1 ± 0.4 
5.4 ± 0.9 
2.6 ± 0.5 
6.6 ± 1.2 
Heart     (DPM / gram) 
               (total DPM) 
18 ± 5a 
7.8 ± 2.1a 
28 ± 3b 
14.1 ± 1.6b 
21 ± 3ab 
9.7 ± 1.5ab 
29 ± 4b 
13.1 ± 2.1ab 
Liver     (DPM / gram) 
               (total DPM) 
29 ± 5 
103 ± 17 
36 ± 4 
135 ± 15 
28 ± 4 
102 ± 13 
31 ± 5 
116 ± 18 
Lungs    (DPM / gram) 
               (total DPM) 
11 ± 1.8a 
15 ± 2.7a 
14 ± 1.4ab 
21 ± 2.7ab 
12 ± 1.4a 
16 ± 2.1a 
19 ± 1.9b 
27 ± 3b 
Kidneys (DPM / gram) 
               (total DPM) 
29 ± 5 
16 ± 3 
29 ± 3 
18 ± 2 
26 ± 3 
13 ± 2 
36 ± 4 
17 ± 3 
Spleen   (DPM / gram) 
               (total DPM) 
14 ± 4 
2.1 ± 0.5 
18 ± 3 
1.9 ± 0.3 
16 ± 3 
1.7 ± 0.4 
20 ± 4 
2.1 ± 0.4 
M.Tric (DPM / gram) 
               (total DPM) 
18 ± 4 
3.8 ± 0.9 
25 ± 3 
5.6 ± 0.8 
15 ± 3 
2.9 ± 0.7 
23 ± 4 
4.6 ± 0.9 
M. Gast (DPM / gram) 
               (total DPM) 
20 ± 4 
2.7 ± 0.6 
23 ± 3 
3.5 ± 0.4 
16 ± 3 
2.3 ± 0.4 
21 ± 4 
2.8 ± 0.6 
Inters    (DPM / gram) 
               (total DPM) 
13.5 ± 2.1 
12.3 ± 2.0 
8.8 ± 1.7 
9.3 ± 1.7 
8.6 ± 1.6 
9.0 ± 1.5 
9.3 ± 2.1 
11.6 ± 1.9 
Periren  (DPM / gram) 
               (total DPM) 
13 ± 1.8 
8.9 ± 1.7 
13 ± 1.3 
11.2 ± 1.3 
11 ± 1.4 
8.9 ± 1.3 
15 ± 1.8 
14.8 ± 1.7 
Retro  (DPM / gram) 
             (total DPM) 
9.7 ± 1.2 
6.6 ± 1.0 
9.1 ± 0.9 
7.2 ± 0.8 
8.3 ± 0.9 
5.9 ± 0.8 
10.7 ± 1.2 
7.6 ± 1.1 
Data expressed as estimated marginal means ± SEM adjusted for the number of viable fetuses per litter.  
M.Gast, gastrocnemius; M.Tric, triceps, Inters, interscapular fat; Periren, perirenal fat; Retro, 
retroperitoneal fat. Superscripts denote significant difference between groups, a vs b, P < 0.05, as 
determined by Linear Mixed Model Repeated Measures with Sidak Post Hoc Tests, using the mother as 
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and +40%, P=0.047, respectively) (Figure 6.2c). IGF-I and Leu27-IGF-II increased total uptake of AIB 
into fetal tissues combined compared with vehicle (+33%, P = 0.045; +30%, P = 0.05, respectively) 
(Figure 6.2c). Total AIB uptake by fetal muscle was 73% greater following maternal IGF-I treatment 
compared with IGF-II (P = 0.029) (Figure 6.2c).  
 
 
6.2.1.6  Sustained effect of exogenous maternal IGF on the clearance of methyl glucose and 
amino isobutyric acid from the maternal circulation  
To determine whether early to mid pregnancy exogenous IGF treatment of the mother altered the 
clearance of MG or AIB from the maternal circulation in late pregnancy, following a bolus injection, 
maternal blood was sampled every 2 minutes for 20 minutes (Figure 6.3).   
 
Maternal IGF-I treatment increased maternal plasma MG at 4 (+87%, P = 0.07), 6 (+61%, P = 0.07),  
8 (+67%, P = 0.068), 10 (+55%, P = 0.048), 12 (+81%, P = 0.02), 14 (+83%, P = 0.03) and 18 (+63%,  
P = 0.07) minutes following analogue administration, although some of these did not reach statistical 
significance (Figure 6.3a). Exogenous IGF-II or Leu27-IGF-II treatment in early to mid pregnancy did not 
alter the clearance of MG from maternal plasma in late pregnancy.  
 
Mothers treated with Leu27-IGF-II, had greater plasma AIB concentrations at 2 (+292%, P = 0.048) and 
subsequently at 20 (+257%, P = 0.022) minutes following administration, compared with vehicle 
animals, with no effect between these time points. However, there was no effect of IGF-I or IGF-II 
treatment of the mother on AIB clearance from maternal plasma (Figure 6.3b). 
 
 
6.2.1.7  Sustained effect of exogenous maternal IGF on uptake of methyl glucose by tissues of 
the mother 
Maternal Leu27-IGF-II treatment in early to mid pregnancy increased total uptake of MG by maternal 
lung although this did not quite reach statistical significance (+33%, P = 0.066). However, Leu27-IGF-II 
treatment reduced total MG uptake by the maternal retroperitoenal fat compared to vehicle (-58%,  
P = 0.004), IGF-I (-69%, P = 0.038) and IGF-II (-61%, P = 0.049) treatment groups, near term (Table 
6.4). There was no effect of maternal IGF treatment on MG uptake by individual maternal organs or 
tissues. Overall, the uptake of MG per gram of tissue was greatest in the maternal kidney and lowest in 




















































Figure 6.3 Sustained effect of maternal IGF treatment in early to mid pregnancy on the 
clearance of methyl-D-glucose from the maternal circulation. Maternal blood was sampled 
every 2 minutes for 20 minutes following bolus injection of [3H]-methyl-D-glucose (MG). Data are 
from 4-7 mothers per treatment and values are expressed as means DPM / ml ± SEM. Asterisks 
denote statistically significant difference of IGF-I compared to the vehicle group, P < 0.048, with P 
values also displayed for time points where significance was almost reached. Data was analyzed 
using Repeated Measures ANOVA. 
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Table 6.4 Sustained effect of maternal IGF treatment in early to mid pregnancy on maternal tissue 
methyl glucose uptake 
  Vehicle IGF-I  IGF-II  Leu27-IGF-II 
Number of dams  6  7  6  4 
Brain      (DPM / gram) 
                  (total DPM) 
189 ± 32 
744 ± 139 
253 ± 29 
1060 ± 125 
195 ± 30 
794 ± 129 
170 ± 35 
673 ± 152 
Heart      (DPM / gram) 
                (total DPM) 
133 ± 41 
289 ± 85 
247 ± 34 
524 ± 72 
201 ± 40 
438 ± 85 
162 ± 48 
382 ± 101 
Liver      (DPM / gram) 
                (total DPM) 
314 ± 74 
8139 ± 1745 
414 ± 56 
11739 ± 1313 
358 ± 59 
9027 ± 1388 
387 ± 73 
10061 ± 1642 
Lungs     (DPM / gram) 
                (total DPM) 
211 ± 35 
896 ± 180a 
270 ± 31 
1075 ± 159ac 
221 ± 30 
1034 ± 156ac 
215 ± 41 
1188 ± 276c 
Kidneys (DPM / gram) 
                (total DPM) 
341 ± 142 
1568 ± 727 
702 ± 117 
3543 ± 598 
502 ± 122 
2359 ± 623 
466 ± 174 
2156± 721 
Spleen    (DPM / gram) 
                (total DPM) 
154 ± 36 
175 ± 49 
222 ± 34 
311 ± 46 
192 ± 37 
307 ± 51 
174 ± 41 
214 ± 55 
Triceps  (DPM / gram) 
                (total DPM) 
77 ± 35 
171 ± 81 
148 ± 35 
330 ± 80 
102 ± 32 
227 ± 74 
93 ± 38 
200 ± 85 
Gastroc. (DPM / gram) 
                (total DPM) 
145 ± 43 
271 ± 85 
241 ± 38 
487 ± 77 
186 ± 40 
364 ± 80 
108 ± 57 
194 ± 93 
Inters (DPM / gram) 
                (total DPM) 
43 ± 10 
433 ± 120 
64 ± 9 
573 ± 108 
36 ± 9 
328 ± 112 
41 ± 12 
295 ± 128 
Periren   (DPM / gram) 
               (total DPM) 
48 ± 28 
220 ± 140 
107 ± 25 
501 ± 126 
67 ± 26 
276 ± 130 
96 ± 37 
321± 154 
Retro   (DPM / gram) 
                (total DPM) 
72 ± 31 
487 ± 236a 
92 ± 25 
658 ± 194a 
64 ± 26 
514 ± 202a 
45 ± 22 
204 ± 40b 
Data expressed as estimated marginal means ± SEM adjusted for the number of viable fetuses per litter. 
Inters, interscapular fat; Periren, perirenal fat; Retro, retroperitoneal fat. Different superscripts denote 
difference between groups, a vs b, P < 0.05 (significant) or a vs c P = 0.066 (not significant), as 
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Maternal IGF-I increased MG uptake by maternal muscle per gram by 78% (mean DPM / gram ± SEM; 
vehicle: 221 ± 68; IGF-I: 394 ± 61; IGF-II: 289 ± 63; Leu27-IGF-II 186 ± 74, P = 0.058) and visceral 
tissue by 97% (mean DPM / gram ± SEM; vehicle: 975 ± 222; IGF-I: 1921 ± 200; IGF-II: 1609 ± 207; 
Leu27-IGF-II: 1078 ± 240, P = 0.014) and combined internal organs and tissues by 101% (mean DPM / 
gram ± SEM; vehicle: 1454 ± 351; IGF-I: 2935 ± 339; IGF-II: 2371 ± 332; Leu27-IGF-II: 1274 ± 365, 
P=0.007).  
 
Exogenous maternal IGF-I increased the total MG uptake into maternal muscle (+82%, P = 0.046), 
visceral (+89%, P = 0.016) and all tissues combined (+102%, P = 0.019) (Figure 6.4a).  
 
 
6.2.1.8  Sustained effect of exogenous maternal IGF on uptake of amino isobutyric acid by 
tissues of the mother 
Early to mid pregnancy maternal IGF-II treatment increased maternal spleen per gram and total AIB 
uptake near term, compared with vehicle treated dams (+98%, P = 0.039; +310%, P = 0.002, 
respectively) (Table 6.5). There was a 2.3 and 2.4-fold difference in per gram and total uptake of AIB by 
the brain between IGF-II and Leu27-IGF-II treated mothers (P = 0.068; P = 0.063, respectively) and a 4-
fold difference in total retroperitoneal fat AIB uptake (P = 0.005) (Table 6.5). Across all treatments, the 
uptake of AIB per gram of tissue was greatest in the maternal liver and lowest in the brain and 
interscapular fat of vehicle treated mothers and lowest in the brain in IGF and Leu27-IGF-II treated 
animals (Table 6.5). 
 
Maternal IGF-I and IGF-II increased AIB uptake per gram by maternal visceral tissues by 54% and 83% 
compared with vehicle, respectively (mean DPM / gram ± SEM; vehicle: 670 ± 91; IGF-I: 1031 ± 81; 
IGF-II: 1225 ± 84; Leu27-IGF-II: 857 ± 107, P = 0.014 and P = 0.002, respectively) and summed internal 
organs and tissues by 52% and 80%, respectively (mean ± SEM; vehicle: 736 ± 96; IGF-I: 1118 ± 92; 
IGF-II: 1319 ± 91; Leu27-IGF-II: 996 ± 121, P = 0.007 and P = 0.002, respectively).  
 
Maternal IGF-I increased total AIB uptake by maternal muscle (+82%, P = 0.044) and both IGF-I and 
IGF-II treatment of the mother increased total AIB uptake by visceral tissues (both +71% and P = 0.048) 
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Figure 6.4 Sustained effect of maternal IGF treatment in early to mid pregnancy on total 
maternal tissue substrate utilization. Total maternal tissue uptake of [3H]-methyl-D-glucose (a) 
and [14C]-aminoisobutyric acid (b) were determined. Data are from 6 vehicle, 7 IGF-I, 6 IGF-II and 
4 Leu27-IGF-II mothers. Values are expressed as mean total DPM ± SEM. Asterisks denote a 
statistically significant difference compared to the vehicle group, P < 0.048, as determined by a 
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Table 6.5 Sustained effect of maternal IGF treatment in early to mid pregnancy on maternal tissue 
amino isobutyric acid uptake 
  Vehicle IGF-I  IGF-II  Leu27-IGF-II 
Number of dams  6  7  6  4 
Brain      (DPM / gram) 
                  (total DPM) 
7.7 ± 1.3ac 
31 ± 5.4ac 
6.2 ± 1.2ac 
26 ± 4.8ac 
8.9 ± 1.2a 
36 ± 5.0a 
3.9 ± 1.4c 
15 ± 1.4 c 
Heart      (DPM / gram) 
               (total DPM) 
38 ± 21 
83 ± 44 
79 ± 17 
171 ± 37 
91 ± 20 
196 ± 44 
83 ± 25 
196 ± 55 
Liver      (DPM / gram) 
               (total DPM) 
526 ± 138 
13766 ± 3417 
570 ± 103 
15871 ± 2570 
618 ± 109 
15659 ± 2718 
386 ± 133 
10020 ± 3331 
Lungs     (DPM / gram) 
               (total DPM) 
19 ± 11ac 
77 ± 23a 
8.7 ± 9.3a 
36 ± 18a 
9.7 ± 9.2a 
41 ± 18a 
50 ± 12c 
274 ± 64b 
Kidneys (DPM / gram) 
               (total DPM) 
186 ± 33 
846 ± 182 
220 ± 27 
1108 ± 150 
281 ± 28 
1329 ± 156 
245 ± 37 
1134 ± 187 
Spleen    (DPM / gram) 
               (total DPM) 
94.9 ± 23a 
110 ± 63a 
109 ± 21ab 
153 ± 58ab 
188 ± 23b 
341 ± 64b 
107 ± 26ab 
136 ± 68ab 
Triceps  (DPM / gram) 
               (total DPM) 
19 ± 6 
42 ± 15 
34 ± 6.2 
77 ± 15 
31 ± 5.7 
69 ± 14 
20 ± 6.7 
44 ± 16 
Gastroc. (DPM / gram) 
               (total DPM) 
12 ± 5.2 
22 ± 11 
14 ± 4.6 
32 ± 9.8 
11 ± 4.8 
21 ± 10 
15 ± 6.9 
27 ± 14 
Inters (DPM / gram) 
               (total DPM) 
7.7 ± 2.1 
78 ± 24 
8.9 ± 1.9 
78 ± 21 
7.5 ± 1.9 
72 ± 22 
5.2 ± 2.3 
39 ± 25 
Periren   (DPM / gram) 
               (total DPM) 
8.2 ± 3.2 
40 ± 16 
13 ± 2.9 
61 ± 15 
13 ± 3.0 
53 ± 15 
14 ± 4.1 
62 ± 21 
Retro   (DPM / gram) 
               (total DPM) 
11 ± 2.8 
74 ± 23ab 
12 ± 2.3 
81 ± 19ab 
15 ± 2.4 
120 ± 19a 
7.0 ± 2.9 
36 ± 18b 
Data expressed as estimated marginal means ± SEM adjusted for the number of viable fetuses per litter. 
Inters, interscapular fat; Periren, perirenal fat; Retro, retroperitoneal fat. Different superscripts denote 
significant difference between groups, a vs b, P < 0.05 (significant) and a vs c P = 0.068 (not significant), 
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6.2.1.9  Sustained exogenous maternal IGF on the concentration of metabolites in the fetal 
circulation 
Maternal IGF-I, IGF-II and Leu27-IGF-II treatment increased fetal circulating amino acid concentrations 
(+196%, P=0.026; +137%, P=0.029; +339%, P = 0.008, respectively) and maternal IGF-I reduced fetal 
circulating cholesterol concentrations (-30%, P=0.049) compared to vehicle, near term (Figure 6.5a). 




6.2.1.10  Sustained effects of exogenous maternal IGF on maternal circulating metabolite 
concentrations 
Maternal IGF treatment did not alter circulating concentrations of glucose, free fatty acids, amino acids, 
triglycerides or cholesterol in the mother near term (Figure 6.5b). 
 
 
6.2.1.11  Sustained effect of exogenous maternal IGF on fetal to maternal metabolite 
concentration gradients 
Maternal IGF-II treatment increased the ratio of maternal plasma glucose concentration to that in fetal 
plasma (estimated marginal mean ratio ± SEM; vehicle: 1.3 ± 0.3; IGF-I: 1.4 ± 0.3; IGF-II: 2.1 ± 0.4; 
Leu27-IGF-II: 1.3 ± 0.3, P = 0.035). Maternal IGF-I, IGF-II and Leu27-IGF-II reduced the ratio of maternal 
plasma amino acid concentration to that in fetal plasma (estimated marginal mean ratio ± SEM; vehicle: 
0.61 ± 0.05; IGF-I: 0.21 ± 0.05; IGF-II: 0.29 ± 0.05; Leu27-IGF-II: 0.16 ± 0.06, effect of treatment P = 
0.027, P = 0.05, P = 0.013, respectively). There was no significant effect of treatment on the 
concentration gradient of other metabolites between the fetal and maternal plasma (data not shown). 
 
 
6.2.1.12  Associations of MG uptake with placental morphology 
To determine the association of placental and fetal MG content with previously determined structural 
correlates of placental function near term (Chapter 5, p 139), correlations between these parameters 
were determined. Overall, MG uptake by placenta (DPM / gram) was correlated positively with the 
placental total surface area for exchange (r = 0.39, P = 0.039). Total placental MG uptake correlated 
positively with volume for placental exchange (r = 0.37, P = 0.019), the placental total surface area for 





































Figure 6.5 Sustained effect of maternal IGF treatment in early to mid pregnancy on 
circulating metabolites in the fetus (a) and mother (b). Fetal data are from all fetuses of all 
mothers (4-7 per treatment) and values are expressed as estimated marginal means adjusted for 
the number of viable pups ± SEM. Maternal data are are expressed as means ± SEM. AA, 
amino acids; Chol, cholesterol; FFA, free fatty acids; Gluc, glucose; Trig, triglycerides. Different 
superscripts denote a statistically significant difference between treatments, a vs b P < 0.049. 
Fetal data were analysed by Linear Mixed Model Repeated Measures with Sidak Post Hoc test, 
using the mother as the subject, the fetus as the repeated measure and the number of viable 
pups per litter as the covariate. Maternal data were analysed by General Linear Univariate 
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(r = 0.32, P = 0.035). Overall, fetal plasma and tissue MG values were correlated positively with volume 
for placental exchange (r = 0.35, P = 0.027 and r = 0.38, P = 0.025, respectively) and that of maternal 
blood spaces (r = 0.47, P = 0.003 and r = 0.40, P = 0.023, respectively). 
 
 
6.2.1.13  Associations of MG uptake with maternal hormones 
Treating the mother with IGF during early to mid pregnancy altered the associations of placental and 
fetal MG content near term with previously determined maternal circulating estradiol concentrations 
(Chapters 4 and 5, p 122 and 134). However, maternal progesterone concentrations did not correlate 
with any parameter analysed (data not shown). There was no association of maternal hormones with 
AIB uptake or circulating metabolite concentrations in the fetus or mother (data not shown). 
 
Maternal plasma estradiol concentration of vehicle treated animals correlated negatively with placental 
MG uptake and transfer capacity (r = -0.86, P = 0.001 and r = -0.85, P = 0.002, respectively), whereas it 
was positively correlated in IGF-I (r = 0.56, P = 0.011 and r = 0.70, P = 0.017, respectively) and IGF-II  
(r = 0.85, P < 0.0001 and r = 0.88, P < 0.0001, respectively), but there was no association in   
Leu27-IGF-II treated mothers. In vehicle treated animals, maternal circulating estradiol was associated 
negatively with total uptake of MG by maternal tissues (r = -0.96, P = 0.003) but in IGF-I and   
Leu27-IGF-II treated mothers there was no correlation and following IGF-II treatment, these parameters 
were positively correlated (r = 0.84, P = 0.036). Chapter 6    Sustained effects of IGF treatment 2 
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6.3  Discussion 
Here we demonstrate for the first time that treating the mother with either IGF during early to mid 
pregnancy has a sustained effect on placental transport of nutrients to the fetus and influences nutrient 
partitioning and likely metabolism, in the mother and conceptus near term. This extends, and provides 
new insight into, our previous observations that increasing the abundance of IGF-I and IGF-II in the 
maternal circulation during early to mid pregnancy enhanced fetal growth and survival near term 
(Chapter 5). 
 
In this chapter, we have shown that early to mid pregnancy maternal IGF treatment, increased placental 
uptake and transfer of methyl glucose to the fetus in late pregnancy. As glucose is the primary source of 
energy for the fetus and the placenta (Owens 1991), enhanced placental transfer of glucose would 
directly increase fetal energy supplies to promote growth. This was certainly the case for maternal IGF-I 
treatment in the current study, and for both IGF treatments in our previous, larger study (Chapter 5), 
where fetal growth and survival were increased near term. 
 
In mothers treated with IGF-II in particular, in early to mid pregnancy, enhanced placental transfer and 
uptake of methyl glucose by the fetus near term was demonstrated but may be secondary to sustained 
effects on placental structural development exerted primarily through IGF2R. IGF-II treatment in early to 
mid pregnancy increased the cross-sectional area, proportion and volume of the placental exchange 
region, as well as the total surface area of placenta functioning in exchange in late gestation (refer to 
Chapter 5, p 139). These structural changes were predicted to enhance the capacity of the placenta to 
deliver substrate and are consistent with the observed increase in methyl glucose transfer in late 
pregnancy, demonstrating here with both IGF-II and Leu27-IGF-II treatments. Indeed, we found positive 
correlations between a variety of placental structural parameters and placental methyl glucose transport 
to the fetus. 
 
In contrast to IGF-II, maternal IGF-I treatment in early to mid pregnancy, did not alter the structure of the 
placental exchange region (Chapter 5). Circulating IGF-I in the mother may influence other determinants 
of placental transport capacity including the abundance, localisation and affinity of transporter proteins 
at the exchange interface, placental blood flow, concentration gradients of substrate between the 
mother and fetus, and placental consumption and modification of substrates. Indeed, maternal 
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between the maternal and fetal circulation was increased in IGF-II treated animals. These alterations in 
maternal glucose concentration may have been partly responsible for increased placental methyl 
glucose transfer as net glucose transport to the fetus is dependent on maternal circulating glucose 
concentrations. 
 
Uptake and transport of glucose across the placenta occurs via facilitated carrier-mediated diffusion 
(Schneider, Calderon et al. 1981) which, in the human, mouse, rat and sheep placenta, primarily 
involves the glucose transporter (GLUT) isoforms-1 and -3 (Currie, Bassett et al. 1996; Das, Sadiq et al. 
1998; Ehrhardt and Bell 1997; Hahn, Hartmann et al. 1995; Illsley 2000; Jansson, Wennergren et al. 
1993; Tadokoro, Yoshimoto et al. 1996; Takata, Kasahara et al. 1994; Wooding, Fowden et al. 2005; 
Zhou and Bondy 1993), although GLUT-4 and -12 placental expression have also been described 
(Ericsson, Hamark et al. 2005b; Gude, Stevenson et al. 2003). Glucose transporters are regulated by 
factors including glucose and glycolytic substrates (Klip, Tsakiridis et al. 1994; Sasson, Kaiser et al. 
1997), oxygen (Ebert, Firth et al. 1995; Esterman, Greco et al. 1997; Hayashi, Sakata et al. 2004) and 
also by insulin, IGF-I and IGF-II (Ericsson, Hamark et al. 2005a; Maher and Harrison 1990; Wilson, 
Mitsumoto et al. 1995). 
 
In a first trimester trophoblast cell line, exposure to either IGF increased glucose transporter activity 
(Gordon, Zimmerman et al. 1995; Kniss, Shubert et al. 1994) and in rats, maternal IGF-I treatment 
increased glucose transporter mRNA expression of Slc2a1 and Slc2a3, which encode GLUT-1 and 
GLUT-3, respectively (Bauer, Harding et al. 1998). Furthermore, GLUT-1 expression on the basal 
membrane of the placental barrier is positively regulated by IGF-I (Baumann, Deborde et al. 2002). The 
latter observation is especially noteworthy, as GLUT-1 protein density on the basal membrane in the 
human placenta is thought to be the rate-limiting step in transplacental glucose transfer (Vardhana and 
Illsley 2002). This is consistent with reports of accelerated fetal growth in insulin-dependent diabetes 
mellitus being associated with increased GLUT-1 activity on the basal membrane (Gaither, Quraishi et 
al. 1999) and enhanced placental glucose transport capacity (Jansson, Ekstrand et al. 2001). 
 
IGF-I may also have enhanced methyl glucose uptake and transfer to the fetus indirectly by increasing 
maternal blood flow to the placenta. During pregnancy, the maternal spiral arterioles that supply the 
uterus are transformed by invading placental trophoblasts into dilated vessels, unresponsive to maternal 
vasocontrol (Aplin 1991; Lyall 2005; Pijnenborg, Bland et al. 1983; Pijnenborg, Vercruysse et al. 2006). 
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that constitutes 30-40% of the total maternal cardiac output (Martin 1968). In culture, IGF-I stimulates 
trophoblast migration and invasion (Lacey, Haigh et al. 2002) through elevated matrix 
metalloproteinase-9 activity (Hills, Elder et al. 2004), activation of integrins (Kabir-Salmani, Shiokawa et 
al. 2004; Kabir-Salmani, Shiokawa et al. 2003) and altered cytoskeletal organisation (Kabir-Salmani, 
Shiokawa et al. 2002). It also inhibits vasoconstrictors, such as thromboxane B2 and prostaglandin F2 
α, in human term placental explants (Siler-Khodr and Forman 1993; Siler-Khodr, Forman et al. 1995). 
Placental synthesis of IGF-I is normally low (particularly compared to IGF-II) in most species analyzed, 
including the guinea pig and human (Han, Bassett et al. 1996; Han and Carter 2000; Han, Carter et al. 
1999). However, in the IGF-I treated mother, elevated maternal circulating IGF-I concentrations may act 
in an endocrine fashion and influence the function of trophoblast surrounding or migrating within uterine 
spiral arteries. Therefore, elevated maternal circulating IGF-I may promote uterine vascular remodelling, 
which would permit increased perfusion of the placenta and indirectly increased substrate flux to the 
fetus. 
 
Despite effects of exogenous maternal IGFs on placental transport of methyl glucose, there was no 
effect of IGF-I or IGF-II treatment on placental uptake and transfer of the amino isobutyric acid in late 
gestation. This was unexpected, as in the current study fetuses from IGF treated mothers had 
substantially increased plasma α-amino nitrogen concentrations near term. These outcomes suggest 
that maternal IGF treatment may not alter the sodium-dependent, System A transporters, which are 
responsible for amino isobutyric acid and neutral amino acid (alanine, serine, proline and glutamine) 
transfer, but rather may target other amino acid transporter systems. There are at least 15 different 
amino acid transporter systems identified in the human and rat placenta (Jansson 2001; Regnault, 
Friedman et al. 2005), which display overlapping substrate specificity (Battaglia 2002). It is also 
important to remember that in some species like the guinea pig, which possess a separate yolk sac 
(vitelline) placenta, substrates including amino acids may be transferred to the fetus via this route (Butt 
and Wilson 1968). Whether IGF treatment to the mother affected yolk sac transport has yet to be 
elucidated. Determining the fetal circulating amino acid profile in response to earlier maternal IGF 
treatment would provide more insight into which amino acid transporters may be affected in the 
placenta, providing a direct link with the observed increased fetal growth (Chapter 5). Indeed, in 
transgenic mice, elevated abundance of IGF-I due to growth hormone over-expression, or deficiency in 
IGF-II by gene ablation, altered placental expression of X-AG transporters which are responsible for 
sodium-dependent uptake and transfer of anionic amino acids like glutamate and aspartate (Matthews, 
Beveridge et al. 1999).  
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In direct contrast to findings with IGF supplementation, Leu27-IGF-II treatment, substantially increased 
placental System A amino acid uptake. As system A transports nonessential amino acids which are 
subjected to catabolism in the placenta, it is possible that Leu27-IGF-II treatment increased placental 
metabolism. This may have occurred indirectly as Leu27-IGF-II  is an analogue of IGF-II, which 
selectively interacts with IGF2R due to reduced binding capacity for the IGF1R and InsR (80 and 220-
fold lower affinity, respectively) (Sakano, Enjoh et al. 1991) and therefore would have reduced the 
availability of IGF2R for endogenous maternal IGF-II. This would permit endogenous IGF-II to interact 
with other receptors, including the InsR, which is known to mediate metabolic effects. Nevertheless, 
enhanced placental metabolism would be expected to increase placental function, which is consistent 
with increased methyl glucose and amino isobutyric acid transfer and improved pregnancy outcome in 
Leu27-IGF-II treated pregnancies. Certainly, determining the maternal plasma concentration of IGF-II in 
the mothers treated with Leu27-IGF-II may provide some insight. 
 
Surprisingly, fetal cholesterol concentrations near term were reduced by earlier maternal IGF-I 
supplementation. The liver is the main source of cholesterol in the guinea pig fetus (Yount and 
McNamara 1991). As previous investigative analysis determined that the fractional weight of fetal liver 
was reduced in response to maternal IGF-I supplementation (Chapter 5, p 146), we speculate that a 
reduction in fetal plasma cholesterol is a direct consequence of inadequate liver growth, proportionate to 
total fetal weight. 
 
Both maternal IGF treatments increased methyl glucose fetal tissue utilization while IGF-I also increased 
that of amino isobutyric in the fetal visceral organs, near term. Furthermore, there was increased 
utilization of methyl glucose and amino isobutyric acid per gram of several fetal tissues of IGF treated 
mothers, without an alteration in wet weight (Chapter 5, p 146). We therefore speculate, that in the 
larger fetuses of the IGF treated mothers particular fetal tissues may be functionally more active and 
therefore metabolising substrate more efficiently, contributing to the rapid growth of the fetus in late 
gestation. This altered fetal growth trajectory may have been established during treatment and 
sustained until term, as fetuses of IGF-I treated mothers on day 35 (Chapter 3, p 112), or treated with 
either IGF on day 40 (Sohlstrom, Fernberg et al. 2001) were also heavier than controls. 
 
Interestingly, in the current study, early pregnancy treatment of the guinea pig with either IGF also 
increased uptake of methyl glucose and amino isobutyric acid by maternal tissues in late pregnancy. 
Particularly in the case of IGF-II, this effect appeared to be independent of the IGF2R, as there was no 
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tissues have reduced abundance of IGF2R, or much more likely, that IGF2R does not mediate 
metabolic effects in cells. Nevertheless, despite increased maternal substrate utilization, maternal organ 
weights were not increased and fetal and placental growth were not compromised near term in 
response to earlier maternal IGF treatment (Chapter 5). These suggest that the IGF treated mothers 
may be metabolically more active than vehicle-treated controls. In humans, total energy expenditure 
increases by 19% by the third trimester of pregnancy compared with non-pregnant women (Butte 2005) 
and during normal pregnancy, endogenous  hepatic glucose production (Assel, Rossi et al. 1993; 
Catalano and Hollenbeck 1992; Catalano, Roman-Drago et al. 1998; Kalhan, D'Angelo et al. 1979), the 
24-h respiratory quotient and basal and sleeping metabolic rates all increase (Bronstein, Mak et al. 
1995; Butte, Hopkinson et al. 1999; Denne, Patel et al. 1991; van Raaij, Schonk et al. 1989). These 
maternal physiological changes presumably contribute to maternal adaptation to pregnancy to meet the 
increasing demands of the placenta and fetus. 
 
Increased maternal amino isobutyric acid and methyl glucose utilization in late pregnancy in response to 
IGF treatment may reflect a maternal metabolic strategy that enabled maternal organs to increase their 
functional capacity and energy expenditure. Indeed, we have found in our guinea pig cohorts that total 
conceptus mass may be equal to as much as 50% of maternal weight near term, which is likely to place 
huge metabolic demands on the mother. Certainly, maternal plasma glucose concentrations tended to 
be increased in response to earlier maternal IGF treatment, suggestive of increased maternal hepatic 
glucose production and improved maternal metabolism. Furthermore, increased concentration of 
glucose in the maternal circulation may have been a mechanism for increasing substrate availability for 
fetal growth. Indeed, in order to divert nutrients to the conceptus, the mother acquires a state of relative 
insulin-resistance as pregnancy advances (Catalano, Tyzbir et al. 1991; Catalano, Tyzbir et al. 1993; 
Catalano, Tyzbir et al. 1992; Ryan, O'Sullivan et al. 1985). Interestingly, in the current study, mothers 
treated with IGF-I during early to mid pregnancy displayed reduced clearance of methyl glucose from 
maternal plasma, although fetal, placental and maternal substrate uptakes were improved, near term. 
This may have reflected substantial differences in the response of other maternal and fetal tissues, not 
analysed in the current study, to maternal IGF treatment. Such tissues include other fat depots and 
skeletal muscles, the gastrointestinal tract, uterus and skin, which are known to vary in their endocrine 
characteristics, including insulin and related molecule sensitivities. In any case, it appears that IGFs in 
the mother may have promoted maternal adaptation to pregnancy, such as development of insulin 
resistance and altered maternal metabolism, thereby enhancing fetal growth and survival. 
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In conclusion, we have shown that increased maternal circulating IGF concentrations in early pregnancy 
sustainedly increase maternal substrate utilization, placental MG transfer to the fetus and fetal utilization 
of MG and AIB, enhancing fetal growth and survival near term. Whether the latter are indirect 
consequences of enhanced maternal adaptation to pregnancy or whether maternal substrate utilization 
was increased in response to enhanced conceptus growth to meet the challenge of pregnancy, remain 
to be elucidated. Nevertheless, we speculate that effects of maternal IGF-II treatment on placental MG 
uptake and transfer are secondary to impacts on placental differentiation, which is primarily exerted via 
IGF2R (Chapter 5). In contrast, actions of exogenous IGF-I on placental transfer and fetal growth and 
substrate utilization are believed to be mediated through IGF1R, as it has little or no affinity for InsR and 
IGF2R, through influencing maternal tissues and possibly placental parameters not assessed in the 
present study. Overall, this study has provided further evidence for a major role of maternal IGFs in the 
regulation of nutrient partitioning during pregnancy. As insufficient supply of nutrients to the fetus is 
associated with IUGR (Cetin, Corbetta et al. 1990; Cetin, Radaelli et al. 2001; Economides and 
Nicolaides 1989), therapeutic approaches that increase maternal IGFs in early to mid pregnancy may be 
effective in ameliorating or preventing its development in pregnancies at risk. The challenge is to identify 
those women at risk of IUGR early in pregnancy before the fetus is compromised. 
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7.1  Discussion  
It is well established that, in humans onset of maternal blood flow to the placenta commences around 
10 weeks of gestation and, prior to this time, the fetus and placenta are developing in a hypoxic 
environment which is essential for a healthy pregnancy outcome. The effects of hypoxia on placental 
trophoblast function are likely to be mediated locally through the regulation of growth factors. For 
instance, components of the IGF system are expressed at the feto-maternal interface, with IGF-II in 
particular, highly expressed by invading EVTs. Certainly, maternally-derived IGFs may also regulate 
fetal growth during pregnancy through actions on the placenta but the mechanisms involved have yet to 
be fully elucidated.   
 
The studies described in this thesis indicate that oxygen and IGF-II interact at the feto-maternal 
interface and regulate placental invasion and growth. In addition, it has been demonstrated that 
maternal circulating IGFs in early to mid pregnancy regulate fetal growth and viability in late pregnancy, 
through enhancing placental substrate transfer capacity and influencing nutrient allocation between the 
mother and conceptus. 
 
7.1.1  Interaction of oxygen and IGF-II during early pregnancy in vitro 
In Chapter 3, first trimester human placental villous explants were prepared from pregnancies 
terminated between 7 and 12 weeks. Initial studies comparing the growth response of villous explants to 
culture under low oxygen atmospheres across the gestational ages sampled, revealed a change at 10 
weeks of gestation. This was seen by declining villous outgrowth. Work of others has demonstrated that 
onset of maternal blood flow to the placenta occurs gradually from 10 weeks of gestation in vivo 
(Burton, Jauniaux et al. 1999; Rodesch, Simon et al. 1992). Thus, our findings showing reduced 
outgrowth of villous explants of greater than 10 weeks of gestation to low concentrations of oxygen are 
consistent with a response to hypoxic stress, as the placenta would have been exposed to higher 
oxygen concentrations in vivo. Furthermore, we detected an inverse relationship between villous 
outgrowth and gestational age of the placenta, suggesting that trophoblasts are programmed to 
proliferate and invade optimally in early stages of gestation, particularly at 7 to 8 weeks of gestation, 
when maternal blood perfusion of the placenta is minimal. Further experiments revealed that villous 
explants from placenta obtained at 7 or 8 weeks of gestation exposed to low oxygen atmospheres 
displayed enhanced villous tip outgrowth, increased Igf2 gene expression and produced almost no 
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(Feldser, Agani et al. 1999; Kim, Bae et al. 1998; Steinbrech, Mehrara et al. 2000; Tucci, Nygard et al. 
1998) and is believed to be mediated by HIF.  
 
In our studies, we found no effect of oxygen availability on Tgfβ1 gene expression or total protein 
secretion, indicating that regulation of TGF-β1 by oxygen occurs at the protein activation level. Further 
experiments performed suggested that IGF-II may be mediating the observed effects of low oxygen on 
the placenta (Figure 7.1). In the present thesis, exogenous IGF-II stimulated villous explant outgrowth 
and inhibited TGF-β1 activation in villous explants cultured in high oxygen, mimicking the response of 
explants to low oxygen. Indeed, IGF-II stimulates trophoblast proliferation (Ohlsson, Holmgren et al. 
1989), migration (Irving and Lala 1995; McKinnon, Chakarborty et al. 2000; McKinnon, Chakraborty et 
al. 2001) and invasion (Hamilton, Lysiak et al. 1998) in first trimester cell lines, in vitro, the former 
mediated via IGF1R (Ohlsson, Holmgren et al. 1989) or potentially via InsR (Morrione, Valentinis et al. 
1997). Furthermore, IGF-II may have promoted villous outgrowth indirectly, by reducing activation of 
TGF-β1, which is well known for its inhibitory effects on trophoblast proliferation (Graham and Lala 
1992), migration (Irving and Lala 1995) and invasion (Graham and Lala 1991; Graham and Lala 1992) 
in vitro.  
 
Indeed, there is considerable overlap between the IGF and TGF-β systems, as outlined in Chapter 1. 
Most noteworthy is IGF2R, which can bind both IGF-II and latent TGF-β1. The latter interaction results 
in activation of the TGF-β1 protein through a complex formed between IGF2R, uPA, uPAR and 
plasminogen (Godar, Horejsi et al. 1999; Leksa, Godar et al. 2005) (refer to Figure 1.14). As IGF2R 
cannot bind IGF-II and TGF-β1 simultanenously and the former has a greater affinity for IGF2R, 
increased expression of Igf2 by exposure to hypoxia or exogenous IGF-II treatment of villous explants, 
is likely to reduce the availability of IGF2R for binding by latent TGF-β1 and thereby prevent its 
activation. Analysis of growth and TGF-β1 activation in villous explants exposed to low oxygen 
atmospheres in the presence of anti-sense RNA, small-interfering RNA or antibodies specific for IGF-II, 
would provide further evidence for the role of IGF-II in the effect of hypoxia on placental outgrowth. As 
Igf1r, Igf2r and Upar genes were unaltered by oxygen concentration or IGF-II, the effect of inhibitors of 
components of the IGF2R-uPAR complex and use of Leu27-IGF-II, an analogue selective for IGF2R, but 
not IGF1R or InsR, on TGF-β1 and trophoblast invasion, would complement the current findings. 
Furthermore, utilizing primary cultures of first trimester trophoblast, rather than villous explants, in these 
experiments would enable more quantitative measures of outgrowth by performing migration and 
invasion assays. Hypoxia
IGF-II
CTB proliferation, migration, invasion











Figure 7.1 IGF-II mediates the effect of hypoxia to promote human placental outgrowth in 
early pregnancy. At 7 to 8 weeks of gestation, prior to the onset of maternal blood flow to the 
placenta, hypoxia stimulates placental outgrowth, induces Igf2 gene expression and inhibits TGF-
β1 activation. Exogenous IGF-II mimics the effect of hypoxia in placenta exposed to high oxygen, 
as it enhances placental outgrowth and inhibits activation of TGF-β1.
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Interestingly, TGF-β1 is involved in trophoblast terminal differentiation into syncytium, a process critical 
for functional maturation of the placenta in later gestation. Therefore, in later pregnancy, following 
maternal blood perfusion of the placenta and when IGF-II abundance is known to decline (Han, Bassett 
et al. 1996), we suspect there would be increased availability of IGF2R for interaction with and activation 
of, latent TGF-β1, which would transform placental functional development. From these studies we 
propose that, oxygen is the regulatory switch during pregnancy, influencing trophoblast proliferation and 
migration/invasion as opposed to trophoblast terminal differentiation through effects on IGF-II 
expression and TGF-β1 activation (Figure 7.2). Certainly, premature onset of maternal blood flow to the 
placenta is associated with early pregnancy loss, highlighting the significance of hypoxia in early 
gestation to pregnancy outcome (Hustin, Jauniaux et al. 1990; Jauniaux, Greenwold et al. 2003; 
Jauniaux, Zaidi et al. 1994). Importantly, regardless of the gestational age of the placenta, exogenous 
IGF-II enhanced villous explant outgrowth in vitro. Enhanced placental growth is expected to increase 
its functional capacity and thereby improve pregnancy outcome.  
 
7.1.2  Role of maternal IGFs during pregnancy in vivo 
Studies performed on genetically modified mice, have demonstrated the role of IGF-II, but not IGF-I, in 
placental development and function, whilst both IGFs are important for optimal fetal growth (Baker, 
Hardy et al. 1996; Constancia, Hemberger et al. 2002; DeChiara, Efstratiadis et al. 1990; Ferguson-
Smith, Cattanach et al. 1991; Liu, Baker et al. 1993; Louvi, Accili et al. 1997). This work implied that 
there may be distinct mechanisms employed by each IGF, for the regulation of fetal growth. Thus, the 
rest of the studies detailed in this thesis aimed to elucidate the roles and effects of IGF-I and IGF-II 
treatment to the mother during early to mid pregnancy (days 20 to 38 of pregnancy) on placental growth 
and function and pregnancy outcome in vivo. These studies were performed in pregnant female guinea 
pigs, which display a similar IGF axis to humans. In mid pregnancy, this treatment elevated the 
concentrations of IGF-I and IGF-II in the maternal plasma by 350% and 240%, respectively. 
Experiments in Chapter 4 sought to determine the acute effects of elevated maternal IGF circulating 
concentrations on placental function, maternal substrate utilization and fetal growth at day 35 of 
gestation. Studies described in Chapters 5 and 6 ascertained the sustained impacts of earlier IGF 
treatment to the mother on maternal and fetal body composition, placental development and function 
and nutrient partitioning near term, on day 62 of pregnancy. 
 










Placental expansion and 
Recruitment of spiral arterioles
Placental functional
maturation
Figure 7.2 Proposed model of oxygen acting as the regulatory switch in placental 
development. In early pregnancy, when there is little to no blood flow to the placenta, IGF-II is 
abundant preventing activation of TGF-β1, resulting in direct and indirect stimulation of 
trophoblast proliferation and invasion. This promotes placental expansion and subsequent 
maternal blood flow to the placenta. In later gestation, when the placenta is perfused with 
maternal blood, oxygen concentrations rise and there is less IGF-II synthesis, there is abundant 
active TGF-β1, which induces trophoblast terminal differentiation by inhibiting proliferation and 
invasion. This results in functional maturation of the placenta.
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7.1.2.1  IGF effects on the fetus 
Both IGF treatments increased fetal survival and growth in late pregnancy, the latter of which was 
evident in mid pregnancy, in IGF-I treated mothers. This is consistent with a previous, similar study also 
undertaken in guinea pigs, demonstrating increased fetal growth on day 40 of pregnancy in response to 
earlier maternal IGF treatment (Sohlstrom, Fernberg et al. 2001) and the well acknowledged influence of 
IGFs on fetal growth in numerous species (Fowden 2003; Murphy, Smith et al. 2006; Owens 1991; Reik, 
Constancia et al. 2003; van Kleffens, Groffen et al. 1998). Analysis of fetal body composition revealed 
that the increase in fetal weight in late gestation in response to earlier maternal IGF supplementation 
was principally due to increased muscle mass and possibly enhanced bone growth (indicated by 
increased carcass weights). IGF-I treatment of the mother, however also reduced the fractional weight 
of the brain, spleen and liver in late gestation. Analysis of circulating metabolites revealed that fetuses 
of IGF-I treated mothers displayed reduced plasma cholesterol concentrations. The impact of these fetal 
alterations on postnatal health outcomes, have yet to be determined. Certainly, there is substantial 
evidence from human epidemiological and animal studies, including the guinea pig, demonstrating that 
alterations in fetal developmental can have impacts on the health of offspring in adult life, including 
increased risks of diabetes, heart disease and obesity (Barker 1998; Barker 2004a; Barker 2004b; 
Barker 2004c; Kind, Clifton et al. 2003; Kind, Clifton et al. 1999; Kind, Simonetta et al. 2002). Postnatal 
studies investigating metabolic profiles, blood pressure and immune and cognitive function in offspring 
of IGF treated mothers would better elucidate long-term outcomes. Nevertheless, we predict increased 
fetal muscle mass induced by earlier maternal IGF treatment, may prove to be metabolically beneficial 
in later life. Certainly, fetuses of IGF treated mothers appear to have an increased metabolic rate as 
fetal substrate utilization is increased near term.  
 
7.1.2.2  IGF effects on the placenta 
As maternal IGFs cannot be transported across the placenta (Brown and Thorburn 1989), we then 
determined whether alterations in fetal growth were secondary to effects on the placenta. In mid 
gestation, IGF-I, but not IGF-II increased placental weight. This was not sustained until term. 
Importantly, however, analysis of placental structural development in late gestation revealed that, IGF-II, 
but not IGF-I, enhanced the development of the labyrinth, the region dedicated to substrate exchange 
between the maternal and fetal circulations. Maternal IGF-II supplementation increased the area, 
proportion and volume of placenta devoted to exchange. More detailed inspection of the labyrinth 
revealed that the volumes of trophoblast and maternal blood spaces and total surface area of placenta 
participating in exchange were increased by earlier maternal IGF-II supplementation. These placental 
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circulating IGF-II (Roberts, Sohlstrom et al. 2001a; Roberts, Sohlstrom et al. 2001b) or studies in mice 
that display perturbed placental Igf2 expression (Constancia, Hemberger et al. 2002; Sibley, Coan et al. 
2004). Furthermore, in the current studies, maternal IGF-II treatment reduced the proportion of placenta 
composed of interlobium (germinative region). Although these effects were not evident in mid gestation 
(Standen et al., in preparation), such alterations near term reflect advanced placental maturation, as it is 
well established that the labyrinth expands at the expense of the interlobium in the final phase of guinea 
pig placentation (Kaufmann and Davidoff 1977; Roberts, Sohlstrom et al. 2001a). This increases 
placental transport capacity and efficiency in late gestation, when the substrate demand of the fetus is 
high and increasing.  
 
To determine whether maternal IGF treatment had altered placental transport, we measured transfer of 
radiolabelled, non-metabolisable analogues of glucose and System A amino acids to the fetus. In 
accordance with anabolic effects of IGF-I treatment on the fetus and placenta in mid gestation and both 
IGF treatments on fetal growth in late pregnancy, placental uptake and transport of substrate to the 
fetus and fetal utilization, were enhanced. Maternal IGF-I administration, enhanced mid gestational 
placenta uptake and transfer of glucose and System A amino acid to the fetus, with both IGF treatments 
sustainedly enhancing placental uptake and transport of glucose to the fetus, in late gestation. Our 
findings are in agreement with in vitro experiments showing enhanced glucose and amino acid uptake 
by human trophoblasts (Bloxam, Bax et al. 1994; Karl 1995; Kniss, Shubert et al. 1994; Yu, Iwashita et 
al. 1998) and villous explants (Ericsson, Hamark et al. 2005a) in response to IGF stimulation in vitro. 
Interestingly, the activity of the placental System A transporters, responsible for placental delivery of 
small neutral amino acids to the fetus, was unaltered in late gestation by earlier IGF supplementation. 
This was interesting as fetuses of IGF supplemented mothers contained significantly elevated fetal 
plasma α-amino nitrogen concentrations, an indication of total amino acid content. These suggest that 
other amino acid transporter systems are altered by earlier maternal IGF treatment. This finding is not 
surprising as studies performed in genetically modified mice have implicated IGFs in the regulation of 
placental cationic amino acid transporter systems (Matthews, Beveridge et al. 1999). Additionally, 
elevated maternal IGFs may promote yolk sac delivery of amino acids, as in the guinea pig, nutrients 
may be transferred to the fetus via this route throughout gestation (Butt and Wilson 1968). Certainly, 
defining the fetal plasma amino acid composition by HPLC or mass spectrometry and then determining 
the abundance of substrate transporters in the placenta and yolk sac in response to maternal IGFs 
would provide clarification.  
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Although maternal IGF-I treatment did not affect placental development in late gestation, it increased 
the ratio of fetal weight to placental weight, suggesting increased placental efficiency. Elevated maternal 
circulating IGF-I may have altered other determinants of placental function that were not measured in 
these studies. For instance, exogenous IGF-I has the potential to influence placental transporter 
expression (Bilan, Mitsumoto et al. 1992a; Bilan, Mitsumoto et al. 1992b; Fladeby, Skar et al. 2003; 
Phillips, Ferraz et al. 2005; Wilson, Mitsumoto et al. 1995), blood flow (Bilan, Mitsumoto et al. 1992a; 
Bilan, Mitsumoto et al. 1992b; Fladeby, Skar et al. 2003; Phillips, Ferraz et al. 2005; Schini-Kerth 1999; 
Siler-Khodr and Forman 1993; Siler-Khodr, Forman et al. 1995; Wilson, Mitsumoto et al. 1995; Yang, 
Chao et al. 2006) and trophoblast migration (Hills, Elder et al. 2004; Kabir-Salmani, Shiokawa et al. 
2002; Kabir-Salmani, Shiokawa et al. 2004; Kabir-Salmani, Shiokawa et al. 2003; Lacey, Haigh et al. 
2002), which affect placental substrate transfer. An examination of the effect of maternal IGF 
supplementation on these parameters would better clarify these speculations.  
 
Despite differences in IGF effects on placental development, both IGF-I and IGF-II appeared to improve 
placental hormone synthesis, as indicated by elevated maternal plasma estradiol and progesterone 
concentrations in mid and/or late pregnancy. These were associated with fetal growth and placental 
development and have established roles in maintenance of pregnancy through modulating maternal 
physiology and adaptation to pregnancy (Butte 2000; Catalano 1999; Ryan and Enns 1988). 
 
7.1.2.3  IGF effects on the mother 
Analysis of maternal body composition and substrate utilization suggested that maternal IGF treatment 
may have increased substrate transfer to the fetus during pregnancy by affecting the mother. There was 
no effect of elevated maternal circulating IGF-I or IGF-II on weight gain during or following cessation of 
treatment until near term. In mid pregnancy, at the time of treatment, we found an increase in the weight 
of maternal kidneys and spleen with IGF-I administration and a trend for increased heart mass with IGF-
II. These effects were not sustained until late pregnancy, however, at this time, maternal adipose stores 
were depleted by earlier IGF-I treatment. These, mid and late gestational effects observed in the mother 
in response to IGF supplementation, suggest enhanced maternal adaptation during pregnancy. For 
instance, increased kidney, spleen and heart mass would be expected to promote maternal blood 
filtration and flow to the uterus. Furthermore, mobilisation of maternal fat depots would increase 
substrate availability in the maternal circulation, for transfer to the fetus.  
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Further studies measuring maternal substrate utilization, provided support for IGFs in the mother 
promoting maternal adaptation throughout pregnancy. Maternal IGF-I increased maternal muscle 
glucose and System A amino acid utilization in mid pregnancy. In later pregnancy, IGF-I increased 
glucose and System A amino acid utilization by muscle, visceral tissues and all tissues combined. IGF-II 
increased late gestational visceral organ and total tissue System A amino acid utilization. Despite 
increased maternal substrate utilization with increased IGF exposure of the mother during early to mid 
pregnancy, this did not significantly alter maternal growth and, importantly, increased placental delivery 
of nutrients to the fetus, enhancing fetal growth near term. These observations suggest that IGF 
supplementation altered maternal physiology, increasing the function and metabolism of maternal 
organs which, in turn, improved maternal and fetal health and conceptus growth during pregnancy. This 
speculation is supported by studies performed in women demonstrating that during pregnancy, their 
daily rate of carbohydrate oxidation increases to meet the demands of the conceptus (Butte 2000; 
Catalano 1999). 
 
There was no effect of IGF supplementation on maternal plasma cholesterol, α-amino nitrogen, free 
fatty acids and triglycerides in mid or late pregnancy. However, there was a trend for increased 
circulating glucose concentration in late pregnancy in mothers treated with either IGF. Women increase 
their hepatic glucose production during normal pregnancy (Assel, Rossi et al. 1993; Catalano, Roman-
Drago et al. 1998; Catalano, Tyzbir et al. 1992), suggesting that this adaptive response to the pregnant 
state is accentuated in guinea pig mothers that were treated during early to mid pregnancy with IGF. We 
suspect that this may reflect a state of enhanced insulin resistance in the IGF treated mothers. 
Additionally, in mothers treated with IGF-I, there was a delay in the clearance of methyl glucose from the 
circulation, which indicating altered maternal insulin sensitivity. Analysis of maternal metabolic 
parameters during pregnancy in response to IGF administration would provide further information on 
these issues. Moreover, the consequence of reduced maternal adiposity on lactation in IGF-I treated 
dams is yet to be determined. 
 
7.1.2.4  Mechanism for distinct IGF actions 
Despite somewhat similar outcomes on fetal growth and survival, placental function and maternal 
substrate utilization, there were distinct effects of IGF treatment (Table 7.1). For instance, IGF-I infusion 
altered maternal body composition and did not affect placental structural development, while IGF-II 
altered placental development but not maternal body composition. We propose that, maternal IGFs may 
play complementary, but overlapping roles during pregnancy to ensure fetal growth and survival. IGF-I 
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Table 7.1 Summary of exogenous maternal IGF effects on the fetus, placenta and mother  
 
Day 35  IGF-I  IGF-II 
Fetus    
Litter  ↔  ↔ 
Weight  ↑  ↔ 
Substrate utilization  ↑ MG 
↑ AIB 
↔ 
Placenta   
Weight  ↑  ↔ 
Structure**  ↑ total area 
↓ area for exchange 
↔ 
Hormone synthesis  ↔  ↑ estradiol  
↑ progesterone 
Substrate uptake  ↑ MG 
↑ AIB 
↔ 
  Mother 
Weight gain  ↔  ↔ 
Body composition  ↑ kidney mass 
↑ spleen mass 
↑ heart mass 
Circulating metabolites  ↔  ↔ 





Substrate utilization  ↑ MG 
↑ AIB 
↔ 
Day 62  IGF-I  IGF-II 
Fetus    
Litter  ↑ viability  ↑ viability 
Weight  ↑  ↑ 
Body composition  ↑ triceps mass 
↓ fractional mass of several tissues 
↑ triceps 
 
Substrate utilization  ↑ MG  
↔ AIB 
↑ MG  
↔ AIB 
Circulating metabolites  ↑ amino acid 
↓ cholesterol 
↑ amino acid 
Placenta   
Weight  ↔  ↔ 
Structure  ↔  ↑ development of exchange region 
Hormone synthesis  ↑ estradiol  ↑ progesterone 





Weight gain  ↔  ↔ 
Body composition  ↓ adiposity  ↔ 
Circulating metabolites  ↑ glucose  ↑ glucose 
Substrate utilization  Delay in plasma MG clearance  
↑ MG and AIB 
↔ MG 
↑ AIB 
**previously determined by Prue Standen (Standen et al., in preparation) Chapter 7    Thesis discussion and conclusion 
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substrate availability for the fetus. IGF-II on the other hand, operates primarily through the placenta, to 
enhance placental development and improves its function and substrate supply to the fetus. 
Nevertheless, there is some degree of overlap between IGF actions, given that both IGFs appear to 
enhance maternal adaptation and improved placental transport function. 
 
The discrete effects of IGF-I and IGF-II are speculated to stem from distinct interactions of the IGFs with 
various receptors. All three receptors, InsR (Kelly, Posner et al. 1974; Posner 1974), IGF1R and IGF2R 
(Chapter 4) are abundantly expressed by the guinea pig placenta at the time of treatment and are 
ubiquitously expressed by maternal tissues, permitting endocrine IGF actions. It is important to 
remember that the abundance of these receptors may also have been altered by maternal IGF 
treatment and that the guinea pig placenta may express InsR/IGF1R hybrid, as the human (Bailyes, 
Nave et al. 1997; Soos and Siddle 1989), which may have modulated IGF actions. 
 
IGF-I has negligible affinity for IGF2R and InsR (De Meyts, Wallach et al. 1994; Jones and Clemmons 
1995). Thus all effects of IGF-I treatment are likely to be mediated by IGF1R, particularly since this 
treatment also reduced maternal plasma IGF-II concentrations in mid pregnancy. IGF-II, on the other 
hand, can bind all three receptors, making it difficult to decipher which one is responsible for exerting 
the effects of exogenous maternal IGF-II. We aimed to define the contribution of IGF2R to the sustained 
impacts of IGF-II during pregnancy by administering Leu27-IGF-II, an analogue of IGF-II, which 
selectively interacts with IGF2R due to reduced binding affinity for IGF1R and InsR (Sakano, Enjoh et al. 
1991) to the mother. Placental structural analysis revealed that many of the effects seen with maternal 
IGF-II treatment on placental labyrinthine development, were also observed in placenta from mothers 
administered Leu27-IGF-II. Like IGF-II, Leu27-IGF-II increased labyrinth proportion and volume, while 
reducing the weight of the interlobium. In terms of labyrinthine development, Leu27-IGF-II treatment was 
demonstrated to be more potent than IGF-II, as seen by increased volume densities of trophoblast and 
maternal blood spaces, increased total surface area of trophoblast for exchange and reduction in the 
thickness of the barrier for diffusion. This is consistent with the previously reported stimulation of IGF-II 
through IGF2R, on trophoblast migration and invasion (McKinnon, Chakarborty et al. 2000) and uterine 
angiogenesis and vascular remodelling (Herr, Liang et al. 2003). Leu27-IGF-II may have also promoted 
labyrinthine development indirectly by inhibiting activation of TGF-β1 activation at IGF2R (Godar, 
Horejsi et al. 1999; Leksa, Godar et al. 2005) in the placenta.  
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The observed placental structural changes following IGF-II and Leu27-IGF-II treatments, were predicted 
to enhance the capacity of the placenta to deliver substrate and are consistent with observed increases 
in methyl glucose transfer, fetal plasma total amino acid concentration, substrate utilization, growth and 
survival in late pregnancy. We are also aware that Leu27-IGF-II may have altered circulating IGF 
concentrations, or forced endogenous IGF-II to interact with IGF1R or InsR, both of which, have 
established roles in transport. Determining the circulating concentration of IGFs, as well as abundance 
of their cognate receptors in response to Leu27-IGF-II treatment, would help to better understand our 
observations.  
 
There was largely no effect of maternal Leu27-IGF-II treatment on body composition and substrate 
utilization in the mother in late pregnancy. This suggests that the observed effect of IGF-II treatment of 
maternal System A amino acid uptake by maternal visceral and combined tissues, was mediated 
through IGF1R or InsR. 
 
Further studies are required to define the downstream molecular pathways involved in maternal IGF 
control of fetal growth and survival. It is likely that the IGFs modulate the expression of molecules in the 
placenta involved in metabolism, transport, trophoblast differentiation, angiogenesis, blood flow 
regulation and maternal adaptation to pregnancy. Certainly, preliminary work in the laboratory, suggests 
that components of the placental renin-angiotensin system are altered in mid gestational guinea pigs, in 
response to maternal IGF supplementation (Standen et al., in preparation). In addition, the IGFs may 
coordinate placental functional development with the environment of the mother and control fetal growth 
via the “nutrient sensor”, mTOR protein, signalling pathway which has established roles in the control of 
cell function and is expressed by the human placenta (Kim and Sabatini 2004; Kim, Sarbassov et al. 
2002). Identification of differentially expressed genes and proteins within the placenta and maternal 
tissues, in response to earlier maternal IGF treatment, will further characterise and dissect the 
mechanisms and signalling pathways that transform placental function and hence promote fetal growth 
and survival late in gestation. 
 
7.1.3  Implications for human health 
The research in this thesis has increased our knowledge and highlighted the importance of maternal 
IGFs in their regulation of fetal growth and survival. Importantly, these studies suggest that elevating 
IGF-II abundance in the mother during early pregnancy may be used as a therapy for women at risk of 
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implicated in common and major disorders of pregnancy, including unexplained miscarriage, 
preeclampsia, intrauterine growth restriction and preterm birth. Combined, the latter three disorders 
combined, affect 1 in 5 pregnancies in Australia, can lead to fetal and maternal mortality and morbidity 
and are currently unpreventable. Furthermore, perturbed fetal growth increases the risk of poor health in 
adult life.  
 
It would be interesting to determine whether early treatment of the mother with IGF-II can improve 
pregnancy outcome in animal models of placental insufficiency. A previous study has demonstrated that 
IGF-I, but not IGF-II, supplementation during early to mid pregnancy in guinea pigs, partially restored 
the effect of maternal under-nutrition on fetal growth, in mid gestation (Sohlstrom, Fernberg et al. 2001). 
Given that the anabolic impacts of IGF-II administration on fetal and placental growth became apparent 
in later gestation in the work of the current thesis, further investigative studies determining the sustained 
impacts of maternal IGF supplementation in this experimental model are required. Certainly future 
investigations that aim to identify protein targets which transduce maternal IGF-II actions in placental 
development and function, have enormous therapeutic potential and may pave the way for prevention of 
pregnancy complications associated with placental insufficiency. 
 
The challenge now is to identify women at risk of developing placental dysfunction. Given the 
fundamental roles of IGF-II in orchestrating placental and fetal growth identified in the present thesis 
and work of others, we suspect that alterations in maternally derived or locally produced IGF-II actions 
in the placenta would predispose a mother to disease during pregnancy. This may arise from impaired 
IGF-II synthesis, abundance of IGFBPs and their regulatory proteases and expression of receptors and 
intracellular signalling molecules, as discussed in Chapter 1. These may originate from genetic 
alterations, caused by polymorphisms, defects in methylation of Igf-2/Igf2r and splice or allelic 
variations, or lifestyle factors, including diet and nutritional status, stress and oxygen availability at the 
feto-maternal interface, all of which can interact with each other.  
 
It is reasonable to assume that if a deficiency of maternal circulating or placental synthesis of IGF-II in 
early gestation were a cause of poor pregnancy outcome, it would be associated with disorders of 
pregnancy that display placental perturbations. Finding support for this hypothesis in the literature is 
difficult, as studies are inconsistent and often investigate in late pregnancy, as discussed in Chapter 1. 
Thus, current efforts in the laboratory are focussed on identifying genetic and protein markers in parents 
and their babies in early pregnancy that predict how the placenta will develop and correlate with 
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7.2  Conclusion 
Analysis of the role of oxygen and IGF-II in first trimester human explants has revealed a novel 
interaction between these factors in the regulation of placentation. This work has suggested that, prior 
to the onset of maternal blood flow to the placenta, IGF-II mediates the low oxygen response to promote 
trophoblast outgrowth and invasion. In addition, work in guinea pigs has shown for the first time that, 
increasing IGF abundance in the mother in early pregnancy has a persistent effect on placental 
transport and nutrient allocation between the mother and conceptus, resulting in enhanced fetal growth 
and survival near term. While IGF-I treatment altered maternal body composition in late gestation, 
increased exposure of the placenta to circulating maternal IGF-II laid the foundation for subsequent 
optimal placental growth and function. This work has suggested that an increased abundance of 
maternal circulating IGF-II during early to mid pregnancy may provide a therapeutic avenue for 
preventing placental insufficiency, which is associated with common and major diseases of pregnancy. 
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